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Summary
In many parts of the world, plants are directly  utilised for their 
medicinal properties.  Traditional medicine from Pakistan, India 
and the Far East is well documented and its history is 
embedded in folklore.  It has been documented that an aqueous 
extract of the desert shrub, Fagonia cretica, is a popular 
treatment for breast cancer in Pakistan.  The administration of 
an aqueous extract of Fagonia cretica is reported effective at 
reducing tumour size and improving the quality of life of breast 
cancer patients, is well tolerated and does not exhibit adverse 
effects like vomiting, diarrhoea or alopecia which are common 
side effects of standard cytotoxic therapy.  In the past, many 
pharmacologically active and chemotherapeutic compounds 
have been isolated from plants which subsequently have 
proven to be successful in clinical trials and been used as 
primary compounds in therapeutic regimes.  Fagonia cretica 
has historical use as a treatment for breast cancer, yet there is 
little scientific evidence which shows chemotherapeutic 
potential towards breast tumours.  Preparation and analysis of 
an aqueous extract of Fagonia cretica may reveal novel 
chemotherapeutic agents that can be used to effectively  target 
cancer cells.  An understanding of the mechanism of any 
activity  may improve our understanding of cancer cell biology 
and reveal novel therapeutic targets.  This thesis describes for 
the first time that an aqueous extract of Fagonia cretica shows 
potent in vitro cytotoxic activity towards breast cancer epithelial 
cell lines which was not seen towards normal mammary 
epithelial cells.  Elucidation and characterisation of the cytotoxic 
mechanism was undertaken by analysing DNA damage, cell 
cycle status, apoptosis, metabolic state and expression of 
transcription factors and their targets.  Finally, methods for the 
isolation and identification of active compound(s) were 
developed using various chromatographic techniques.
An aqueous extract of Fagonia cretica was able to reduce cell 
viability  significantly in two phenotypically different breast 
cancer cell lines (MCF-7 and MDA-MB-231).  This activity was 
markedly  reduced in normal mammary epithelial cells (HMEpC). 
Further investigation into the mode of action revealed that 
extract treatment induced cell cycle arrest and apoptosis in both 
MCF-7 and MDA-MB-231 cell lines.  This coincided with the 
formation of DNA double stranded breaks and the DNA repair 
marker γ-H2AX.  In MCF-7 cells, ATM/ATR activation resulted in 
increased p53 expression and of its transcriptional targets p21 
and bax, suggesting a role for a p53-mediated response. 
Furthermore, inhibition of extract-induced p53 expression with 
siRNA reduced the cytotoxic effect against MCF-7 cells.  Extract 
treatment was also associated with increased FOXO3a 
expression in MCF-7 and MDA-MB-231 cells.  In the absence of 
functional p53, siRNA knockdown of extract-induced FOXO3a 
expression was completely  abrogated, suggesting that FOXO3a 
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plays a vital role in extract-induced cytotoxicity.  Isolation and 
characterisation of the active compound(s) within the extract 
was attempted using liquid chromatography and mass 
spectrometry in conjunction with a cell viability  assay.  Multiple 
fractionations generated an active fraction that contained four 
major compounds as detected by  mass spectrometry. 
However, none of these compounds were identified structurally 
or chemically due to constraints within the methodology.
Key Words: DNA damage, FOXO3a, breast cancer, p53, 
cancer metabolism
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Chapter 1:  Introduction
! 1.1:  Breast cancer
Malignant breast neoplasm is a category of cancers that 
originate from within the breast tissue and primarily arise 
from the lactiferous duct or connected lobules of the 
mammary gland.  Breast cancer represents the third most 
frequent cancer worldwide and amongst females, is the most 
common malignancy, making up 21% of all new diagnoses. 
Overall, breast cancer is ranked fifth as the cause of death in 
cancer patients but in females, represents the most common 
cause of cancer mortality, making up  14.1% of female cancer 
deaths [1].  Although mortality as a result of breast cancer is 
still common, survival rates over the past 50 years have 
nevertheless been steadily  increasing, primarily due to 
improvements in diagnosis and treatment.  In the UK, five-
year survival rates for patients diagnosed between 
2001-2006 reached 82%, compared to 52% for patients 
diagnosed between 1971-1975 [2].  Breast cancer is a 
disease that primarily  affects females but it can also presents 
in males, although rarely, contributing to about 1% of total 
breast cancer cases [3].
As with all cancers, tumorigenesis within the breast occurs 
as a result of a combination of dysregulated oncogenes and 
deactivation of tumour suppressors, resulting from functional 
mutations within specific genes [4].  This can occur not only 
as a consequence of spontaneous mutations from DNA 
replication or endogenous genomic insult during cellular 
energetics but also by exogenous agents such as UV-light, 
radiation and carcinogenic compounds [5].  Familial genetics 
can also increase the risk of neoplastic transformation.  For 
example, hereditary mutations to the breast cancer type-1 
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and 2 susceptibility genes (BRCA1 and BRCA2), increases 
the risk of developing breast cancer by age 90 to 60% [6]. 
Other risk factors related to increased breast cancer 
incidence include age, diet, weight, alcohol intake, smoking, 
use of oral contraception and use of hormone replacement 
therapy [7].
Breast cancer is a complex, multi-factorial disease and thus, 
tumours are classified clinically based on various histological, 
molecular and phenotypic characteristics.  The majority of 
breast cancers appear as mammary ductal carcinomas and 
are characterised as either being invasive or noninvasive [8]. 
Invasive mammary ductal carcinomas account for 
approximately 55% of all breast cancers and are 
characterised as a malignant proliferation of mammary 
epithelial cells with metastatic behaviour [9].  Non-invasive 
ductal carcinomas are neoplasms of the breast epithelium 
that have not yet infiltrated the surrounding tissue.  In breast 
cancer classification, the standard TNM (Tumour, Nodes, 
Metastasis) malignant tumour staging system, is used to 
provide an in-depth physical description of the tumour type. 
It is based on three main parameters that take into account 
tumour size, presence of tumour cells in the lymph nodes 
and degree of metastasis, which combined, help to give an 
indication of patient prognosis [10].  
The treatment options available for a patient diagnosed with 
breast cancer include surgery, radiotherapy, cytotoxic 
chemotherapy, hormone therapy or targeted therapy.  The 
treatment choice is based on the staging and classification of 
the tumour.  As well as the staging system mention above, 
breast cancer tissue is also characterised based on 
molecular phenotypes.  In mammary epithelial cells, the 
presence of steroid hormone receptors such as estrogen 
receptor (ER) and progesterone receptor (PR), are vital for 
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normal mammary development [11].  However, either over-
expression or over-activation of these receptors is implicated 
in tumorigenesis due to stimulation of cellular proliferation 
[12].  Activation of estrogen receptor signalling by estrogen 
modulates the activity  of multiple signal transduction 
cascades involved in cell survival and proliferation [13]. 
Estrogen receptors are over-expressed in approximately 
70% of breast cancers and thus represents a useful 
therapeutic target [14].  The most successful breast cancer 
therapy to-date for ER-positive tumours has been Tamoxifen. 
Metabolism of tamoxifen in the liver produces active 
metabolites (primarily afimoxifene and endoxifen) which act 
as ER-antagonists and suppress tumour cell growth [15]. 
However, even with its widespread use, around half of 
patients with ER-positive breast cancer in an advanced stage 
will fail to respond to tamoxifen.  Furthermore, an initial 
response to tamoxifen treatment, is often followed by 
progression to a resistant phenotype [16].  There is currently 
little understanding of how this resistance occurs but analysis 
of cell transcriptome and proteome phosphorylation status 
revealed distinct signal transcription programs involved in 
tamoxifen resistance [17, 394].  For example, Zhou et al. 
demonstrated that tamoxifen resistance in breast cancer was 
associated with down-regulation of ER-regulated genes and 
activation of survival signalling coupled with an increased 
migratory capacity.
Human epidermal growth factor receptor 2 (HER2/neu) is a 
member of the epidermal growth factor receptor (EGFR) 
family and regulates multiple signalling pathways involved in 
cell proliferation, differentiation and survival [18].  The HER2/
neu signalling pathway directs cell growth and division and 
its importance in tumorigenesis is demonstrated by the fact 
that over-expression of HER2/neu is prevalent in around 
25% of early-stage breast cancers [19].  Targeted therapy 
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using trastuzumab (Herceptin) can be effective at slowing 
tumour growth for patients with tumours over-expressing 
HER2/neu [20].  Trastuzumab is a human monoclonal 
antibody with specificity towards an extracellular domain of 
HER2/neu.  This blocks normal receptor signalling and 
inhibits cell proliferation regulated by  the phosphoinositide 3-
kinase (PI3K)/protein kinase B (Akt) signalling pathway [21]. 
Although trastuzumab has high affinity for HER2/neu, it has 
been reported that 70% of HER2-positive tumours do not 
respond to therapy, highlighting the complexity of breast 
cancer pathology.  As well as this, nearly all of the patients 
treated with trastuzumab develop resistance during the 
treatment program [22].  It is not currently known why 
patients are or become resistant but genomic approaches 
have revealed the PI3K signalling pathway as major 
determinant of trastuzumab resistance [23].  In some 
tumours PI3K may be mutated, which prevents trastuzumab-
mediated inhibition of Akt signalling and subsequent 
downstream effects [24].  It has also been postulated that 
receptor cross-talk with insulin-like growth factor-1 (IGF-1) 
may contribute to resistance [25].
There also exists a highly aggressive sub-type of breast 
cancer, which has been coined ʻtriple negativeʼ.  This form of 
breast cancer is characterised as tumours that lack 
expression of ER, PR and HER2/neu.  This sub-set 
comprises of around 15% of breast cancer cases and is 
associated with a poor clinical prognosis [26].  The lack of 
receptor expression in this sub-set render treatments such as 
tamoxifen and trastuzumab redundant.  Currently  there is no 
targeted treatment regime for this type of breast cancer and 
many patients experience relapse to cytotoxic chemotherapy. 
Recently, it was discovered that the triple-negative 
phenotype shares similarities with breast cancer type 1 
susceptibility protein (BRCA1) mutant breast cancers, 
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particularly with deficiencies in the repair of DNA double 
strand breaks [27].  Therefore, it has been proposed that 
DNA-damaging agents are most likely  to be effective against 
this aggressive sub-type.  BRCA1 normally forms part of a 
DNA repair complex during homologous recombination of 
double strand breaks.  In the absence of functional BRCA1, 
this role is carried out by poly [ADP-ribose] polymerase 1 
(PARP-1), thus it has been predicted that the use of PARP-1 
inhibitors in combination with DNA-damaging agents could 
provide a therapeutic option for triple negative breast cancers 
[28].  Indeed, it was recently  demonstrated in a clinical trial 
that co-treatment of a PARP-1 inhibitor plus chemotherapy, 
was significantly more effective then chemotherapy alone 
[29].  The use of PARP inhibitors in cancer therapy has 
recently been proposed to be effective against any tumour 
that harbours defects within DNA repair pathways as a 
means of sensitising cells to classical cytotoxic agents [395].
!
! 1.2:  Tumorigenesis
The development of a tumour results from the abnormal 
proliferation of any cell in the body.  One of the principle 
features of tumours is that the population of proliferating cells 
show clonality.  This means that tumour development occurs 
from a single progenitor that develops a survival advantage 
and demonstrates abnormal proliferation [30].  Tumour 
formation and progression can be divided into four main 
states which are:
1) Precursor neoplastic lesion
2) Intermediate lesion
3) Primary invasive cancer
4) Metastasis
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The precursor lesion is the initial alteration to a cell that 
confers an advantage for cell survival over the surrounding 
tissue and promotes clonality  [31].  These transformations 
are benign, cease growth after an initial phase and are often 
removed through natural progression and differentiation 
pathways [32].  Those precursor lesions which are not 
removed may go on to form intermediate lesions.  This 
second group of neoplastic lesions is still contained to the 
tissue area where they originated but now begin to proliferate 
slowly  without termination [33].  At this stage the probability 
of the intermediate lesion becoming a primary tumour are 
high and represents the most important transformation to a 
pathological condition [34].  Progression to primary invasive 
cancer is characterised by  unrestricted proliferation, clonal 
expansion and growth outside of the initial tissue 
compartment [35].  At this stage many primary tumours do 
not exhibit metastatic ability and removal of the tumour by 
surgery often results in cure [36].  The final stage in tumour 
progression is metastasis of the cancer.  Vascularisation of 
the tumour allows the expanding tumour to deposit malignant 
cells into the vascular network [37].  Metastasis enables 
tumour cells to infiltrate other areas of the body where their 
survival advantage can lead to clonal expansion in a 
secondary tumour site [38].
!
! 1.3:  DNA damage
Generation of a neoplastic lesion occurs as a result of a 
genomic mutation that leads to cellular transformation and 
abnormal proliferation.  This is caused by damage to DNA 
which alters the chemical structure of the double helix and 
effects gene transcription.  DNA damage can be induced by 
a wide variety  of exogenous and endogenous sources. 
Endogenous reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) are able to directly modify nucleotide 
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bases and cause structural modifications to DNA [39].  It is 
well established that ROS such as superoxide anion radicals, 
hydrogen peroxide and hydroxyl radicals are cytotoxic and 
that oxidative DNA damage can lead to neoplastic mutations 
[40].  The most common oxidative base modification present 
in tumours is a guanine to thymidine transversion and when 
occurring in oncogenes (such as Ras) or tumour suppressor 
genes (such as p53) can promote tumorigenesis [41].  As 
well as this, natural replication errors are capable of inducing 
DNA damage and activating the DNA damage response [42].
Exogenous DNA damage can occur from a variety of sources 
including ultra-violet light, x-ray and gamma-ray  radiation, 
plant toxins, viruses and mutagenic chemicals [43,44].  The 
most common DNA lesions associated with these agents 
include DNA cross-links, indirect oxidation of bases and 
single or double strand breaks.
It has been shown that DNA damage is associated with 
breast cancer risk [45].  This is not only a result of direct 
DNA damaging agents such as those mentioned previously 
but also because of common dysregulation of DNA repair 
pathways that are normally activated in response to DNA 
damage [46].  Defects to the DNA repair mechanism 
potentially allow accumulation of pathological mutations 
leading to tumorigenesis.  An important protein involved in 
the repair of double strand breaks is BRCA1.  The BRCA1 
protein forms a complex with Rad51 during the repair of 
double strand breaks which binds DNA and inhibits the 
exonuclease activity  of MRN (described in section 1.4) [47]. 
This helps to promote homologous recombination of DNA 
rather then non-homologous end joining which can result in 
chromosomal translocations [48].   It is thought that as many 
as 30% of all breast cancers have some degree of BRCA1 
inactivation [49].  
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! 1.4:  The DNA damage response
The DNA damage response (DDR) is a complex signalling 
network responsible for activating DNA repair mechanisms, 
cell cycle arrest and apoptosis, in response to DNA damage 
[50].  The network involves recognition of damaged sites by 
sensor proteins and transduction of the damage ʻsignalʼ to 
effector molecules to elicit a cellular response (figure 1.1) 
[51].  It is thought that members of the rad protein family are 
responsible for sensing DNA damage [52].  The proteins rad1 
and rad9 have been shown to be directly  involved in sensing 
aberrant DNA structures caused by DNA damage [53].  In 
fact, a heterotrimeric complex involving rad1, rad9 and a third 
checkpoint protein, Hus1, has been shown to interact at sites 
of single strand breaks [54].  It has also been demonstrated 
that upon DNA damage rad17 and rad24 are associated with 
DNA and that removal of both proteins can delay repair of 
damaged DNA [55,56].  In response to double strand breaks 
a heterotrimeric protein complex involving Mre11, Rad50 and 
Nbs1 (MRN) is rapidly localised to damaged sites to initiate a 
DNA repair response [57].  Recruitment of the MRN complex 
is essential for stabilisation of double strand breaks, initiation 
of cell cycle checkpoint signalling cascades and regulation of 
chromatin remodelling at sites of DNA damage [58].
Transduction of the DNA damage signal primarily occurs 
through the serine/threonine protein kinases ataxia 
telangiectasia mutated (ATM) and ataxia telangiectasia and 
Rad3-related (ATR) proteins.  These transducers are 
members of the phosphoinositide-3-kinase-related protein 
kinase (PIKK) family  and are rapidly activated and recruited 
to sites of DNA damage.  The function of these protein 
kinases is to relay the DNA damage signal to other 
transducers, often transcription factors, so that a cellular 
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response can be elicited [59,60].  Activation of cell cycle 
checkpoints, apoptosis and DNA repair as a result of DNA 
damage is required to maintain genomic integrity and 
suppress tumorigenesis.
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Figure 1.1.  Overview of ATM/ATR mediated 
response to DNA damage.  In response to double 
strand breaks the sensor proteins Mre11, NBS1 and 
Rad50 are recruited to sites of damage which 
facilitates co-recruitment of the transducer ATM. 
Activation of ATM induces downstream effector 
cascades including p53, CHK2, BRCA1 and H2AX, 
resulting in transcriptional regulation of apoptosis cell 
cycle arrest and DNA repair.  Single strand breaks to 
DNA recruits RPA and ATRIP and the trimeric Rad9-
Rad1-Hus1 complex which both co-recruit ATR and 
TopB1.  Interaction between TopB1 and ATR results in 
activation of ATR-mediated signalling cascades 
including CHK1-mediated cell cycle arrest.
 
The ATM kinase is primarily  involved in the detection of 
double strand breaks and is dysregulated in ataxia-
telangiectasia disorder.  This disease is characterised by 
neurodegenerat ion, suscept ib i l i ty  to cancer and 
immunodeficiency brought on by genomic instability [61]. 
ATM is recruited to sites of DNA damage following 
recruitment of the MRN complex via conserved carboxy-
terminal motifs within Nbs1 [62,63].  However, in order for 
ATM to remain associated with sites of DNA damage and 
sustain a response, auto-phosphorylation at serine-1981 on 
ATM, is also required [64].  This phosphorylation step  is also 
required to initiate kinase activity against ATM substrates and 
activate the DDR [65].  Once activated, ATM causes the 
phosphorylation of many substrates, including the 
transcription factor p53, the protein kinase CHK2 and the 
DNA repair proteins BRCA1 and H2AX [66,67] . 
Phosphorylation and activation of p53 and CHK2 leads to cell 
cycle arrest following inhibition of cyclin-CDK complexes [68]. 
Activation of CHK2 occurs rapidly with persistent ATM 
signalling leading to secondary p53 activation [69]. 
Furthermore, CHK2 exhibits kinase activity towards p53 
which can increase its stability, half-life and thereby amplify 
p53 signalling and lead to apoptosis in the face of lethal 
DNA damage [70].  CHK2 also phosphorylates CDC25 and 
BRCA1 to induce cell cycle arrest and DNA repair [71,72] 
(table 1.1). 
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ATR is activated in response to persistent single-stand 
breaks such as those formed at stalled replication forks [73]. 
In a general mechanism, single-strand breaks become 
coated with replication protein A (RPA), which prevents the 
damaged strand from forming secondary structures [74]. 
This allows access for DNA repair proteins during nucleotide 
excision repair.  ATR and its partner protein, ATR-interacting 
protein (ATRIP) are co-recruited to DNA-RPA sites and are 
both required to initiate a response to single-strand breaks 
[75].  As mentioned previously, ATR is also recruited to sites 
of single-stranded DNA damage by the Rad9-Rad1-Hus1 
complex.  Once recruited to sites of DNA damage, ATR 
becomes active after interacting with DNA-topoisomerase II 
binding protein 1 (TopBP1) [76].  ATR can then exert kinase 
activity  on its many target substrates, including CHK1 and 
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Key ATM/ATR substrates Targets (effect)
p53
CDKN1A (cell cycle arrest)
BAX (apoptosis)
GADD45 (DNA repair)
PUMA (apoptosis)
FasL (apoptosis)
CHK2
p53 (stabilisation/activation)
CDC25 (cell cycle arrest)
BRCA1 (DNA repair)
BRCA1
Rad51 (DNA repair)
γ-H2AX (repair factor 
recruitment)
γ-H2AX
BRCA1 (repair factor 
recruitment)
Nibrin (DDR)
CHK1 CDC25 (cell cycle arrest)
Table 1.1.  Key substrates of ATM/ATR and their 
downstream targets and effects.  ATM and ATR are protein 
kinases involved in transduction of DNA damage response 
signalling.  Both kinases interact with various target proteins 
to initiate cell cycle arrest, DNA repair and apoptosis in 
response to DNA damage.
TopBP1, which amplifies ATR-activity in a positive feedback 
loop [77].  The kinase activity of CHK1 blocks CDC25 
resulting in cell cycle arrest and is required to activate the 
G2/M DNA damage checkpoint (table 1.1) [78].
The response of ATM and ATR to DNA damage is not entirely 
a parallel response and it has been shown that ATM 
functions upstream of ATR following exposure to ionising 
radiation [79].  It has also been demonstrated that ATR-
ATRIP complexes are recruited to sites of double-strand 
breaks which is stimulated by ATM activity  [80].  Both ATM 
and ATR also appear to exhibit kinase activity towards each 
other.  In response to UV treatment ATM is phosphorylated 
by ATR resulting in ATM-dependent phosphorylation of CHK2 
and induction of cell cycle arrest [81].  It is also apparent that 
ATM and ATR share kinase activity towards substrates.  In 
particular, the tumour suppressor p53, is phosphorylated at 
serine-15, in response to DNA damage by both ATM and 
ATR [82,83].  Other post-translational modifications of p53, 
such as acetylation, cooperate in conjunction with 
phosphorylation to provide a stimulus-specific response 
[396].
Dysfunction of DNA damage pathways in cancer represents 
a double edged sword, where on one side loss of an effective 
response can drive tumorigenesis, and on the other hand 
provides a potential therapeutic target (figure 1.2).  A 
complex network of DNA repair mechanisms ensures cellular 
survival by maintaining genomic integrity.  Single-strand 
breaks can be repaired by base-excision repair involving 
PARP-1, XRCC1 and Ligase 3 interaction at the site of 
damage [84].  Double-stranded DNA breaks are repaired by 
homologous recombination or non-homologous end joining 
(NHEJ) involving ATM, BRCA1/2, CHK 1/2 and Rad51 
[85,86].  As well as strand breaks, alterations to DNA 
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structure by alkylating agents, formation of bulky adducts or 
base mis-matches, can induce DNA repair by nucleotide 
excision repair (NER), mismatch repair or direct reversal [87]. 
Dysfunction within any of these DNA repair pathways can be 
exploited for cancer therapy and examples of drugs and the 
pathway they target are outlined in figure 1.2 [88].
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Figure 1.2.  DNA repair pathways as drug targets for 
cancer therapy (Adapted from Lord 2012 [88]).  Specific 
DNA repair mechanisms are activated in response to 
different types of DNA damage.  Single strand breaks are 
repaired by  base excision repair (BER) involving the repair 
proteins PARP1, XRCC1 and ligase 3.  Double strand 
breaks are are repaired by homologous recombination or 
non-homologous end joining (NHEJ) involving ATM, 
BRCA1/2, DNA-PK and KU70/80.  Dysregulation in these 
repair mechanisms are common and contribute to 
tumorigenesis.  They also represent a therapeutic target as 
these cells cannot respond to DNA damage as effectively 
and are thus more susceptible to DNA damaging agents. 
For example PARP inhibitors can be effective at blocking 
DNA repair induced by double strand breaks in cells that 
lack functional BRCA1/2.
The overall function of the DDR is to initiate cell cycle arrest, 
DNA repair and if required, cell death.  This is controlled by 
the kinase activity  of ATM/ATR, which initiates a response by 
directly or indirectly  phosphorylating target proteins.  As 
mentioned previously, p53 is phosphorylated by  ATM/ATR in 
response to DNA damage.  This site-specific phosphorylation 
is important for regulatory control of p53 and will be 
described in more detail later.  As well as this, ATM can 
phosphorylate murine double minute 2 (MDM2) and 
destabilise the MDM2-p53 repressor complex [89,90].  These 
post-translational modifications serve to increase 
transcriptional activity of p53 and up-regulate target genes 
involved in DNA repair, cell cycle arrest and apoptosis.  It is 
known that ATM dysfunction caused by mutations within the 
ATM gene is associated with breast cancer risk [91] and that 
ATM mutations that cause ataxia-telangiectasia are 
associated with breast cancer susceptibility alleles [397]. 
Furthermore, suppression of tumorigenesis by p53 is 
dependent on activation of functional ATM, highlighting the 
importance of the ATM-p53 pathway in tumour suppression 
[92].
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" 1.5:  The tumour suppressor p53
The tumour suppressor, p53, is encoded in human by the 
TP53 gene.  The gene itself is located on the short arm of 
chromosome 17 (locus: 17p13.1) and spans 20kb  [93].  The 
TP53 gene is evolutionarily  conserved amongst mammals, 
but its existence predates the appearance of cancer, 
suggesting that the original functions of p53 may have been 
un-related to its tumour suppressive properties [94]. 
Structurally, p53 is a 393 amino acid long polypeptide with 
seven domains including an acidic N-terminus transactivation 
domain, a zinc DNA-binding core domain, and a homo-
oligomerisation domain [95].  p53 also contains a proline-rich 
and a second transactivation domain which are involved in 
the pro-apoptotic activity of p53 and its interaction with other 
proteins [96].  The homo-oligomerisation domain is essential 
for tetramisation of p53 and subsequent in vivo activity [97]. 
p53 is involved in many cellular functions including 
apoptosis, cell cycle arrest, DNA repair and senescence.  It is 
modulation of these functions that have led to p53 being 
labelled ʻthe ʻguardian of the genomeʼ.  Furthermore, 
mutations to TP53 which result in functionally  deficient p53 
expression, are present in over 50% of all tumours [98].
Under normal conditions, p53 is maintained at a low level by 
ubiquitination, which targets the protein for degradation by 
the proteasome [99].  This is achieved via interaction with the 
negative regulator of p53, MDM2, an E3 ubiquitin ligase 
which binds p53 protein and marks it for degradation [100]. 
MDM2 forms a stable complex with p53 by binding to the N-
terminal domain [101].  The C-terminal RING domain of 
MDM2 is vital to its ability  to mark p53 for degradation, as it 
recruits ubiquitin-conjugating enzyme E3, resulting in 
polyubiquitination of p53 [102].  The p53-MDM2 repressor 
complex is vital to organismal development as shown by the 
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fact that MDM2 knockout mice die early in embryonic 
development.  Interestingly, this effect can be reversed by 
co-inactivation of p53, demonstrating that MDM2 is crucial to 
the repression of p53 [103].  As well as this, mutations within 
the proline-rich region of p53 increase MDM2 binding 
capability, suggesting that this region is important in 
protecting p53 from degradation [104].  Reducing p53 half-
life is not the only effect MDM2 exerts on p53 and it has been 
demonstrated that MDM2 also directly  inhibits p53 
transcriptional activity [105].  MDM2 binds to the 
transactivation domain of p53, which shields it from 
interaction with other proteins associated with transcriptional 
activation [106].  The MDM2 gene is a transcriptional target 
for p53, thus, p53 regulates itself in a negative feedback loop 
by increasing expression of its own inhibitor [107].
The p53 transcriptional programme can be activated by a 
variety of cellular stressors such as DNA damage, oxidative 
st ress, osmot ic shock and nucleot ide deplet ion 
[108,109,110,111].  The first step in p53 activation involves 
destabilisation of the MDM2-p53 repressor complex, which 
increases p53 half-life, and induces a rapid accumulation of 
p53 protein.  Secondly, p53 is subjected to post-translational 
modifications such as acetylation and phosphorylation, which 
activate its transcriptional activity by driving nuclear 
accumulation of p53 [112,113].  Activation of p53 plays a 
major role in coordinating cell cycle arrest, DNA repair and 
apoptosis in response to DNA damage.  As described in 
section 1.4, the protein kinase ATM is rapidly activated upon 
detection of double strand breaks, resulting in activation of 
the DNA damage response.  Activation of ATM plays a pivotal 
part in the p53-mediated effect following DNA damage [114]. 
It has been shown that loss of ATM prevents p53 
accumulation following DNA damage and blocks p53-
mediated cell cycle arrest [115].  In response to DNA 
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damage, the ATM kinase increases p53 protein levels by 
site-specific phosphorylation of serine-15 (figure 1.3) [116].  It 
has also been shown that ATM activates CHK2 which 
phosphorylates p53 at serine-20 [70].  These residues are 
situated within the MDM2 interacting region of the N-terminal 
domain of p53, suggesting that phosphorylation of p53 at 
serine-15/20 destabilises the p53-MDM2 complex [117]. 
However, mutation of these residues does not prevent p53 
stabilisation in vitro, suggesting that other mechanisms are 
involved in p53 stabilisation in response to DNA damage 
[118].  ATM also demonstrates kinase activity towards 
MDM2.  In particular, ATM-dependent phosphorylation of 
serine-395 results in p53 stabilisation following DNA damage 
[89].  Effective degradation of p53 is dependent on controlled 
nucleo-cytoplasmic shuttling.  Both p53 and MDM2 are 
exported from the nucleus simultaneously by their nuclear 
localisation signal and nuclear export signal sequences [119]. 
Phosphorylation of p53 at serine-15 induced by DNA damage 
inhibits p53 nuclear export thus reducing p53 degradation 
and increasing p53 activation [120].
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Figure 1.3.  Post-translational modifications of p53 by ATM/
ATR and SIRT1.  ATM/ATR phosphorylate p53 at serine-15 
and serine-20, which reduces binding affinity for MDM2 and 
increases transcriptional activity.  SIRT1 de-acetylates p53 
lysine-382 within the nuclear localisation signal and represses 
p53 transcriptional activity.
N-terminal C-terminalDNA binding domain
ATM/ATR
S15/S20
SIRT1
K382
Acetylation is another important post-translational 
modification that regulates p53 activity [121].  The same 
lysine residues on p53 that are involved in ubiquitination are 
susceptible to acetylation and it has been shown that 
acetylation of these residues inhibits MDM2 binding [122]. 
Furthermore, acetylation potentiates transcriptional activity 
by promoting co-activator recruitment at p53-target genes, as 
well as enhancing DNA binding [123,124].  It has also been 
established that loss of p53 acetylation sites abrogates a 
p53-mediated response to DNA damage [125].  Sirtuin 1 
(SIRT1), a NAD+ dependent deacetylase, is a p53 co-factor 
which inhibits p53 activity by site-specific deacetylation of 
lysine 382 within the nuclear localisation signal of p53 (figure 
1.3) [126].  Up-regulated SIRT1 expression is associated 
with many cancers as a result of enhanced p53 suppression. 
Furthermore, functional loss of the tumour suppressor 
hypermethylated in cancer 1 (HIC-1) increases SIRT1 activity 
and attenuates p53-mediated cell cycle arrest and apoptosis, 
in response to DNA damage [127].
The pro-apoptotic features of p53 are key to its tumour 
suppressor ability [128].  Central to p53-mediated apoptosis 
in response to DNA damage is Bcl-2-associated X protein 
(bax).  The bax protein is encoded by the p53-inducible BAX 
gene and is up-regulated in response to DNA damage [70]. 
Bax is a member of the Bcl-2 protein family containing 
multiple BH-domains, which are characteristic of the Bcl2 
family, and provide sites for hetero- or homo-dimerisation 
[129].  During apoptosis, bax forms oligomeric complexes 
within the outer-mitochondrial membrane, resulting in 
cytochrome C  release and induction of apoptosis.  The role 
of p53 and bax in apoptosis will be discussed in detail later.
Although much data exists describing the role of p53 in 
coordinating cell cycle arrest and apoptosis, our knowledge 
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of how p53 mediates cell fate under different responses, is 
not as well understood [130].  It is known that cell fate 
decisions made by p53 are tissue and stimulus specific [131]. 
As well as this, specific post-translational modifications and 
co-factor interaction, are involved in determining p53 
transcriptional programmes [132,133,134].  The proliferative 
rate of a cell is associated with apoptotic induction by p53 in 
response to DNA damage and it has been shown that 
pharmacological induction of quiescence protects cells from 
genotoxic stress [135].  As well as this, cycling cells 
demonstrate increased E2F activity, which is associated with 
cell priming towards p53-mediated apoptosis [136]. 
Recently, a model based on p53 pulses has been proposed, 
which states that p53 target genes are selectively induced 
based on an oscillatory signal relayed by ATM [137].  At low 
levels of DNA damage, cell cycle arrest and cell survival is 
promoted by transcription of p21, as a consequence of a low 
level of p53 pulses.  In the presence of sustained p53 pulses, 
apoptosis is triggered and cell death occurs [138].
" 1.6: The eukaryotic cell cycle
The eukaryotic cell cycle is a sequential and temporal 
process which ultimately leads to cellular replication and 
division.  Efficient and complete cell cycle is required for 
proper organismal development, from zygote maturation, 
through to tissue renewal and regeneration.  Therefore, it is a 
critical that effective regulation and control of the cell cycle is 
maintained to avoid potentially  catastrophic consequences 
such as neoplastic transformation [139].  In a developed 
organism, many cells are quiescent or senescent, meaning 
that they have exited the cell cycle and are in a resting 
phase.  This phase is one of five cell cycle phases and is 
termed gap 0 or G0 phase [140].  In some cell types, such as 
heart muscle cells or neurones, this phase represents a 
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terminal differentiation step where complete cellular maturity 
is reached [141].  In the presence of growth factors and/or 
cytokine stimulation, cells become primed for proliferation 
and various signalling pathways are activated to initiate cell 
cycle progression from G0 [142].  Initiation of cell division 
begins with entry into gap 1 (G1) phase of the cell cycle. 
This is the first step within the pre-mitotic stage called 
interphase.  This phase is commonly known as the growth 
phase as it is during this period that biosynthesis of proteins 
and enzymes required for successful replication and cell 
division occurs.  Once conditions are optimal, the cell cycle 
progresses to S-, or ʻsynthesisʼ phase, where DNA content is 
doubled in preparation for cell division.  Once the cell is 
ready it enters the final interphase stage called gap 2 (G2) 
phase.  During this phase, further biosynthesis occurs, 
primarily of microtubules and other structures required for 
mitosis.  Finally, the cell cycle progresses into M-, or ʻmitoticʼ 
phase, where two daughter cells are generated from the 
parent (figure 1.4) [143,144].
Throughout the cell cycle the status of the cell is monitored 
periodically to ensure cell division occurs correctly and to 
avoid the replication of pathogenic genomic mutations.  The 
transition between G1/S-phase, S/G2-phase and G2/M-
phase is tightly controlled by cell cycle checkpoints [145]. 
These checkpoints are ultimately controlled by the sequential 
and temporal formation of cyclin-cyclin dependent kinase 
(CDK) complexes (figure 1.5) [146].  The cyclins are a family 
of proteins that activate CDKs to drive cell cycle progression. 
Their intracellular concentrations vary  depending on the 
phase of the cell cycle and the expression of specific cyclins 
is required for complete cell cycle progression.  The 
formation of specific cyclin/CDK complexes during distinct 
phases of the cell cycle is crucial to regulation of target 
proteins involved in cell cycle progression [147].
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Figure 1.4.  The eukaryotic cell cycle (Adapted from 
Freeman 1995 [144].  The cell cycle consists of four distinct 
phases; Gap1 (G1), S-phase, Gap  2 (G2) and mitosis (M). 
Quiescent cells are held in GO phase until stimulated to enter 
the cell cycle at G1-phase.  At this point conditions are 
monitored for effective cell cycle progression to occur and 
biosynthesis of proteins required for cell cycle progression 
occurs.  During S-phase all genomic material is duplicated 
(2n) and cell components for replication are manufactured. 
Gap 2 phase allows for further biosynthesis of components for 
cellular replication.  The cell then enters mitosis where two 
daughter cells are generated from the parent.
Figure 1.5.  Expression of specific cyclins regulate 
cell cycle progression.  Progression through the cell 
cycle is controlled by the formation of specific cyclin-CDK 
complexes at distinct cell cycle phases.  The sequential 
expression of phase specific cyclins helps to control the 
cell cycle.
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Cellular progression through the G1/S transition is controlled 
by temporal formation of cyclin D/CDK4/6 and cyclin E/CDK2 
complexes driven by growth factor stimulation [148].  The 
formation of these complexes during G1-phase results in 
phosphorylation of the target protein, retinoblastoma protein 
(pRB), which controls progression to S-phase via its 
associating with E2F transcription factors (figure 1.6) [149]. 
E2F transcription factors exist within the cell as heterodimers 
comprised of E2F and DP subunits.  Both DP and E2F 
contain DNA-binding motifs and synergistically act to 
promote transcription [150,151].  Under normal conditions i.e. 
cellular quiescence, E2F-DP is stably associated with pRB, 
which restricts E2F transactivation [152].   Stimulation of cell 
proliferation by growth factors and mitogenic signals results 
in activation of cyclin D/E and subsequent binding to pRB as 
a result of upstream signalling pathways including Ras/MAP 
kinase and PI3K.  Following this, phosphorylation of pRB by 
CDK4/2 induces a conformational change to pRB, which 
results in E2F-DP dissociation from the repressor complex 
[153,154].  Activation of the E2F-transcriptional programme 
initiates cell cycle progression by up-regulating genes such 
as CDK2, which is required for progression from G1-phase to 
S-phase [155].  The importance of pRB in controlling cell 
cycle progression is highlighted by its role as a tumour 
suppressor.  Consequently, pRB mutations and dysregulation 
of pRB activity is common in many cancers [156].
The progression of the cell cycle through S-phase is driven 
by the temporal increase in cyclin A-CDK2 complexes. 
These complexes remain elevated through G2-phase but are 
rapidly degraded as the cell enters M-phase [157].  However, 
it is the formation of cyclin B/CDK1 complexes that is 
required for complete G2/M-transition [158].  The regulation 
of CDK1 expression during the G2/M transition is complex 
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and involves tight regulation by a variety of proteins (figure 
1.7).  Newly formed complexes are imported into the nucleus 
where they are phosphorylated by CDK-activating kinase 
(CAK) and polo-like kinase (PLK) [159].  As this step occurs 
early in G2-phase, inactive cyclin B/CDK1 complexes are 
held in a hyper-phosphorylated state by Wee1 and Myt1.  At 
the G2/M transition boundary, CDK1 is activated by an 
opposing de-phosphorylation step catalysed by the 
phosphatase, cell division cycle 25 (CDC25) [160,161].  The 
rapid activation of CDK1 is maintained by  a positive feedback 
loop involving activation of CDC25 via phosphorylation from 
CDK1.  It is no surprise that CDC25 is over-expressed in 
many tumours considering the regulatory function it plays in 
cell cycle progression [162].
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Figure 1.6.  Regulation of E2F transcription by pRB and 
cyclin D-CDK4.  In its hypo-phosphorylated state pRB is in 
complex with E2F and DP and represses E2F transcriptional 
activity.  Formation of cyclin D/CDK4 complexes during G1-
phase of the cell cycle results in phosphorylation of pRB and 
dissociation from the E2F-DP dimer.  This allows E2F-DP to 
bind to E2F response elements and initiate gene 
transcription and cell cycle progression.
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The tight regulation of cell cycle control through these 
checkpoints ensures correct replication of cells and prevents 
tumorigenesis by suppressing cellular proliferation.  A major 
dysfunction in tumour cells is activation of a hyper-
proliferative state and the dysregulation of cell cycle 
checkpoints is common in many cancers [163,164].  It has 
been shown that cyclin E is over-expressed in around 70% of 
breast cancer cases and this has been associated with 
defects in pRB function in 40% of tumours compared to no 
pRB defects in tumours with normal cyclin E levels [165,166]. 
As well as this, over-expression of cyclin D is common in 
human cancers, particularly in mammary carcinogenesis 
[167].  Over-expression of cyclin D has been shown to be a 
neoplastic marker in breast tissue and its amplification is 
maintained throughout disease progression [168].
A major part of cell cycle checkpoints is to monitor genomic 
stability and remove damaged DNA bases prior to cell 
division.  The G2/M transition is the primary checkpoint 
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Figure 1.7.  Regulation of CDK1/cyclin B1 complexes 
during the cell cycle.  Early in G2-phase, CDK1/cyclin B 
complexes are imported into the nucleus, where they are 
activated following phosphorylation by CAK.  Cyclin/CDK 
complexes are held in an inactivate state following hyper-
phosphorylation by Wee1/Myt1.  Late in G2-phase, 
complexes are rapidly activated as a result of de-
phosphorylation by CDC25, which drives progression into M-
phase.
activated in response to DNA damage and involves a 
multitude of proteins and signalling networks.  Dysregulation 
of single proteins within the G2/M transition can drive 
tumorigenesis by allowing replication of damaged DNA [169]. 
In particular, the tumour suppressor p53, plays a central role 
in regulating the G2/M transition in response to DNA damage 
and is dysfunctional in over 50% of all human cancers.  p53 
is responsible for inducing cell cycle arrest in response to 
DNA damage.  The cyclin-dependent kinase inhibitor p21WAF/
CIP1 is transcriptionally  regulated by p53 and is vital for DNA 
damaged induced growth arrest [170].  Regulation of the cell 
cycle is controlled by p21-dependent inhibition of cyclin-
CDK2/1 complexes and subsequent abrogation of pRB-
dependent cell cycle progression [171].  In response to DNA 
damage, p53-mediated increases in p21 expression are 
required to induce cell cycle arrest in G1-phase [172].  In 
addition to this, p21 has been shown to interact with 
proliferating cell nuclear antigen (PCNA), a co-factor for 
DNA polymerase activity.  Over-expression of p21 inhibits 
PCNA and DNA synthesis resulting in cell cycle arrest in G1 
and G2-phase [173].  Furthermore, it has been shown that 
p53 and p21 are both essential, to sustain G2-arrest 
following DNA damage [174].  Other transcription factors 
such as those of the FOXO family  are also involved in 
regulation of the cell cycle and in conjunction with p53, 
provide a signalling framework that ensures effective control 
of cell proliferation, cell metabolism and cell death.
"
" 1.7:  Forkhead box class O3 transcription factor
The forkhead box (FOX) proteins are a family of transcription 
factors characterised by the presence of a fork head DNA-
binding domain [175].  There are more than 100 members 
that have been discovered in humans and are categorised as 
FOXA to FOXR [176].  Members of the FOXO class of FOX 
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proteins share the characteristic of being regulated by the 
insulin/PI3K/protein kinase B (Akt) signalling pathway [177]. 
The four human FOXO isoforms have been designated 
FOXO1, FOXO3a, FOXO4 and FOXO6.  All have been 
identified as important regulators of cellular proliferation, cell 
cycle arrest, apoptosis, autophagy and metabolism 
[178,179,180].  The FOXO proteins have been implicated as 
potential therapeutic targets in a wide range of diseases 
because of their control over angiogenesis, stem cell 
proliferation, neurodegeneration, tumorigenesis and cellular 
ageing [181].  Down-regulation of FOXO3a activity is often 
seen in cancers and ERK-mediated inhibition of FOXO3a 
has been shown to promote tumorigenesis [182]. 
Furthermore, inhibition of FOXO3a by IκB kinase, has been 
shown to promote breast cancer tumorigenesis [183]. 
Enhancing FOXO3a activity has recently emerged as an 
effective therapeutic target for cancer chemotherapy.  In 
particular,  FOXO3a regulation of genes involved in cell cycle 
and apoptosis, has been suggested to explain the cytotoxic 
effect of many anti-cancer agents [184].  As well as this, 
over-expression of FOXO3a, has been shown to inhibit 
breast tumour growth in vitro and in vivo [183].  It is 
uncommon that FOXO3a is mutated or dysfunctional in 
cancer but more often it is apparent that the problem lies with 
the regulatory pathways controlling FOXO3a activity  [185]. 
Therefore, FOXO3a cannot be considered a direct tumour 
suppressor like p53, but rather acts as ʻsilent guardianʼ which 
is activated to preserve the cell under harsh conditions [186]. 
In fact, p53 has been shown to transactivate FOXO3a within 
a longevity intron of the FOXO3 gene, suggesting that p53 
and FOXO3a form a regulatory network to guard against 
age-related diseases [187].
The PI3K/Akt signalling pathway is involved in cell growth, 
differentiation and development and as such is frequently 
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dysregulated in cancer (figure 1.8) [188].  PI3K are members 
of a lipid kinase family characterised by their ability  to 
phosphorylate the hydroxyl group of inositol in phospholipids. 
PI3K exist as dimers compromised of an adaptor sub-unit 
(p85) and a catalytic sub-unit (p110) [189].  
PI3K signalling is activated by membrane bound receptor 
tyrosine kinases (RTKs).  RTKs can be activated by a variety 
of extracellular substrates including growth factors, cytokines 
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Figure 1.8.  PI3K/Akt signalling regulated by receptor 
tyrosine kinase.  Activation of membrane bound receptor 
tyrosine kinases recruits PI3K to the cytoplasmic domain. 
This in turn brings PI3K within range to phosphorylate PIP2 
to PIP3.  Akt interacts with PIP3 via its PH-domain which 
exposes regulatory sites on Akt.  Phosphorylation of these 
sites by PDK1 results in Akt activation and subsequent 
regulation or cell survival and cell proliferation.
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and hormones [190].  Activation of receptor tyrosine kinases 
in the plasma membrane induces an association of PI3K with 
the cytosolic component of the receptor.  This in turn 
generates production of phosphatidylionsitol-3,4,5-
t r i p h o s p h a t e ( P I P 3 ) b y p h o s p h o r y l a t i o n o f 
phosphatidylinositol-4,5-bisphosphate (PIP2), mediated by 
RTK-mediated activation of p110 [191].  Proteins, such as 
Akt, contain a pleckstrin homology (PH) domain which 
enables binding to PIP3 and subsequent Akt activation [192]. 
The interaction of PIP3 with Akt induces a conformational 
change that exposes two regulatory phosphorylation sites 
[193].  The protein kinase, phosphoinositide-dependent 
kinase-1 (PDK1), phosphorylates Akt in a process that is 
crucial for effective Akt membrane dissociation and activation 
[194].  Akt is a serine/theronine protein kinase with multiple 
cellular targets that regulate cellular survival and metabolism 
[195].  It is not surprising then that alterations of the PI3K/Akt 
signalling pathway are associated with tumorigenesis and 
disease progression.
FOXO transcription factors are directly regulated by Akt in 
response to RTK activation by insulin or growth factors [196]. 
Phosphorylation of FOXO3 at three conserved sites 
(threonine-32, serine-253 and serine-315) by Akt triggers a 
rapid localisation from the nucleus to the cytoplasm [197]. 
This re-localisation of FOXO3a protein negatively regulates 
its transcriptional activity, thus, Akt activation in the presence 
of growth factors effectively suppresses FOXO3a activity 
[198].  This is in part mediated by FOXO3a association with 
the nuclear export protein 14-3-3, which has affinity for 
phosphorylated FOXO3a within the nucleus [199].  Binding of 
14-3-3 to FOXO3a induces a conformational change within 
the nuclear localisation signal (NLS) and promotes nuclear 
export (figure 1.9) [185].  Phosphorylation of FOXO3a by Akt 
is directly associated with 14-3-3 binding and the opposing 
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dephosphorylation of FOXO3a by PP2A is required for its 
dissociation from 14-3-3 [200].  Nuclear export of FOXO3a is 
also required for proteasomal degradation following 
ubiquitination promoted by  Akt-mediated cytoplasmic 
localisation of FOXO3a [201]. However, stress-induced 
phosphorylation of 14-3-3 by c-Jun N-terminal kinase (JNK) 
reduces its FOXO3a binding capacity and directly inhibits 
nuclear export of FOXO3a thereby increasing its 
transcriptional activity.
FOXO3a is also regulated by acetylation and the deacetylase 
SIRT1 is a critical regulator of FOXO3a activity [202]. 
Deacetylation of FOXO3a by SIRT1 produces a dual effect 
which inhibits FOXO3a promotion of cell death but increases 
FOXO3a-dependent cell cycle arrest and stress resistance 
[203].  In this way, SIRT1 can directly  modulate the cellular 
response under different conditions by determining cell fate 
orchestrated by FOXO3a [204].  It is thought that this is 
responsible for longevity  associated with increased SIRT1 
activity.  However, in tumour cells, over-active SIRT1 can 
inhibit apoptosis and promote cell survival in the face of 
cellular stress [205].  This can not only  cause tumorigenesis 
but also lead to chemotherapeutic drug resistance [206]. 
FOXO transcription factors are activated in response to 
oxidative stress, metabolic dysregulation, growth factor 
withdrawal and DNA damage.  Removal of growth factors 
inhibits PI3K/Akt signalling and increases nuclear localisation 
of FOXO3a leading to gene transcription.  In the nucleus, 
FOXO3a interacts with target gene promoters via the FOX 
DNA-binding domain, to promote transcription.  Nuclear 
FOXO3a can induce cell cycle arrest through expression of 
the CDK-inhibitor p27kip1 [207].  Activation of p27 induces cell
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cycle arrest at the G1/S-phase checkpoint and it has been 
shown that p27 expression is vital for FOXO3a induced cell 
cycle arrest [179].  As well as this, FOXO3a can also 
promote expression of p21 and repress expression of cyclin 
D, contributing to G1-phase arrest [208].  It has also been 
shown that FOXO3a can induce arrest in G2-phase by 
promoting expression of growth arrest and DNA damage-
inducible protein 45 (GADD45) [209].  One of the important 
functions of FOXO3a-driven transcription is to regulate 
cellular stress resistance by increasing cellular defence to 
stress.  In the presence of excess cellular oxidants FOXO3a 
increases cellular levels of the anti-oxidant enzymes, 
manganese superoxide disumutase and catalase, which 
remove specific reactive oxygen species [210].  
Cellular energy homeostasis is tightly regulated and FOXO3a 
has been identified as a key transcription factor that controls 
cellular responses to energy depletion [211].  FOXO3a can 
be activated by an increased AMP/ATP ratio mediated by 5ʼ 
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Figure 1.9.  PI3K/Akt regulated nuclear-cytoplasmic 
shuttling of FOXO3a.  In the presence of growth 
signals PI3K.Akt signalling phosphorylates nuclear 
FOXO3a at three conserved residues and promotes its 
binding to the nuclear export protein 14-3-3.  This 
induces cytoplasmic localisation of FOXO3a and 
switches off FOXO3a transcription.
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AMP-activated protein kinase (AMPK) [212].  In the presence 
of increased AMP concentrations, AMPK undergoes a 
conformational change, which exposes an active site within 
its α-subunit [213].  This allows an AMPK-kinase (AMPKK), 
such as liver kinase B1 (LKB1), to phosphorylate 
threonine-172 and activate AMPK [214].  Activation of AMPK 
due to energy depletion directly results in phosphorylation of 
FOXO3a and promotion of FOXO3a nuclear translocation 
[186].  It has been shown that FOXO3a is phosphorylated by 
AMPK at six conserved sites, five of which are located within 
the transactivation domain [215].  The role of the AMPK-
FOXO3a axis in longevity  was shown to be vital to the effects 
of dietary restriction on healthy ageing and lifespan [216]. 
Interestingly. the AMPK-FOXO3a pathway is still inducible in 
cancer, providing a potential therapeutic target for cancer 
chemotherapy [186].  Decreasing energy levels through 
glycolysis inhibit ion effectively  activates FOXO3a 
transcriptional programmes associated with cell cycle arrest, 
autophagy and apoptosis [217,218].  In response to a 
reduced energy  supply  FOXO3a drives cell cycle arrest and 
autophagy in an attempt to retain energy and produce more 
ATP.  This is mediated by the transcription of autophagy 
genes such as ATG6, 7, 12 and up-regulation of catabolic 
enzyme expression [219].  
Under certain conditions, FOXO3a activation can induce an 
apoptotic transcriptional programme, including transcription 
of TRAIL, Fas-L and bim [220,221].  This suggests FOXO3a 
as a potential anti-cancer drug target and indeed the 
chemotherapeutic drug, paclitaxel, has been shown to induce 
apoptosis in breast cancer cells via nuclear localisation of 
FOXO3a and transcription of bim [222,223].  Furthermore, 
cytoplasmic localisation of FOXO3a has been shown to 
correlate with poor survival in breast cancer patients [224]. 
As well as this, persistent metabolic stress leads to a 
51
FOXO3a transcriptional switch from cell survival to cell 
death.  This is characterised by an increase in apoptotic 
gene transcription associated with autophagic cell death 
[225,226].
! 1.8: Cancer cell metabolism - the ʻWarburg effectʼ
A definitive feature that distinguishes cancer cells from 
healthy cells is an alteration in their metabolic programming. 
Under normal conditions cells undergo aerobic respiration to 
produce ATP via oxidative phosphorylation and the electron 
transport chain in the mitochondrial membrane.  In contrast 
to this, cancer cells undergo high rates of glycolysis in the 
cytosol, which is coupled with lactic acid fermentation and a 
comparatively  low ATP output compared to oxidative 
phosphorylation [227].  This phenomenon was termed the 
Warburg effect after Otto Warburg, who discovered that even 
in the presence of ample oxygen, cancer cells will 
preferentially  metabolise glucose by glycolysis [228].  The 
Warburg effect is associated with an increased cellular 
uptake of glucose in order to maintain energy homeostasis in 
the absence of efficient ATP production [229].
The main theory behind the Warburg effect dictates that 
clonal selection favours glycolytic respiration.  This means 
that natural selection at a cellular level results in the 
emergence of clones that are able to survive in low oxygen 
conditions [230].  This theory is highly probable due to the 
fact that the early tumour microenvironment is hypoxic as 
access to local blood supplies are restricted [231].  This is 
regulated by the hypoxia-inducible transcription factors (HIF) 
which respond to changes in oxygen availability.  Under 
normoxic conditions, HIF becomes hydroxylated at 
conserved proline residues, which marks then for 
proteasomal degradation following ubiquitination [232].  The 
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hydroxylation of HIF is dependent on the presence of 
oxygen, thus, in hypoxic conditions HIF is stabilised and 
transcriptionally active [233].  HIF activation results in 
increased expression of enzymes and proteins associated 
with glycolysis, including glucose transporters and inhibitors 
of mitochondrial metabolism [234].  Interestingly, in tumours, 
HIF remains dependent on oxygen levels and therefore 
cannot be entirely responsible for the Warburg effect [235].
As mentioned in section 1.7, the PI3K/Akt signalling pathway 
plays a role in inhibiting FOXO3a-mediated regulation of 
metabolism.  As well as this, Akt signalling is associated with 
increased glucose uptake and HIF-independent glycolysis 
[236,237].  Mutations within the tumour suppressor PTEN, a 
negative regulator of Akt activation, can result in 
constitutively  active Akt and alterations in cellular metabolism 
[238].  It has been shown that Akt over-activation can 
increase membrane translocation of glucose receptors, 
a c t i v a t e r a t e - l i m i t i n g e n z y m e s s u c h a s 
phosphofructokinase-1 (PFK1) and inhibit FOXO3a [239].  In 
turn, FOXO3a inhibition prevents suppression of glycolytic 
gene expression, which could contribute to the Warburg 
effect [240].
The metabolic regulation of AMPK by the tumour suppressor 
LKB1 links cell metabolism to tumorigenesis [241].  LKB-1 is 
an upstream activator of AMPK and is often mutated in 
human lung and cervical cancers [242,243].  The protein 
kinase mTOR is a suppressed by AMPK activity, thus, 
dysregulation in AMPK signalling could enhance mTOR-
mediated gene expression [244].  Consequently, one of the 
mTOR targets is HIF-1, which provides a link between AMPK 
dysregulation and cancer cell metabolism [245].  Recently, 
the use of AMPK modulators, has been proposed as 
potential anti-cancer therapy [246].  Reducing glycolysis in 
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cancer cells using p38α MAPK inhibitors has been shown to 
induce FOXO3a-dependent changes in metabolic 
programming and push tumour cells towards autophagic cell 
death [218].  This highlights the potential for targeting the 
AMPK-FOXO3a axis in cancer chemotherapy. 
" 1.9:  Cell death - Apoptosis, necrosis and 
autophagy
Apoptosis is a process of controlled or programmed cell 
death resulting in elimination of a cell. It is an energy-
dependent process which leads to characterist ic 
morphological changes including membrane blebbing, 
reduction in cellular volume, nuclear fragmentation, 
chromatin condensation and DNA fragmentation [247]. 
Apoptosis is an evolutionarily conserved process and several 
of the key  enzymes involved in apoptosis have shared 
homology with bacteria [248].  Apoptosis is an essential 
process for organism development and homeostasis.  For 
example, apoptosis is required for effective tissue 
remodelling, such as generation of digits by selective killing 
of cells in the intervening webbing and also the shaping of 
organs [249].  Apoptosis is also a vital part of immune system 
development as it is essential for removal of self-reactive T 
and B cells [250].  Furthermore, apoptosis is the process by 
which infected cells are induced to die by cytotoxic T-
lymphocytes [251].  Defects in apoptosis are associated with 
a variety of pathologies including atrophy, cancer, HIV 
progression, autoimmunity, developmental defects and result 
in increased cell survival [252,253,254].
The process of apoptosis can be divided into two effector 
arms termed the intrinsic and extrinsic apoptotic pathways. 
The intrinsic pathway, also known as the mitochondrial 
pathway, of apoptosis is dependent on mitochondrial 
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permeabilisation by Bcl-2 family proteins and subsequent 
release of pro-apoptotic factors (figure 1.10) [255,256]. 
Intracellular stress from DNA damage, heat-shock, radiation, 
nutrient deprivation, hypoxia and viral infection results in 
activation of pro-apoptotic Bcl-2 family proteins including bax, 
bad, bim, bid and bak [257].  Oligomerisation of these 
proteins is responsible for formation of the mitochondrial 
apoptosis-induced channel (MAC) and subsequent release of 
pro-apoptotic mediators including cytochrome C  and Smac/
Diablo [258].  Permeabilisation of the mitochondria outer 
membrane via MAC formation represents the commitment 
step in apoptosis.  It has been shown that expression of bax 
and/or bax is essential for MAC formation and induction of 
apoptosis [259].  Under normal conditions, bak is associated 
with the mitochondrial outer membrane, but is prevented 
from oligomerisation by the presence of voltage-dependent 
anion-selective channel protein 2 (VDAC2) [260].  Bak 
oligomerisation is induced during apoptosis following 
disruption of the bak-VDAC2 interaction by a truncated(t) 
form of bid [261].  In comparison, bax is located in the 
cytosol, until mitochondrial membrane translocation is 
stimulated by apoptotic signals.  Translocation of bax to the 
outer mitochondrial membrane is associated with a rapid loss 
of mitochondrial membrane potential and release of 
cytochrome C [262,263].
Formation of the MAC results in depolarisation of the outer 
membrane and release of mediators of apoptosis including 
cytochrome C and second mitochondria-derived activator of 
caspases (Smac/diablo) [264].  Cytochrome C  is a direct 
mediator of apoptosis through activation of the caspase     
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cascade [265].  The caspase cascade is the final stage in the 
initiation of apoptosis and is responsible for the characteristic 
morphological changes associated with cell death by 
apoptosis.  Caspases are a group of aspartate-specific 
cysteine proteases that are sequentially activated to promote 
apoptosis [266].  Activation of the intrinsic apoptotic pathway 
triggers autocatalytic cleavage of the initiator caspase 9 from 
the pro-caspase isoform to generate a catalytic sub-unit. 
Activated caspase 9 directly cleaves pro-caspase 3 and 7 to 
form active caspases that induce the morphological changes 
of apoptosis [267].  Caspase 9 is activated by self-cleavage 
upon formation of the apoptosome, a large multi-protein 
complex which is formed in the presence of cytochrome C 
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Figure 1.10.  Intrinsic apoptosis pathway (Adapted 
from Testa 2004 [256]).  The intrinsic apoptosis pathway 
relies on mitochondrial permeabilisation following 
formation of MACs in the outer membrane by Bcl-2 family 
proteins such as bax and bak.  Depolarisation of the outer 
membrane releases cytochrome C and Smac/Diablo 
which promote caspase cleavage and induction of 
apoptosis.  Cytochrome C interacts with APAF-1 to form 
the apoptosome which initiates a caspase cascade 
following proteolytic cleavage of pro-caspase 9.  Smac/
Diablo inhibits IAPs which promotes pro-caspase 
cleavage.
and the adaptor protein, apoptotic protease activating factor 
1 (APAF-1) [268].  The apoptosome structure is a heptameric 
wheel-shaped complex with APAF-1 at i ts core. 
Oligomerisation of APAF-1 is dependent on cytochrome C 
binding within the C-terminus of APAF-1 and binding of 
dATP [269,270].  This then allows the synchronised 
recruitment of pro-caspase 9 to the caspase activation and 
recruitment domain (CARD) of APAF-1 [271].  The active 
apoptosome requires seven APAF-1 molecules in a 1:1 ratio 
with cytochrome C  before cleavage of the caspase 9 
zymogen is initiated [272].  Although APAF-1 is required for 
mitochondrial dependent apoptosis, it has also been 
demonstrated that the process can be initiated in a 
cytochrome C/apoptosome-independent manner [273].
The release of Smac/DIABLO from mitochondria after 
formation of the MAC can also facilitate caspase activation. 
Smac is an inhibitor of inhibitor of apoptosis proteins (IAPs), 
a family of proteins, which bind to and inactivate caspases 
[274].  Smac contains an IAP-binding motif within the N-
terminus, which is exposed upon mitochondrial export, 
following proteolytic cleavage of the mitochondrial 
localisation signal of Smac.  Cytosolic Smac forms 
homodimers which bind IAPs and prevent inhibition of 
caspase activity [275].  Within the intracellular environment, 
the balance of IAPs and pro-apoptotic signals from 
cytochrome C and Smac, are in a dynamic equilibrium [276]. 
This means that the presence of IAPs can block an apoptotic 
response to small amounts of cytochrome C release but 
increased mitochondrial damage can cause leakage of 
Smac, inhibition of IAPs, and amplification of a pro-apoptotic 
signal.  Consequently,  tumour cells have been shown to 
express high levels of IAPs, which may contribute to 
chemotherapy resistance and tumorigenesis [277].
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The second method of apoptosis induction is known as the 
extrinsic pathway (figure 1.11) [278].  Activation of this 
pathway is initiated by membrane-associated death 
receptors, which belong to the tumour necrosis factor (TNF) 
receptor family, and are characterised by the presence of a 
cytoplasmic death domain [279,280].  The most commonly 
studied of these receptors is the FAS receptor (FasR) also 
known as cluster of differentiation 95 (CD95).  Activation of 
the FasR is mediated by trimerisation of the type-II 
transmembrane protein Fas ligand (FasL), which in turn 
induces trimerisation of the FasR [281].  This produces 
aggregation of the FasR death domains and induces 
internalisation of the receptor complex allowing the adaptor 
molecule, Fas-associated protein with death domain (FADD), 
to bind to the death domains of FasR [282].  FADD contains 
a death effector domain (DED) which is able to bind and 
induce self-cleavage of the zymogen of initiator caspase 8 
[283].    Oligomerisation of active caspase 8 causes its 
release from the death-inducing signalling complex (DISC) 
where it cleaves effector caspases and initiates apoptosis 
[284].
The tumour suppressor, p53, plays an important role in 
regulating apoptosis.  Activation of p53 by cellular stress has 
been shown to induce apoptosis via transcription dependent 
and independent mechanisms [285].  p53 has been 
implicated in the activation of both the extrinsic and the 
intrinsic apoptotic pathways [286].  Transcriptionally  active 
p53 up-regulates genes for FasL, death receptor 5 (DR5) 
and p53 apoptosis effector related to PMP-22 (PERP) 
proteins which are involved in activation of the extrinsic 
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apoptosis pathway.  DR5 and PERP are up-regulated in 
response to DNA damage and contribute to apoptosis 
induced by genotoxic stress [285].  The intrinsic pathway is 
mediated by pro-apoptotic members of the Bcl-2 family  of 
proteins. The BAX gene is a transcriptional target of p53 and 
the requirement for bax in apoptosis appears to be cell-type 
specific [287].  In response to DNA damage, p53-mediated 
transcription of p53 up-regulated modulator of apoptosis 
(PUMA), induces apoptosis via bax activation [288].  PUMA 
dissociates bax and bak from their repression complex with 
Bcl-2 and other anti-apoptotic Bcl-2 family proteins.  The 
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Figure 1.11.  Extrinsic apoptosis pathway (Adapted from 
Bazzoni 1996 [278]).  The extrinsic apoptosis pathway is 
initiated by membrane-associated death receptors such as 
FasR.  Trimerisation of FasR recruits FADD and pro-caspase 
8 to the intracellular death domain of FasR.  Proteolytic 
cleavage of pro-caspase 8 initiates a caspase cascade that 
results in apoptosis.
APAF-1 promoter also contains p53-responsive elements 
and transactivation of p53 has been shown to directly 
promote apoptosome formation [289].
Transactivation of p53 is not essential for it to carry out its 
pro-apoptotic functions and mechanisms of transcription 
independent apoptosis have been described [290,291].  In 
the presence of stress stimuli, p53 is localised to the 
mitochondrial membrane, where it promotes membrane 
permeabilisation by inhibiting Bcl-2 [292].  In vitro 
experiments have demonstrated that purified p53 directly 
induces mitochondrial outer membrane permeabilisation and 
cytochrome C release from isolated mitochondria [293].  It is 
thought that cytosolic p53 acts as a BH3-only protein and 
interacts with other Bcl-2 family proteins containing multiple 
BH-domains to form the MAC  [294].  The effect of 
transcription-independent apoptosis is present in cell lines 
carrying mutations generating non-transcriptional forms of 
p53 [289,295].  As discussed in section 1.5, activation of p53 
induces nuclear translocation and transcriptional activation, 
suggesting that transcription-independent apoptosis must be 
part of a wider regulatory programme influenced by other co-
factors.  It has been proposed that specific post-translational 
modifications could regulate nuclear shuttling of p53 and 
drive transcription-independent apoptosis [294].  Acetylation 
of p53 at lysine-120 has been shown to promote 
mitochondrial association of p53 during apoptosis. 
Acetylation of p53 at lysine-120 displaces the bak-inhibitory 
protein, induced myeloid leukaemia cell differentiation protein 
(MCL-1), from bak allowing oligomerisation and MAC 
formation [296].  Furthermore, it has been demonstrated that 
acetylation at lysine-320, 373 and 382 is required for 
transcription-independent apoptosis mediated by p53 [297]. 
As well as this, up-regulation of the transcription factor, 
forkhead box O3 (FOXO3a), has been shown to induce 
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cytoplasmic accumulation of p53  and induce apoptosis upon 
serum starvation [298].
Necrosis is defined as premature cell death in an un-
progammed and inflammatory manner [299].  In contrast to 
apoptosis, necrosis does not result in cytokine release or 
exposure of phosphatidylserine which signals apoptotic cells 
for phagosome removal.  This consequently results in a 
localised inflammatory build-up of cell debris.  As well as this, 
membrane integrity  and apoptotic bodies are not formed 
during necrosis, which can lead to leakage of cellular 
lysosomes and proteases that may damage near-by cells 
causing contiguous tissue necrosis [300].  Necrosis is 
characterised by distinct morphological features including cell 
swelling, chromatin degradation, loss of membrane integrity 
and DNA hydrolysis [301].  Necrosis is thought of as 
accidental cell death but it is known that in the absence of 
phagocytosis, apoptotic bodies may undergo a type of 
necrosis induced by the apoptotic programme [302]. 
Effective cancer chemotherapy should ideally induce 
apoptotic, not necrotic, cell death in cancer cells.
Autophagy, also known as macroautophagy, is a catabolic 
process characterised by  self-degradation of cellular 
components through the lysosomal machinery [303].  It is 
involved in cell growth, development and homeostasis.  It is 
also a means by which a cell can increase energy levels 
during metabolic stress to coordinate cell survival [304].  De-
regulation of autophagy is involved pathologically in 
neurodegeneration, cancer, cardiomyopathy, liver diseases 
and gastrointestinal disorders [305].  There are several types 
of autophagy, which are distinguished by  the selectivity of the 
autophagic programme, but all converge on the same cellular 
outcome [303].  The process first involves the vacuolation of 
organelles or proteins in a double-membraned autophagic 
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vesicle.  This is followed by fusion of the vesicle with the 
membrane of a lysosome to form an autophagosome.  Within 
the lysosome the vesicle contents are degraded by 
lysosomal enzymes [306].  During starvation this process can 
be used to catabolically  break down of non-vital components 
into free energy  and nutrients.  It has been shown that the 
PI3K product, PIP3, is required for autophagy [307].  PIP3 
appears to localise at membranes of autophagosomes and 
their inhibition prevents effective autophagosome formation 
[308].  Other important proteins in the autophagy process 
include Beclin-1 and LC3.  LC3 is recruited to 
autophagosomes and converted to LC3 II by site-specific 
proteolysis.  The presence of autophagosomes containing 
LC3 II are a hallmark of autophagy activation [309].  Beclin-1 
is involved in the formation of autophagosomes following 
interaction with PI3K [308].   Furthermore, PI3K/Akt signalling 
is linked to mammalian target of rapamycin (mTOR), which 
represses autophagy in the presence of insulin and growth 
factors [310].
Although autophagy is associated with cellular survival, it has 
become evident that the autophagic machinery  can be 
recruited to kill cells using a caspase-independent form of 
programmed cell death, also termed autophagic cell death 
[311].  Autophagic cell death is morphologically  distinct from 
apoptosis and is characterised by early  organelle 
degradation and very late DNA fragmentation.  Similar to 
apoptosis but in contrast to necrosis, autophagic death is a 
non-inflammatory form of cell death.  It was thought that 
autophagy triggers cell death by inducing apoptosis but 
removal of apoptotic machinery showed that non-necrotic cell 
death could still be induced by an autophagic response. 
Interestingly, removal of the autophagy  genes beclin-1 and 
atg5, prevented cell death in bax and bak double knockout 
murine embryonic fibroblasts [312].  This suggests that 
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autophagic cell death may be involved when apoptosis is 
compromised.  This has positive implications for the 
treatment of cancers, where mutations in apoptotic pathways 
are commonplace.  Beclin-1 deficient mice show reduced 
levels of autophagy and hyper-proliferation of mammary 
epithelial cells suggesting a role for autophagy in tumour 
suppression [313].  However, beclin-1 null cells are not 
resistant to UV-induced cell death, suggesting that the 
tumour suppressor function of beclin-1 is not attributed to 
autophagic cell death [305].  Autophagic cell death plays a 
crucial role to organismal survival as it is able to prevent 
survival of metabolically stressed cells.  Extensive activation 
of autophagic pathways contributes to autophagic cell death 
in cancer cells and provides a potential therapeutic target for 
chemotherapy.
Our increased understanding of cancer cell metabolism, 
evasion of apoptosis and the importance of autophagy has 
been important in identifying novel drug targets for cancer 
therapy.  It is important to expand on current ideas and 
theories in order to better understand how these processes 
interact with each other depending on the conditions 
presented.  This could provide routes to effective 
combination therapies that can selectively target cancer cells 
based on their neoplastic and tumorigenic properties.  High-
throughput synthetic chemistry has been the main method of 
drug discovery in recent years due to rapid technological 
advances and the ability to screen large compound libraries 
[314].  It has become apparent that this method has not 
produced the results that were originally expected and so the 
industry is returning to a ʻback-to-basicsʼ approach involving 
drug discovery from natural products [315,316].
"
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" 1.10:  Fagonia cretica
Fagonia cretica is a herbaceous plant of the Zygophyllaceae 
family.  It is widely  distributed throughout the worlds desert 
regions and can be found growing near dry calcareous rocks 
[317].  In Pakistan Fagonia cretica is part of the indigenous 
system of medicine and its uses as a treatment for many 
ailments is well documented.  It has been reported that it can 
be used to treat fever, dysentery, asthma, urinary discharges, 
liver troubles, typhoid and skin diseases [318].  It is also 
believed that an aqueous decoction is used to treat breast 
cancer.  However, no study has ever been conducted that 
verifies the chemotherapeutic activity of an aqueous extract 
of Fagonia cretica, or attempts to understand the mechanism 
by which the treatment may be effective.  An in-depth 
investigation into the anti-cancer characteristics of Fagonia 
cretica could unveil new and exciting therapeutic targets as 
well as potentially revealing new compounds with anti-cancer 
activity.
Fagonia cretica has been shown to elevate GSH levels as 
well as having strong free radical scavenging properties 
[319].  Compounds isolated from Fagonia cretica also 
demonstrate cytotoxic activity  towards erythrocytes and 
leukocytes [317].  As well as this, Fagonia cretica has been 
shown to have anti-inflammatory  properties including platelet 
aggregation, down-regulation of COX-2 and up-regulation of 
VEGF [319].  Antibacterial effects of Fagonia cretica have 
also been reported [320].  A saponin isolated from another 
species of Fagonia plant, Fagonia indica, has been shown to 
selectively induce apo-necrosis in cancer cells.  Furthermore, 
an aqueous extract of Fagonia indica, was able to 
significantly increase survival time in mice with induced 
tumours.
!
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! 1.11: Aim and hypothesis
The overall aim of this project is to understand the cytotoxic 
mechanism of an aqueous extract of Fagonia cretica on 
human breast cancer cells and to elucidate the active 
component(s) of the extract.  The hypothesis is that an 
aqueous extract will demonstrate selective bioactivity 
towards human breast cancer cells by  inducing cell death or 
growth inhibition.  Furthermore, it can be hypothesised that 
the extract may contain multiple bioactive compounds that 
could work alone or in combination to restrict cell survival.
!
" 1.12:  Objectives
The specific objectives of this project are:
1) To develop methods for the preparation of an 
aqueous Fagonia cretica extract.
2) To determine the specific cytotoxicity of the 
extract towards human breast cancer epithelial cells.
3) To determine the mechanism(s) by which the 
extract treatment inhibits cell proliferation and/or 
induces cell death.
4) Isolate and identify  bio-active compounds from 
the extract for a possible patent.
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Chapter 2:  Materials and Methods
" 2.1:  Reagents, buffers and solutions
" " 2.1.1:  Cell culture
MCF-7 and HMEpC cells were obtained frozen from HPA 
cultures.  MDA-MB-231 cells were a gift from Dr. Stephane 
Gross (Aston University).   For experiments, cells were used 
between passage numbers 8-60.  Cell doubling time for 
MCF-7 and MDA-MB-231 cells was approximately 24 hours.
RPMI 1640 cell culture media with stable glutamine (PAA, 
UK) was supplemented with 10% v/v foetal calf serum 
(Lonza, UK) and 1% v/v penicillin/streptomycin (Lonza, UK) 
(50 U/ml).  Mammary epithelial growth media (Invitrogen, 
UK) was supplemented with mammary  epithelial cell growth 
supplements (Invitrogen, UK) (bovine pituitary extract, 0.4% 
v/v, bovine insulin, 0.5 μg/ml, hydrocortisone, 0.5 μg/ml, 
human epidermal growth factor, 3 ng/ml) and 1% penicillin/
streptomycin (50 U/ml).  Cell culture media was stored at 4°C 
and discarded after 2 months.
! ! 2.1.2:  General reagents
Phosphate buffered saline (PBS) stock solution was 
prepared by dissolving 137 mM NaCl, 2.7 mM KCl, 8 mM 
Na2HPO4 and 1.46 mM KH2PO4 in distilled H2O.
Caffeine stock solution was prepared fresh just before use by 
dissolving  300 mM caffeine in DMSO. For experiments, 
stock solution was diluted in culture media to a final test 
concentration of 3 mM.
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N-Acetyl-L-cysteine (NAC) stock solution was made fresh 
just before use by dissolving 30 mM NAC in culture media. 
For experiments, stock solution was diluted in culture media 
to a final test concentration of 3 mM.
Hydrogen peroxide stock solution (8.8 M) was stored at 4°C 
at diluted immediately before use to 1 M in culture media.
Resveratrol stock solution was made fresh just before use by 
dissolving 3 mM resveratrol in DMSO.
All chemicals were from Sigma unless stated otherwise.
!
! ! 2.1.3:  MTT assay
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) stock solution was prepared to give a concentration of 
12 mM in PBS and stored at 4°C in the dark.
Cell lysis buffer stock solution was prepared by  dissolving 0.7 
M s o d i u m d o d e c y l s u l p h a t e ( S D S ) i n 5 0 % 
dimethylformamide (DMF) with the pH adjusted to pH 4.7 by 
addition of anhydrous glacial acetic acid.
! ! 2.1.4:  DCF-DA assay
Phenol red-free RPMI 1640 cell culture media (PAA, UK) was 
supplemented with penicillin/streptomycin (50 U/ml) and 
stored at 4°C.
2ʼ,7ʼ-Dichlorofluorescien diacetate (DCFH-DA) stock solution 
was made by dissolving in DMSO to a concentration of 10 
mM and was stored at -20°C in the dark.
! !
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! ! 2.1.5:  Cell cycle analysis
Cell fixation stock buffer was prepared with 1% v/v 
formaldehyde in PBS.  Buffer was stored at room 
temperature for up to 1 month.  
Cell permeabilisation buffer was prepared just before use by 
dissolving 0.5% w/v bovine serum albumin (BSA) in PBS with 
0.25% v/v Triton X-100.
Mouse anti-human cyclin A-FITC  antibody (BD Biosciences, 
UK) was supplied ready to use by manufacturer.  Further 
details are specified in chapter 2.6.
Propidium iodide stock solution was made by dissolving 20 
μg/ml propidium iodide in PBS and stored at 4°C in the dark 
for up to 1 month.
!
! ! 2.1.6:  Annexin V apoptosis assay
Annexin V apoptosis detection kit (Abcam, UK) was supplied 
with binding buffer, annexin V-FITC and propidium iodide 
solution ready to use. 
! ! 2.1.7:  Comet assay
Cell lysis buffer was prepared just before use by dissolving 
100 mM ethylenediaminetetraacetic acid disodium salt 
dihydrate (Na2.EDTA), 2.5 M NaCl, 10 mM tris-HCL and 1% 
v/v Triton X-100 in distilled H2O, adjusted to pH 10.0 with 10 
M sodium hydroxide.
Fapy DNA glycosylase (FPG) stock buffer was prepared at 
10 times concentration with 40 mM HEPES, 0.1 M potassium 
chloride, 0.5 mM EDTA and 0.2 mg/ml BSA in distilled H2O, 
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adjusted to pH 8.0 with potassium hydroxide and stored at 
-20°C for up to 6 months.
Alkaline electrophoresis buffer was prepared just before use 
by dissolving 0.3 M sodium hydroxide and 1 mM EDTA in 
distilled H2O.
Propidium iodide stock solution was prepared by dissolving 
150 μM propidium iodide, 10 mM potassium phosphate and 
150 mM NaCl in distilled H2O and stored at 4°C in the dark 
for up to 1 month.
! ! 2.1.8: SDS-PAGE and western blot
Lysate stock buffer was prepared by dissolving 150 mM 
NaCl, 1 % v/v Triton X-100, 0.5 %  w/v SDS and 50 mM tris-
base in distilled H2O.  Aliquots of 500 μl were stored at 4°C 
for up  to 3 months  Protease inhibitor cocktail (Sigma, UK) 
(AEBSF 104 mM, Aprotinin 80 μM, Bestatin 4 mM, E-64 1.4 
mM, Leupeptin 2 mM and Pepstatin A 1.5 mM) was added at 
0.1% v/v  immediately before use.
Resolving gel stock buffer was prepared by dissolving 1.5 M 
tris-base and 0.4% w/v  SDS in distilled H2O, adjusted to pH 
8.4 with 10 M concentrated HCl and stored at room 
temperature for up to 3 months.
Stacking gel stock buffer was prepared by dissolving 0.5 M 
tris-base and 0.4% w/v  SDS in distilled H2O, adjusted to pH 
6.8 with concentrated HCl and stored at room temperature 
for up to 3 months.
SDS-PAGE running buffer was prepared just before use by 
dissolving 25 mM tris-base, 190 mM glycine and 0.1% w/v 
SDS in distilled H2O.
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Transfer buffer was prepared just before use by dissolving 25 
mM tris-base, 190 mM glycine and 20% v/v methanol in 
distilled H2O.
TBS-Tween (TBST) was prepared just before use by 
dissolving 50 mM tris-base, 200 mM NaCl and 0.05% v/v 
Tween-20 and adjusted to pH 7.5 with concentrated HCl.
! ! 2.1.9:  Nuclear extraction
Buffer A stock solution was prepared by dissolving 10 mM 
HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT and 0.05% 
v/v Triton X-100 and adjusted to pH 7.9 with concentrated 
HCl.  Aliquots of 500 μl were stored at -20°C for up  to 3 
months.
Buffer B stock solution was prepared by dissolving 5 mM 
HEPES, 1.5 mM MgCl2, 0.2 mM EDTA, 0. 5mM DTT and 
26% v/v  glycerol and adjusted to pH 7.9 with concentrated 
HCl.  Aliquots of 500 μl were stored at -20°C for up  to 3 
months.
! ! 2.1.10:  Enliten ATP assay
ATP extraction stock solution was made by dissolving 0.02 M 
glycine, 0.05 M MgCl and 0.004 M EDTA.  Aliquots of 1 ml 
were stored at -20°C for up to 3 months.
! ! 2.1.11:  Fagonia cretica
Dried Fagonia cretica originating from Pakistan was a gift 
from Amtul Carmichael (Dudley Group Hospitals).
"
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" 2.2  Generation of Fagonia cretica  extracts
! ! 2.2.1:  Principles
Extracts of Fagonia cretica were obtained using a Soxhlet 
reflux extraction method (figure 2.2.1) [321].  The Soxhlet 
extraction represents a relatively  straight forward   method of 
solid-liquid extraction by treatment of the solid with a solvent. 
This method uses the partition coefficient of individual 
compounds to isolate species from a mixture of compounds. 
The process involves heating a desired solvent in a still pot 
attached to a Soxhlet chamber containing the sample of 
interest to reflux.  As the condenser cools the evaporated 
solvent it begins to submerge the sample and extract specific 
compounds.  When the Soxhlet chamber reaches maximum 
capacity the solvent is siphoned back to the still pot.  Over a 
matter of hours or days the recycled solvent in the still pot 
becomes concentrated with the extracted compounds.
! ! 2.2.2:  Method
In a soxhlet extraction, dried Fagonia cretica plant material 
was extracted  under reflux using a range of solvents based 
on their polarity index (table. 2.2.1).  The solvents used were 
PET-Ether 40-60, toluene, diethyl ether, dichloromethane, 
methanol and water. Fresh plant material was used for 
extraction in each solvent.  A total of 25g dry  weight of plant 
material was extracted in 500 ml of solvent for either 2 hours, 
5 hours or 24 hours.  After the extractions had completed, 
solvents were removed under reduced pressure in a rotary 
evaporator at a temperature not exceeding 50°C before 
desiccating under vacuum overnight.  Powder extracts were 
stored at 40C  until use.  Plant material for cell viability assays 
and aqueous extracts used in experiments outlined in this 
thesis was extracted as above for 5 hours.
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Figure 2.2.1:  Soxhlet extraction apparatus set-up (Adapted 
from AM Glassware.com/soxhletextraction [321].  Plant 
material is placed in the soxhlet chamber and compounds are 
extracted by heating solvent in the still-pot to boiling point.  The 
evaporated solvent is condensed and collected in the soxhlet 
chamber, submerging the plant material and extracting 
compounds of interest.  The solvent is then siphoned back to 
the still post and the cycle restarted.
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Solvent Polarity Index
PET-ether (40-60) 0.1
Toluene 2.4
Diethyl ether 2.8
Dichloromethane 3.1
Methanol 5.1
Water 9
Table 2.2.1.  Polarity index of solvents used in extraction 
process.  Several solvents spanning a range of polarities were 
selected for extraction of compounds from Fagonia cretica. 
The greater the polarity index the more polar the solvent.
Solvent % 
Recovery - 
2 hours
% Recovery 
- 5 hours
% Recovery 
- 24 hours
PET-ether (40-60) 11.6% 10.43% 14.21%
Toluene 2.4% 5.32% 6.1%
Diethyl ether 5.2% 5.89% 5.01%
Dichloromethane 16.34% 12.73% 19.43%
Methanol 9.87% 13.24% 12.9%
Table 2.2.2.  Percentage recovery of dry weight following 
Soxhlet extraction.  Several solvents spanning a range of 
polarities were selected for extraction of compounds from 
Fagonia cretica.  25g of plant material was extracted in 500 ml 
of solvent by Soxhlet extraction.  Extracts were dried under 
reduced pressure and desiccated under vacuum overnight.
! 2.3  Thin layer chromatography of Fagonia cretica 
extracts
! ! 2.3.1:  Principles
Thin layer chromatography (TLC) is a a standard 
chromatographic technique for the separation of compounds 
in a mixture.  It is most commonly carried out by blotting a 
small amount of a mixture onto a silica gel (stationary phase) 
plate and applying a solvent or solvent mixture (mobile 
phase) to be drawn up the plate by capillary action. 
Compounds in a mixture that demonstrate different solubility 
properties in the mobile phase will migrate to different 
positions on the stationary phase allowing the separation of 
compounds.  The separated compounds can then be 
visualised using a wide range of different methods, including 
vanillin or iodine staining and UV detection.
! ! 2.3.2:  Method
A small amount of dried extract produced in chapter 2.2 was 
solubilised in its extraction solvent and applied 1.5 cm from 
the bottom of a silica gel, aluminium backed TLC plate 
(Fisher Scientific), cut to 6cm by 10cm (W x H).  Ethyl 
acetate:methanol (90:10) mobile phase was used to separate 
the compound mixtures.  After the solvent front had migrated 
to within 2 cm of the top of the plate the  solvent was 
removed by air drying and the compounds stained by 
submerging the plate in vanillin solution and heating on a hot 
plate at 60°C until compounds were visible.
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! 2.4  Cell culture
" " 2.4.1:  Background of cell lines
MCF-7 cells are a human breast adenocarcinoma cell line 
derived from the pleural effusion of a 69 year old caucasian 
female.  The adherent cell line expresses both wild-type and 
variant oestrogen receptors as well as the progesterone 
receptor and have been shown to express functional wild-
type p53.
MDA-MB-231 cells are a human breast adenocarcinoma cell 
line derived from the pleural effusion of a caucasian female. 
The cell line is considered basal-type or triple negative as it 
does not express either oestrogen, progesterone or HER2/
neu receptors.  The cell line also carries a mis-sense 
mutation in codon 280 resulting in an arginine-lysine residue 
change which is responsible for expression of a non-
functional form of p53.
HMEpC cells are derived from human mammary glands. 
They are an epithelial cell line and demonstrate high levels of 
cyclin-dependent kinase (CDK) 6 activity which is 
responsible for restraining cell proliferation.
! ! 2.4.2:  Method
MCF-7 and MDA-MB-231 cells were cultured in RPMI 1640 
with stable glutamine, supplemented with FCS (10%) and 
penicillin/streptomycin (50 U/ml) and incubated at 37°C under 
5% CO2.  Cells were passaged with trypsin-EDTA (PAA, UK) 
when 90% confluent and seeded at a density of 5 x 105 cells 
per 75 cm2.
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HMEpC cells were cultured in mammary epithelial growth 
medium supplemented with growth supplements and 
penicillin/streptomycin (50 U/ml) and incubated at 37°C under 
5% CO2.  Cells were passaged with trypsin-EDTA when 90% 
confluent and seeded at a density of 5 x 105 cells per 75 cm2.
"
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" 2.5:  MTT assay
" " 2.5.1:  Principle
Changes in cell metabolic activity as a marker of viability 
after treatment with chemotherapeutic drugs can be 
measured using the colorimetric MTT assay.  The assay is 
based on the principle that MTT, a yellow tetrazole, will be 
reduced by mitochondrial reductase in viable cells to produce 
a purple formazan product.  Due to the nature of the assay, it 
is not possible to differentiate between cell death (apoptosis/
necrosis/autophagy) or an arrest of cellular growth, as the 
chemical reduction of MTT is based on the metabolic output 
of the cell population.
" " 2.5.2: Method
Cultured cells were seeded in 96-well plates at a density  of 2 
x 105 cells per ml in a volume of 100 μl and allowed to 
adhere overnight.  The media was then refreshed with 100 μl 
fresh media, followed by treatment as indicated in the 
relevant chapters.  Hydrogen peroxide at a final 
concentration of 160 μM was used as a positive control. 
Post-treatment, the media was refreshed with 100 μl fresh 
media and 10 μl stock MTT solution was added to each well. 
After 4 hours incubation at 37°C the formazan product was 
solubilised with 50 μl of MTT lysis buffer.  Culture plates were 
left overnight for formazan solubilisation before absorbances 
were recorded spectrophometrically  at 570nm.  Data was 
expressed as a percentage of cell viability, calculated as a 
percentage of the mean of untreated controls for each 
independent experiment.
! !
!
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! ! 2.5.3:  Assay validation
In order to assess the reliability of the MTT assay to detect 
changes in MCF-7 cell viability  post-treatment with a 
cytotoxic agent, cultured cells were treated with the 
chemotherapeutic agent methotrexate or hydrogen peroxide. 
MCF-7 cells were seeded into 96-well culture plates as 
described in 2.5.1 and were treated with up  to 10 μM 
methotrexate (MTX) or 320 μM H2O2 for 24 hours prior to 
MTT analysis.  Figure 2.5.1 shows the effects of 
methotrexate (MTX) and hydrogen peroxide treatment on 
MCF-7 cell viability  after 24 hours as measured by MTT 
reduction.  Both agents significantly reduce MCF-7 cell 
viability at micro-molar concentrations with MTX and H2O2 
demonstrating an IC50 of 0.67 μM and 163.11 μM, 
respectively (figure 2.5.1a and b).  Cytotoxicity of MTX to 
MCF-7 cells in this model agrees with the work of Hattangadi 
et al [322]. who report an IC50 of 0.3 μM towards MCF-7 
cells.
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Figure 2.5.1.  Methotrexate and H2O2 reduce MCF-7 cell 
viability.  MCF-7 cells were treated with indicated 
concentrations of (a) methotrexate (MTX) or (b) H2O2 for 24 
hours prior to MTT analysis.  Data denoted ** (p<0.01) and 
*** (p<0.001) are significant compared to untreated controls 
analysed by one-way ANOVA with Dunnettʼs multiple 
comparison post test.  Data is from at least three 
independent experiments performed in triplicate and 
presented as mean ± standard deviation.
! 2.6:  Cell Cycle Analysis
! ! 2.6.1:  Principles
The cell cycle status of individual cells within a population 
can be analysed using dual fluorescent staining coupled to 
flow cytometry.  The cell cycle is controlled in a temporal 
manner by the formation of active cyclin-CDK complexes that 
drive the transitions between cell cycle phases.  It is known 
that at different stages of the cell cycle, expression of specific 
cyclins reach a peak.  Utilising this principle, it is possible to 
stain for cyclin A, which is expressed at low levels during G1 
phase before rising through S-phase, peaking during G2 
phase and finally  declining into M-phase.  Using a FITC-
conjugated mouse IgE antibody raised against human cyclin 
A, it is possible to measure fluorescence emission by flow 
cytometry.  Co-staining with the DNA dye propidium iodide 
allows the user to separate cell populations into G0/G1, S, 
G2 or M-phase.  Cell cycle phases can be gated based on 
their fluorescent profiles.  Cells in G0/G1 phase of the cell 
cycle show low levels of cyclin A staining and low, or N=1 
level of PI staining, associated with normal diploid DNA 
content (figure 2.6.1 A).  Cells in S-phase demonstrate low to 
high levels of cyclin A  staining depending how far through S-
phase they are committed (figure 2.6.1 B).  Cells in G2-
phase show high levels of cyclin A staining and high, or N=2 
levels of PI staining (figure 2.6.1 C).  In M-phase, levels of 
cyclin A  are in decline, thus M-phase populations show a 
mid-level of cyclin A staining but retain a N=2 level of PI 
staining (figure 2.6.1 D).
! ! 2.6.2:  Method
Cultured cells were seeded into a six well plate at a density 
of 2 x 105 cells per ml in 2 ml and allowed to adhere 
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overnight.  Cells were treated with a final concentration of 2 
mg/ml of extract for up  to 24 hours.  After treatment, cells 
were collected by scraping the cells in 1ml of fresh media 
and counted on a haemocytometer.  A total of 5x105 cells 
were centrifuged at 300 g for 5 minutes, the supernatant 
discarded and the cells washed in 1 ml PBS.  Cells were 
fixed in 1 ml 1% v/v formaldehyde in PBS for 15 minutes. 
Cells were centrifuged at 300 g for 5 minutes, the 
supernatant discarded and the cells permeabilised in 100 μl 
of permeabilisation buffer for 15 minutes.  Permeabilised 
cells were then incubated with 20 μl anti-cyclin A FITC for 60 
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Figure 2.6.1.  Characteristic staining of untreated MCF-7 
cells with anti-cyclin A FITC and propidium iodide.  MCF-7 
cells were stained with anti-cyclin FITC A and propidium iodide 
prior to analysis by flow cytometry.  FITC fluorescence was 
detected using FL1 (Em: 670nm) and propidium iodide was 
detected on FL3 (Em: 525nm).  Cell populations were gated 
based on fluorescent profiles (A = G0/G1, B = S, C  = G2, D = 
M).
minutes in the dark at room temperature with 20 μl propidium 
iodide solution added for the final 10 minutes.  Stained cells 
were diluted with 400 μl permeabilisation buffer and 
centrifuged at 300 g for 5 minutes.  The supernatant was 
discarded and the pellet resuspended in 500 μ l 
permeabilisation buffer before analysis.  Stained cells were 
analysed on a Beckman-Coulter Cell Lab Quanta-SC  flow 
cytometer measuring FITC fluorescence (FL1; Em: 670nm) 
and PI fluorescence (FL3; Em: 525nm) for 20,000 events per 
sample and gated for non-specific antibody binding using an 
isotype negative control mouse IgE.  Log FL1 was plotted 
against linear FL3 to generate histograms.  Cell cycle 
populations were gated according to their fluorescent profiles 
and data expressed as percentage of cells compared to 
untreated control population.
"
" " 2.6.3:  Assay validation
Cell cycle analysis was validated by inducing growth arrest in 
MCF-7 cells by serum starvation for 24 hours or incubation 
for 24 hours with 0.1 μM colchicine.  Figure 2.6.2b  shows 
that serum starving MCF-7 cells for 24 hours results in a shift 
in cell populations towards G0/G1 and S-phase of the cell 
cycle with a 45.9% increase in G0/G1 cells (figure 2.6.3b). 
This is expected as it is known that serum starvation of cells 
can synchronise cells to G0/G1 phase of the cell cycle [323]. 
Treatment with the microtubule disrupter colchicine for 24 
hours resulted in a significant shift in cell population to M-
phase (figure 2.6.2c) with a 100% increase in M-phase cells 
(figure 2.6.3d).  These results demonstrate that the dual stain 
anti-cyclin A FITC and PI can be used to analyse the cell 
cycle by flow cytometry.  
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Figure 2.6.2.  Serum starvation and colchicine treatment induces growth arrest in 
MCF-7 cells.  MCF-7 cells, (a) untreated, (b) serum starved or treated with (c) 0.1μM 
colchicine for 24 hours were subjected to cell cycle analysis by flow cytometry.  
Histograms were generated by plotting log levels of FITC (FL1) against linear propidium 
iodide (FL3).  Data is representative of three independent experiments performed in 
duplicate.  
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Figure 2.6.2.  Serum starvation and colchicine treatment 
induces growth arrest in MCF-7 cells.  MCF-7 cells, (a) 
untreated, (b) serum starved or treated with (c) 0.1μM 
colchicine for 24 hours were subjected to cell cycle analysis by 
flow cytometry.  Histograms were generated by plotting log 
levels of FITC  (FL1) against linear propidium iodide (FL3).  A = 
G0/G1, B = S-phase, C = G2, D = M-phase  Data is 
representative of three independent experiments performed in 
duplicate.  
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Figure 2.6.3.  Effect of serum starvation and colchicine 
treatment on cell cycle.  MCF-7 cells were either untreated, 
serum starved or treated with 0.1μM colchicine for 24 hours 
prior to cell cycle analysis by flow cytometry. (a) G0/G1, (b) S, 
(c) G2, and (d) M populations were gated according to 
fluorescence profile and expressed as percentage of total cell 
population.  Data denoted ***  (p<0.001) and **  (p<0.01) are 
statistically significant compared to untreated control analysed 
by one-way ANOVA with Dunnettʼs multiple comparison post 
test (mean ±  standard deviation).  Data is from three 
independent experiments performed in duplicate.
" 2.7:  Detection of apoptosis
" " 2.7.1:  Principles
Apoptosis is a form of programmed cell death that is vital to 
normal organism development, the immune response to 
infection and removal of oncogenic cells.  It is a process 
characterised by distinct morphological changes such as 
membrane blebbing, nuclear fragmentation and chromatin 
condensation [128].  Apoptosis also induces plasma 
membrane changes such as the translocation of 
phosphatidylserine (PS) from the inner leaflet to the outer 
leaflet of the cell membrane [324].  Under normal conditions, 
PS is held on the inner leaflet of the plasma membrane by 
the enzyme flippase until it is cleaved by caspases following 
apoptotic activation, which causes the ʻflipʼ of PS to the outer 
cell membrane [325].  Phosphatidylserine expressed on the 
cell surface can be detected by staining with a fluorophore 
and detection using flow cytometry.  The protein annexin V is 
part of the annexin group  of proteins and has high affinity for 
PS binding, in vitro, in the presence of calcium ions.  Thus, 
using FITC-conjugated annexin-V protein, it is possible to 
detect PS present on the surface of apoptotic cells [324]. 
Co-staining with the DNA dye propidium iodide allows the 
user to isolate cell populations that are live, apoptotic or 
necrotic as propidium iodide is not cell permeable.  Flow 
histograms generated by  plotting FITC against PI 
fluorescence can be quadrant gated according to the 
fluorescent profile of untreated controls (figure 2.7.1). 
Quadrant 2 (Q2) represents necrotic cells displaying high 
levels of FITC and PI, while quadrant 4 (Q4) represents 
apoptotic cells with high FITC  and low PI fluorescence. 
Quadrant 3 (Q3) is representative of the live cell population 
(low FITC, low PI).
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" "
" " 2.7.2:  Method
MCF-7 cells were seeded into a six well plate at a density  of 
2x105 cells per ml in a volume of 2 ml and allowed to adhere 
overnight.  Cells were refreshed with 1 ml of fresh media and 
treated with a final concentration of 2 mg/ml extract for up to 
72 hours.  At indicated time points, cells were scraped into 
1ml PBS and centrifuged at 300 g for 5 minutes.  The 
supernatant was discarded and the cells resuspended in 100 
μl PBS.  Cell number was determined by trypan blue staining 
and 1x105 cells transferred to an eppendorf in a total volume 
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Q3 Q4
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Figure 2.7.1.  Typical flow cytometric dot-plot of 
untreated MCF-7 cells stained for annexin V (FL1) and 
propidium iodide (FL3).  MCF-7 cells were stained with 
annexin V-FITC  and propidium iodide prior to analysis by 
flow cytometry.  Cells were gated so Q3 (live cells) > 95% 
total cells.  Q2: necrotic cells, Q3: live cells, Q4: apoptotic 
cells.  Data is representative of three independent 
experiments performed in triplicate.
of 500 μl PBS.  Cells were centrifuged at 300 g for 5 minutes 
and resuspended in 500 μl of annexin V binding buffer.  Cells 
were incubated with 5 μl of annexin V-FITC and 5 μl 
propidium iodide solution for 5 minutes in the dark at room 
temperature.  Stained cells were analysed on a Beckman-
Coulter Cell Lab Quanta-SC flow cytometer measuring FITC 
fluorescence (FL1; Em: 670) and PI fluorescence (FL3; Em: 
525) for 20,000 events per sample.  Log FL3 was plotted 
against log FL1 to generate histograms.  Cells were gated 
using quadrant gating dependent on fluorescent profile of 
untreated controls (Q3 > 95% cells).
"
" " 2.7.3:  Assay Validation
To validate the detection of apoptosis using the supplierʼs kit, 
MCF-7 cells were treated with 160 μM H2O2 for 5 hours, prior 
to analysis by flow cytometry.  Figure 2.7.2 and 2.7.3 
demonstrates that treatment with 160 μM H2O2  induced 
apoptotic cell death in MCF-7 cells after 5 hours that was 
detectable using the annexin V apoptosis detection kit from 
Abcam.
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a)
b)
Figure 2.7.2.  Hydrogen peroxide treatment induces 
apoptosis in MCF-7 cells.  MCF-7 cells (a) untreated or 
treated with (b) 160μM H2O2 for 5 hours were subjected to 
an apoptosis detection assay using annexin V-FITC.  Dot-
plots were generated as a plot of log FL3 (propidium iodide) 
against log FL1 (FITC).  Data is representative of three 
independent experiments performed in triplicate.
89
Li
ve
 C
el
ls
Li
ve
 C
el
ls
A
po
pt
ot
ic
 C
el
ls
A
po
pt
ot
ic
 C
el
ls
N
ec
ro
tic
 C
el
ls
N
ec
ro
tic
 C
el
ls
0
25
50
75
100
***
***
160µM H2O2                 -            +            -          +            -           +           
%
 C
el
ls
Figure 2.7.3.  Hydrogen peroxide treatment induces 
apoptotic cell death in MCF-7 cells.  MCF-7 cells were 
either untreated or treated with 160μM H2O2 for 5 hours 
prior to staining with annexin V-FITC and detection of 
apoptosis using flow cytometry.  Data denoted ***  (p<0.001) 
is significant compared to untreated as indicated by capped 
bar analysed by one-way ANOVA with Bonferroniʼs multiple 
comparison post-test (mean ±  standard deviation).  Data is 
representative of three independent experiments performed 
in triplicate.
" 2.8  Measurement of intracellular reactive oxygen 
species
" " 2.8.1:  Principles
Alterations in the levels of reactive oxygen species (ROS) in 
cultured cells can be measured fluorometrically using the 
probe 2ʼ.7ʼ-dichlorofluorescien diacetate (DCFH-DA).  The 
non-fluorescent probe is readily taken up by cells where local 
esterases hydrolyse it to DCFH, which in turn can be 
oxidised to highly fluorescent DCF by cellular oxidants such 
as superoxide (O2-) and hydrogen peroxide (H2O2).  The use 
of DCFH-DA as a probe for oxidative stress is not 
recommended if one is trying to study specific  radical 
species, but due to its indiscriminate nature, it allows the 
assay to measure the overall oxidative stress in a cell 
population [326].
" " 2.8.1:  Method
Cultured cells were seeded into a 24-well plate at a density 
of 1 x 105 cells per ml in 500 μl and allowed to adhere 
overnight.  The cells were then washed with 500 μl of sterile 
PBS before being refreshed in phenol red free/serum free 
RPMI 1640 and incubated for 2 hours to equilibrate.  At this 
stage cells were treated.  One hour before the end of 
treatment, the cells were probed with 50 μl of 100 μM DCFH-
DA (10 mM stock diluted in phenol red free/serum free RPMI 
1640) to give a final concentration of 10 μM.  After incubation 
with the dye for 60 minutes, the media was removed and the 
cells were washed in sterile PBS. Finally, the cells were 
refreshed with 500 μl PBS and fluorescence was detected 
immediately on a Molecular Devices SpectraMAX Gemini EM 
plate reader (Ex: 504 nm; Em: 524 nm).  Data was 
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expressed as a fold change of DCF-fluorescence (DCF-FL) 
compared to untreated control.
" " 2.8.2:  Assay validation
To assess the suitability of the DCF assay to measuring 
intracellular ROS production, the level of DCF fluorescence 
generated by H2O2 treatment in the presence of NAC was 
determined in MCF-7 cells.  Cells were pre-treated with 3 
mM NAC or vehicle for 60 minutes prior to treatment with and 
without 160 μM H2O2 for 3 hours.  Treatment with hydrogen 
peroxide induced a significant 2.0 fold increase in DCF 
fluorescence which was significantly attenuated by 
pretreatment with 3 mM NAC (figure 2.8.1).
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Figure 2.8.1.  H2O2 treatment of MCF-7 cells increases 
DCF fluorescence which can be attenuated with NAC. 
MCF-7 cells were pretreated with 3mM NAC for 60 minutes 
prior to treatment with 160μM H2O2 for 3 hours.  Intracellular 
reactive oxygen species were detected using the DCFH-DA 
probe and measured fluorometrically (Ex: 504nm, Em: 
524nm).  Data denoted *** (p<0.001) are significant compared 
to control or as indicated analysed by one-way  ANOVA with 
Bonferroniʼs multiple comparison post test (mean ±  standard 
deviation).  Data is from three independent experiments 
performed in triplicate.
" 2.9:  Detection of the DNA damage lesion 8-oxo-
guanine
! ! 2.9.1:  Principles
The presence of DNA damage in individual cells can be 
detected using the comet assay.  The comet assay is a 
single cell gel electrophoretic method based on the principle 
that smaller fragmented DNA will migrate in an electric field 
easier than larger intact DNA.  Cells are first lysed in a 
detergent and high salt buffer, which disrupts cellular proteins 
including RNA and removes the cell membrane.  The 
exposed DNA is denatured with an alkaline pH that causes 
strand separation leaving a single stranded nucleoid [327]. 
An electric field facilitates separation of nucleoid content to 
produce the characteristic comet that can be visualised with 
a DNA stain such as propidium iodide or ethidium bromide.
Using the DNA glycosylase protein, FPG, it is possible to 
modify the comet assay  to detect the presence of the most 
common oxidative DNA lesion, 8-oxo-guanine.  FPG protein 
recognises the oxidised guanine base of 8-0xo-guanine and 
is involved in its removal during base excision repair creating 
a single strand break at the site of mutation.  This means that 
in the presence of FPG protein, more strand breaks will be 
generated if 8-oxo-guanine is present, thus generating a 
larger comet tail.  It should be noted that FPG also has 
specificity for other oxidative DNA lesion and so is not a 
single measure of 8-oxo-guanine but of oxidative DNA 
damage in general.
" " 2.9.2:  Method
Cultured cells were seeded into a 6-well plate at a density of 
2 x 105 cells per ml in a volume of 3 ml and incubated 
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overnight to allow adherence.  The medium was removed 
and replaced with 1 ml fresh media, followed by  treatment 
with either vehicle control, 0.25, 0.5, 1 or 2 mg/ml of extract 
for up to 3 hours.  Hydrogen peroxide at a final concentration 
of 80 μM for 60 minutes was used as a positive control to 
induce strand breaks.  After treatment, the media was 
removed and the cells washed in 1 ml PBS before being 
scraped into 1 ml fresh PBS.  The cells were centrifuged at 
400 g for 5 mins and the supernatant discarded.  The pellets 
were resuspended in 300 μl of 0.6% low melting point (LMP) 
agarose in PBS and 50 μl was applied to a microscope slide 
pre-coated with 1% normal melting point (NMP) agarose in 
water with the aid of a coverslip.  The LMP gel was allowed 
to set at 4°C for 10 minutes before the cover slip was 
removed, the slide was submerged in ice cold lysis buffer 
and left for 1 hour at 4°C in the dark.  For the detection of 8-
oxo-guanine, slides were washed 3 times with ice cold FPG 
buffer before either 50 μl of FPG protein (20 U/ml) diluted in 
FPG buffer or 50 μl of FPG buffer alone was applied to the 
LMP gel with the aid of a coverslip.  The slides were then 
incubated at 37°C for 30 minutes.  The slides were then 
submerged in ice cold electrophoresis buffer for 40 minutes 
in order for alkaline unwinding to take place before 
electrophoresis in a flat bed tank for 30 minutes (25V, 
300mA) at 4°C in the dark.  The slides were removed and 
washed with neutralisation buffer (0.4 M tris-HCL, pH 7.5) 
three times, followed by  three washes in distilled H2O.  The 
slides were stained with 1 ml of propidium iodide solution for 
20 minutes in the dark at room temperature, washed three 
times with distilled H2O and allowed to dry at 37°C in the 
dark.  Comets were visualised using an Axiovert 200M (Carl 
Zeiss Microimaging Inc.) microscope equipped with a digital 
CCD camera (Hamamatsu Photonics) and Metamorph 
software (Universal Imaging Corp.).  Photos were analysed 
using COMETscore (autocomet.com).  For each experiment 
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ten photos were taken and all comets in view were analysed 
totalling at least 50 comets per slide.  Data was expressed as 
percentage DNA present in the tail.
! ! 2.9.3:  Assay validation
The comet assay was validated by treating MCF-7 cells with 
a known DNA damaging agent H2O2 and measuring the 
change in DNA damage compared to untreated control. 
MCF-7 cells were treated with 160 μM H2O2 for 30 minutes 
prior to comet assay as shown in 2.9.2.    Samples were 
incubated with and without FPG protein for the assessment 
of oxidative DNA damage.  Treatment of MCF-7 cells with 
160 μM H2O2  for 30 minutes significantly increased the 
percentage of DNA in comet tails, which could be 
significantly increased by incubation with FPG protein.  In 
response to hydrogen peroxide treatment, DNA damage 
increased by approximately 135% which was increased by a 
further 52% in the presence of FPG (figure 2.9.1).  These 
results demonstrate that the comet assay can detect 
significant changes in DNA damage and is sensitive to 
specific detection of oxidative lesions induced by a known 
oxidative DNA damaging agent.
95
96
+ FPG
Figure 2.9.1.  Hydrogen peroxide treatment induces DNA 
damage detectable by comet assay.  MCF-7 a were treated 
with 160μM H2O2 for 30 minutes prior to analysis by comet 
assay with and without FPG protein incubation.  Data is 
expressed as % DNA in tail as analysed by COMETscore 
software.  Data denoted **  (p<0.01) and *** (p<0.001) are 
significant compared to untreated control or as indicated. 
Data was analysed by  one-way ANOVA with Bonferroniʼs 
multiple comparison post test (mean ±  standard deviation). 
Data is from three independent experiments performed in 
duplicate.
" 2.10  Protein characterisation by western blot
! ! 2.10.1:  Principles
Western blotting is an analytical technique used primarily  for 
the identification and semi-quantitation of proteins.  The 
technique is based on antibody antigen interactions between 
the protein to be characterised and the probing antibody.  Gel 
electrophoresis of a sample is undertaken to separate the 
proteins before they are transferred to a suitable membrane 
which can be probed with an antibody  against the protein of 
interest.  A secondary antibody labelled with a detection 
enzyme, such as horseradish-peroxidase (HRP), against an 
antigenic site on the primary antibody can be used to 
visualise the presence of the bound protein.  Analysis of 
protein expression by western blot allows quantification of 
specific protein levels in a sample by measuring band 
intensity using densitometry.  Densities can be normalised to 
a standard that is unaffected by the experimental conditions 
and is in high abundance such as β-actin or GAPDH.
! ! 2.10.2:  Method
Cultured cells were seeded into a 6-well plate at a density of 
2x105 cells per ml in a volume of 2 ml.  After treatment, as 
described in relevant chapters, the media was removed and 
the cells washed with 1 ml of sterile PBS before scraping into 
1 ml of fresh PBS.  The cell suspension was centrifuged at 
400 g for 5 minutes and the supernatant discarded.  The cell 
pellet was resuspended in 1 ml of PBS before centrifuging 
again at 400 g for 5 minutes.  The cell pellet was then 
resuspended in 100 μl of cell lysis buffer and heated at 90°C 
for 10 minutes followed by storage on ice for 15 minutes. 
The total protein content of the cell lysate was determined by 
absorbance at 560nm using a bicinchonic acid protein kit 
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(Sigma).  Total protein, 20 μg, was loaded onto a SDS-PAGE 
gel and subjected to electrophoresis (constant 115V) for 120 
minutes.  The migrated proteins were transferred to a PVDF 
membrane (Bio-Rad) and electro-blotted (constant 240 mA) 
in transfer buffer for 65 minutes.  After the transfer, the 
membrane was blocked with 3% BSA in TBST overnight at 
40C.  The membrane was then briefly  washed with TBST for 
5 minutes before incubation with a primary antibody diluted 
to an optimised concentration in 0.2% BSA in TBST for 2 
hours at room temperature.  The primary antibody was then 
removed and the membrane was washed six times in TBST 
for 5 minutes each.  This was followed by  incubation with a 
HRP-conjugated secondary  antibody diluted 1/20,000 in 
TBST containing 0.2% BSA for 2 hours at room temperature. 
The membrane was then washed six times in TBST for 5 
minutes each before HRP-conjugated secondary antibody 
was detected using ECL detection reagent (CalBioChem). 
Each gel was controlled for equal loading by stripping the 
membrane with Restore (Thermo Scientific) stripping buffer 
for 15 minutes before washing in TBST three times for 10 
minutes each.  The membrane was then blocked with 3% 
BSA in TBST for 60 minutes before probing with a mouse 
anti-human β-actin primary (Sigma) at a 1/10,000 dilution in 
0.1% BSA in TBST for 1 hour at room temperature.  The 
primary antibody was removed and the membrane washed 
six times in TBST for 5 minutes each before probing with a 
relevant HRP conjugated secondary at a dilution of 1/20,000 
in 0.1% BSA in TBST for 1 hour at room temperature.  The 
antibody as then removed and the membrane was washed 6 
times in TBST for 5 minutes each before HRP was detected 
using ECL detection reagent.  Primary antibody species and 
concentrations are listed in table 2.10.1.
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Antibody Dilution
rabbit anti-human p53 1/1000
mouse anti-human p21 1/100
rabbit anti-human λH2AX 1/1000
rabbit anti-human Bax 1/1000
rabbit anti-human SIRT1 1/1000
rabbit anti-human FOXO3a 1/1000
mouse anti-β-actin 1/10000
Table 2.10.1.  Primary antibody dilutions used for 
western blot.
" 2.11:  siRNA interference
" " 2.11.1:  Principles
Small interfering RNA or siRNA are double stranded RNA 
molecules that use RNA interference to influence target gene 
expression.  Sequences of specific siRNA can be generated 
that are complementary to the mRNA of a particular gene 
product.  Thus, through the RNA interference pathway, 
siRNA are capable of degrading target mRNA and reducing 
gene expression.  This tool is useful for understanding the 
importance of specific gene products involved in disease 
pathology or treatment efficiency.    The siRNA is incubated 
with a transfection reagent that acts as a delivery platform for 
the siRNA to the target cells.  The silencer plasmid is then 
transfected into the cells where the siRNA is released in the 
nucleus.  The free siRNA can then interact with target mRNA 
and mark it for degradation, thus, inhibiting protein 
translation.  This process is transient and does not inhibit 
protein translation permanently.
! " 2.11.2:  Methods
Validated siRNA for TP53 (Ambion) and FOXO3 (Ambion) 
were used to transiently  silence p53 and FOXO3a 
expression in MCF-7 cells or MDA-MB231 cells.  Sequences 
of siRNA strands are detailed in table 2.11.1.  Silencer 
siRNA supplied as a powder was diluted to 3 pmol/μl with 
RNAase free water and mixed 1:50 with Opti-MEM in either a 
24-well (MTT assay) or 6-well (western blot) plate.  After 
addition of 1% lipofectamine RNAiMAX plates were 
incubated at room temperature for 20 minutes.  Cells were 
diluted to 1x105 cells per ml in cell culture media free from 
antibiotics.  Either 5x104 (24 well plate) or 2x106 (6 well 
plate) cells in suspension were added to siRNA-lipofectamine 
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complexes and incubated for 24 hours.  Cells were then 
treated with up to 2 mg/ml of aqueous extract for 24 hours 
prior to analysis of cell viability by MTT assay or 
determination of protein expression by western blot.
! ! 2.11.3:  Assay validation
To validate the use of Ambion TP53 silencer siRNA to 
successfully  knockdown p53 expression, MCF-7 cells were 
transfected with siRNA for 24 hours using lipofectamine 
RNAiMAX according to the manufacturerʼs protocol.  MCF-7 
cells were transfected with either 2.5 nM, 5 nM, 10 nM 
siRNA, lipofectamine alone or a validated negative control 
(Ambion) for 24 hours prior to analysis of cell viability by 
MTT assay and protein quantification by western blot. 
Figure 2.11.1 shows the effects of TP53 siRNA incubation on 
MCF-7 cell viability after 24 hours.  None of the tested 
siRNA concentrations induced a significant reduction in cell 
viability indicating that TP53 siRNA up  to 10nM can be used 
for siRNA interference assays (figure 2.11.1).  Analysis of 
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Target Strand Sequence (5ʼ--> 3ʼ)
TP53 sense GGGUUAGUUUACAAUCAGC(dtdt)
anti-sense GCUGAUUGUAAACUAACCC(dtdt)
FOXO3 sense GGCUCCUCCUUGUACUCAAtt
anti-sense UUGAGUACAAGGAGGAGCCtg
Table 2.11.1.  Validated Silencer siRNA sequences from 
Ambion.  Validated siRNA oligonucleotides were obtained from 
Ambion and used to transiently knockdown p53 and FOXO3a 
expression in MCF-7 or MDA-MB-231 cells.
p53 expression by western blot showed that TP53 siRNA 
inhibited p53 expression in a dose dependent manner (figure 
2.11.2).  Treatment of MCF-7 cells with 10 nM TP53 siRNA 
resulted in a near complete depletion in basal p53 
expression as detectable by western blot.  Therefore, all 
following experiments were performed with transfection of 10 
nM TP53 siRNA for 24 hours prior to treatments.  
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Figure 2.11.1.  Silencer TP53 siRNA transfection does 
not effect MCF-7 cell viability.  MCF-7 cells were 
transfected with TP53 siRNA plus lipofectamine RNAiMAX 
for 24 hours prior to analysis of cell viability  by MTT assay. 
Negative control was a validated non-reactive siRNA 
sequence (Ambion).  Data is from three independent 
experiments performed in triplicate and is representative of 
the mean ± standard deviation.
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Figure 2.11.2.  Silencer siRNA TP53 knockdown in MCF-7 
cells.  MCF-7 cells were transfected with TP53 or negative 
control siRNA plus lipofectamine RNAiMAX for 24 hours.  (a) 
Characterisation of p53 protein expression was determined 
by western blot. (b) Densitometry  for was calculated as a 
ratio to β-actin and expressed as fold change compared to 
control (time=0 hours).  Data denoted **  (p<0.01) and *** 
(p<0.001) are significant compared to control analysed by 
one-way ANOVA with Dunnettʼs multiple comparison post 
test.  Data is representative of three independent 
experiments.  Negative control was a validated non-reactive 
sequence from Ambion.  β-actin was used as a loading 
control.  Blot is representative of three independent 
experiments.
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β-actin
   Con      -ve con (10nM)" 2.5nM " 5nM           10nM
[TP53 siRNA] nMa)
b)
To validate the use of Ambion FOXO3 silencer siRNA to 
successfully  knockdown FOXO3a expression, MCF-7 and 
MDA-MB-231 cells were transfected with siRNA for 24 hours 
us ing l ipofectamine RNAiMAX accord ing to the 
manufacturerʼs protocol.  Cells were transfected with either 
2.5 nM, 5 nM, 10 nM siRNA, lipofectamine alone or a 
validated negative control (Ambion) for 24 hours prior to 
analysis of cell viability by MTT assay and protein 
quantification by western blot.    Figure 2.11.3 shows the 
effects of FOXO3 siRNA incubation on MCF-7 and MDA-
MB-231 cell viability after 24 hours.  Transfection with 10nM 
siRNA induced a significant reduction in cell viability  in both 
cell lines indicating that FOXO3 siRNA up to 5nM can be 
used for siRNA interference assays (figure 2.11.3).  Analysis 
of FOXO3a expression by western blot showed that FOXO3 
siRNA inhibited FOXO3a expression in a dose dependent 
manner (figure 2.11.4).  Treatment of MCF-7 and MDA-
MB-231 cells with FOXO3 siRNA resulted in a dose 
dependent decrease in basal FOXO3a expression as 
detectable by western blot.  As shown in figure 2.11.3, 
treatment of 10 nM siRNA is cytotoxic to both cell lines, 
therefore all following experiments were carried out with 
transfection of 5nM FOXO3 siRNA for 24 hours prior to 
treatments.
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Figure 2.11.3.  Effects of Silencer FOXO3 siRNA 
transfection on human breast cancer cell viability.  (a) 
MCF-7 and (b) MDA-MB-231 cells were transfected with 
FOXO3 siRNA plus lipofectamine RNAiMAX for 24 hours 
prior to analysis of cell viability by MTT assay.  Negative 
control was a validated non-reactive siRNA sequence 
(Ambion).   Data denoted * (p<0.05) and ***  (p<0.001) are 
significant compared to control (mean ± standard deviation). 
Data is from three independent experiments performed in 
triplicate.
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Figure 2.11.4.  Silencer siRNA FOXO3 knockdown in 
human breast cancer cells.  (a) MCF-7 and (b) MDA-
MB-231 cells were transfected with FOXO3 or negative 
control siRNA plus lipofectamine RNAiMAX for 24 hours. 
Characterisation of FOXO3a protein expression was 
determined by western blot.  Negative control was a 
validated non-reactive sequence from Ambion.  β-actin was 
used as a loading control.  Blot is representative of three 
independent experiments.
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2.12:  SIRT1 activity assay
" " 2.12.1:  Principles
SIRT1 is a NAD+ dependent histone/protein deacetylase 
involved in chromatin dynamics, gene repression and 
transcription factor regulation.  The SIRT1 assay kit (Sigma) 
is based on a two-step enzymatic reaction that utilises a 
novel SIRT1 substrate with an acetylated lysine side chain. 
Cleavage of the deacetylated substrate by  a developer 
solution releases a highly fluorescent group  which can be 
measured fluorometrically.  The measured fluorescence is 
directly proportional to the deacetylation activity  of SIRT1 
present in the sample.  The SIRT1 activity  assay can be 
carried out cell-free with purified SIRT1 enzyme for screening 
of inhibitor/activators and as part of in vitro experiments 
using cellular nuclear extracts to measure enzymatic activity.
! ! 2.12.2:  Methods
Nuclear extracts were isolated from MCF-7 cells treated for 
24 hours with 2 mg/ml extract with and without 50 μM 
resveratrol (SIRT1 activator) pre-treatment for 60 minutes. 
MCF-7 cells were cultured in a T75 until 80% confluent 
before treatments.  After treatment, cell were washed with 5 
ml ice-cold PBS before scraping into 5ml PBS and 
centrifugation at 300g  for 5 minutes.  Cell pellets were 
washed with 1 ml ice-cold PBS before re-suspending in 500 
μl of buffer A containing 0.1% protease inhibitor cocktail 
(AEBSF 104 mM, Aprotinin 80 μM, Bestatin 4 mM, E-64 1.2 
mM, Leupeptin 2 mM, Pepstatin A, 1.5 mM) and retaining on 
ice for 10 minutes.  Cells were centrifuged at 800 g for 10 
minutes at 4°C.  Cell pellets were resuspended in 374 μl of 
buffer B with 26 μl 4.6 M NaCl.  Cell pellets were 
homogenised by passing through a 25-gauge needle 20 
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times and stored on ice for 30 minutes.  Cell extracts were 
centrifuged at 16000 g for 20 minutes at 4°C and the 
supernatant retained for BCA protein assay and SIRT1 
activity  assay.  SIRT1 activity assay was carried out 
according to the manufacturerʼs protocol (Sigma CS1040) 
using 15 μg total protein from nuclear extracts.
!
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! 2.13:  ATP assay
" " 2.13.1:  Principles
The ENLITEN® ATP assay system (Promega, FF2000) is a 
bioluminescence detection kit for the measurement of ATP.  It 
uses a recombinant luciferase reagent which is used to 
catalyse the following reaction:
where ATP is the rate limiting component of the reaction. 
The amount of light generated is directly  proportional to the 
amount of ATP present in the sample.
! ! 2.13.2:  Method
MCF-7 cells at a density of 2 x 105 were seeded into a 6-well 
tissue culture plate in 2 ml media and allowed to adhere 
overnight.  Media was refreshed and cells were treated with 
2 mg/ml aqueous extract or serum-free media for up to 24 
hours.  After treatment, cells were washed in ice cold PBS, 
scraped into 1 ml fresh PBS and centrifuged at 300 g for 5 
minutes.  Cells were washed with 1 ml ice-cold PBS and 
centrifuged at 300 g for 5 minutes.  Cell pellet was 
resuspended in 100 μl ATP extraction buffer and incubated at 
90°C for 45 seconds.  10 μl of cell extract was used to assay 
for ATP content using the ENLITEN ATP assay kit according 
to the manufacturers instructions.
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! 2.13:  ATP assay
! ! 2.13.1:  Principles
The ENLITEN® ATP assay system (Promega, FF2000) is a bioluminescence d tection kit 
for the measurement of ATP.  It uses a recombinant luciferase reagent which is used to 
catalyse the following reaction:
where ATP is the rate limiting component of the reaction.  The amount of light generated is 
directly proportional to the amount of ATP present in the sample.
! ! 2.13.2:  Method
MCF-7 cells at a density of 2 x 105 were seeded into a 6 well tissue culture plate in 2ml 
media and allowed to adhere overnight.  Media was refreshed and cells were treated with 
2mg/ml extract or serum-free media for up to 24 hours.  After treatment, cells were washed 
in ice cold PBS, scraped into 1ml fresh PBS and centrifuged at 300g for 5 minutes.  Cells 
were washed with 1ml ice-cold PBS and centrifuged at 300g for 5 minutes.  Cell pellet was 
resuspended in 100μl ATP extraction buffer and incubated at 90°C for 45 seconds.  10μl of 
cell extract was used to assay for ATP content using the ENLITEN ATP assay kit according 
to the manufacturers instructions.
ATP + D-Luciferin + O2 Oxyluciferin + AMP + PPi + CO2 + light (560nm)
" 2.14  Bio-assay guided fractionation
"
" " 2.14.1  Principles
I n o rde r to i so la te and cha rac te r i se po ten t i a l 
chemotherapeutic compounds from an aqueous extract of 
Fagonia cretica a bio-assay guided fractionation (BAGF) 
method was employed.  BAGF is a common method in 
research development of new drug compounds from natural 
sources.  It involves multiple step  fractionations using 
analytical chemistry techniques such as solid-phase 
e x t r a c t i o n ( S P E ) a n d h i g h - p e r f o r m a n c e l i q u i d 
chromatography (HPLC) to separate compounds of interest. 
At each step the isolated fractions, or pure compounds, can 
be tested with a bioassay, such as the MTT assay, for activity 
before identifying candidate leads.  Compounds of interest 
can be identified and/or characterised using analytical 
methods such as mass-spectrometry and nuclear magnetic 
resonance (NMR).
In this investigation BAGF was carried out using SPE and 
HPLC methods.  Solid-phase extraction is an extraction 
method involving separation of compounds, based on their 
physical or chemical properties, in a liquid mobile phase on a 
solid stationary phase such as a silica gel matrix.  For 
example, a C18 column contains a stationary  phase packed 
with inert silica particles attached to non-polar C18 carbon 
chains.  This generates a hydrophobic surface on the column 
allowing more polar compounds to be eluted first.  
HPLC is a common chromatographic technique for the 
separation of a mixture of compounds.  It has wide 
applications covering compound isolation, quantification and 
identification.  Generally a column containing a similar matrix 
to that seen in a C18 SPE column is densely packed to 
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provide a stationary phase tightly packed with straight carbon 
chains.  The dense packing of the stationary phase creates a 
surface area with high hydrophobicity that provides sensitive 
separation of compounds based on their polarity.  As with 
SPE, a polar liquid mobile phase applied to a C18 HPLC 
column will elute the most polar compounds first.  Increasing 
the level of organic solvent present in the mobile phase will 
allow compounds with high hydrophobicity  to be eluted. 
Employing a gradient of organic solvent as a mobile phase 
allows fine separation of compounds in a mixture.
Mass-spectrometry is a powerful analytical tool that 
measures the mass to charge ratio of charged particles, thus, 
providing accurate mass calculations of observed 
compounds.  Commonly, electrospray-ionisation is used to 
generate the ions needed for mass spectrometry and is 
referred to as ESI-MS.  In the electrospray method, the 
compound of interest is suspended in an appropriate solvent 
and acidified to increase the conductivity of the compound. 
The sample is fed into the vacuum stage where the solvent is 
evaporated under heat producing charged droplets that 
eventually deform to produce an aerosol by Coulomb fission 
[328].  The ions produced can then be observed by mass 
spectrometry.  Tandem mass-spectrometry  (MS/MS) involves 
fragmentation of the precursor ion to generate a 
fragmentation profile of product ions.  In analytical chemistry 
it can be used to identify  the particular structure of a 
precursor ion by analysing the fragmentation profile. 
Fragmentation of precursor ions is induced by collision-
induced dissociation where gas-phase particles are 
accelerated by  and electrical potential.  This shifts the 
charged particles to a higher state of kinetic energy and 
enables collision with neutral molecules resulting in bond 
breakage and fragmentation [329].
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! ! 2.14.2  Methods
In this study, SPE was carried out using a 1.5 ml Bond Elut 
C18 reverse phase column (Analytichem International).  The 
SPE column was first equilibrated with 7.5 ml of 0.5% acetic 
acid before applying 20 mg of aqueous extract dissolved in 1 
ml of 0.5% acetic acid.  The sample volume was allowed to 
fully enter the column before being washed through with 5 ml 
of 0.5% acetic acid and collected.  The column was then 
eluted with 5 ml of 100% ethanol and collected.  The flow-
through and elution fractions were then dried in a vacuum 
centrifuge before being used in a MTT cell viability assay or 
subjected to further purification techniques.
HPLC was carried out using a 1 ml C18 RP-HPLC column 
(150 x 4.6 mm, 5 micron) (Phenomenex) in conjunction with 
an AKTA Prime system (GE Healthcare) coupled to a UV 
detector (254 nm).  The mobile phase was a mixture of 0.5% 
acetic acid and methanol.  Fractions of 1 ml were collected 
periodically throughout the method.  The flow rate was set to 
0.8 ml/min.  The column was first equilibrated with 5 ml of 
0.5% acetic acid before a developed automatic method was 
applied to the system (table 2.14.1).  Samples for loading 
were prepared by drying SPE fractions to under reduced 
pressure before resuspending in 500 μl of 0.5% v/v acetic 
acid for injection.  
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After the fractions had been collected, they were pooled 
according to their retention times and dried using a vacuum 
centrifuge before being used in a MTT cell viability assay or 
subjected to further purification and analytical techniques. 
Fractions from SPE or HPLC purification that were subjected 
to testing with the MTT assay were resuspended in 200 μl of 
fresh media before using as a treatment.
Composition of fractions was determined by ESI-MS using a 
Thermo Finnigan LCQ quadropole ion-trap mass 
spectrometer.  Fractions were resuspended in 100 μl 0.5% 
formic acid (aq.) and applied to the ESI system by direct 
infusion with a hamilton syringe.  Stable spray was 
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Time (mins) Action
0 0% MeOH
2.5 Sample injection
12.5 25% MeOH
17.5 50% MeOH
27.5 75% MeOH
37.5 100% MeOH
47.5 0% MeOH
50 End method
Table 2.14.1.  Method for HPLC separation of Fagonia 
cretica using C18 column.  Isolation of compounds from a 
solid-phase extraction purified aqueous extract was 
performed on an AKTA Prime system.  The column used was 
a 1 ml C18-HPLC equilibrated in 0.5% acetic acid.  A 
methanol elution gradient was employed which increased 
step-wise by 25% over time.  Flow rate was 0.8 ml/min, the 
eluate was monitored at 254 nm and fractions were collected 
at 1 ml intervals.
established and precursor ion profiles were generated by 
mass spectrometry in negative ion mode.
! ! 2.14.3:  Validation of mass-spectrometry as 
a method of identifying natural products from a mixture.
In order to show that ESI-MS/MS could be used to identify 
natural compounds from a mixture, a mixture of several plant 
polyphenol standards was subjected to ESI-MS and 
precursor ions fragmented to validate MS/MS as a method 
for characterising compounds.  The polyphenols selected to 
make up the standard mixture represent various classes of 
plant polyphenols and are outlined in figure 2.14.1.  The 
mixture of polyphenols was solubilised in methanol with 0.5% 
v/v formic acid prior to direct infusion with the ESI system. 
Precursor ions were resolved in negative ion mode and 
fragmentation profiles generated with a CID energy of 30%. 
Figure 2.14.2a shows single stage mass spectral analysis of 
the polyphenol standard mixture with standard molecular 
weights highlights.  ESI-MS/MS of gallic acid ([M-H]- 168.9) 
produced a product ion of 124.8 due to loss of the carboxyl 
group (fig. 2.14.2b).  Caffeic acid ([M-H]- 179.0) also lost a 
carboxyl group, generating a product ion of 134.8, in 
response to fragmentation (fig. 2.14.2c).  Fragmentation of 
phloretin ([M-H]- 273.0) generated a product ion of 166.9 
owing to the loss of ring A from the conjugate system (fig 
2.14.2d).  Quercetin ([M-H]- 301.0) generated a more 
complex fragmentation profile with product ions forming at 
193.0, 178.9, 150.9 ad 106.8 (fig. 2.12.3e).  Product ion 
193.0 corresponds with the loss of the benzoyl system (ring 
A) while the remaining product ions represent dissociation 
ring B which has become unstable.  Fragmentation of 
quercetin 3-β-glucoside generated a product ion of 301.0 due 
to the loss of the sugar motif from the parent ion (fig. 2.14.2f). 
Fragmentation of product ion 301.0 generated the 
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characteristic profile seen with fragmentation of quercetin 
(fig. 2.14.2e).  This data demonstrates that ESI-MS/MS can 
be used to detect polyphenols in a mixture.  Furthermore, 
product ions can be dissociated to generate product ions that 
a re charac ter is t i c to the compounds s t ruc tura l 
characteristics.
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a) b)
c) d)
e)
Figure 2.14.1.  Polyphenol standards used to validate ESI-
MS.  a) Gallic acid [hydroxybenzoic acid], b) Caffeic acid 
[hydroxycinnamic acid], c) Phloretin [dihydrochalcone], d) 
Quercetin [Flavonoid]. e) Quercetin-3-β-glucoside [Flavanoid 
glycoside]
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e)
f)
[M-H]-
 [M-H]- -
[M-H]-
[M-H]- -
Figure 2.14.2.  ESI-MS-MS of polyphenol standards. 
Polyphenol standards were subjected to ESI-MS/MS in 
negative ion mode.  Parent ions [M-H]- are highlighted in red 
and precursor ions highlighted in blue.  a) Full ESI-MS scan, b) 
Gallic acid, c) Caffeic acid, d) Phloretin, e) Quercetin, f) 
Quercetin-3-β-glucoside.
Chapter 3:  Extract  production and effects on breast 
cancer cells
! 3.1:  Rationale
Traditionally, an aqueous extract of Fagonia cretica, prepared 
as a tea, is administered to breast cancer patients in the 
expectation that it can aid in reducing tumour size and 
improving the patientsʼ quality of life.  However, as no 
scientific evidence exists linking the tea to treatment effect, it 
is not known if Fagonia cretica has any chemotherapeutic 
potential.  Many current chemotherapeutic agents have been 
developed based on bioactive molecules obtained by 
extraction and purification from natural products.  Therefore, 
providing scientific evidence for the cytotoxicity  activity of 
Fagonia cretica will demonstrate its chemotherapeutic 
potential as described in traditional medicine.  The methods 
by which these compounds are obtained within a laboratory 
are common analytical techniques and include thin layer 
chromatography, l iquid-l iquid parti t ions and high-
performance-liquid chromatography.
The bioactivity of plant compounds can be determined by 
any assay that tests the effects on biological function.  For 
the development of novel anti-cancer compounds, a 
bioassay that evaluates the effects of treatment on cancer 
cell viability is often used.  Bioactive candidates can then be 
implemented into the drug discovery pipeline that involves 
further purification and characterisation of active compounds 
as well as understanding the biological mechanisms that the 
compounds interfere with.
Many anti-cancer agents currently in clinical use are either 
directly isolated or are derived from the structures of 
bioactive molecules discovered in natural products. 
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Advances in synthetic chemistry and high-throughput 
screening of chemical libraries have become  popular 
methods for drug development in recent years.  However, 
there has been a resurgence in a ʻback-to-basicsʼ approach 
in drug discovery based on natural product chemistry, due to 
the successes enjoyed in the past.  
This chapter aims to describe methods for extraction of dried 
Fagonia cretica plant material that can be used in vitro to 
investigate the effects on breast cancer and normal breast 
epithelial cells.  The bioactivity  of the various extracts in 
terms of their ability  to reduce breast cancer cell viability and 
modulate cellular oxidant levels has also been investigated.
"
" 3.2:  Introduction
Interpreting ethno-pharmacological information accurately, 
constitutes the primary step in determining the medicinal 
potential of a plant, and whether or not one should consider it 
for further scientific investigation.  It is well documented in 
traditional medicine of the Eastern world that Fagonia cretica 
is used as a treatment for many ailments including fever, 
thirst, vomiting, dysentery and typhoid [317,318].  It is also 
documented that a tea or aqueous preparation of Fagonia 
cretica is a popular remedy for cancer.  This substance is 
well tolerated and does not exhibit adverse effects like 
vomiting, diarrhoea or alopecia, which are common side 
effects of standard cytotoxic therapy.  However, there is no 
scientific evidence to back up these claims and so it is not 
known if Fagonia cretica is at all useful therapeutically. 
Isolation of natural products from plants has plays an 
important role in the discovery of novel chemotherapeutic 
agents.  For example, the group of drugs called Vinca 
alkaloids are derived from Catharanthus roseus, also known 
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as the Madagascar Periwinkle [330].  They  include drugs 
such as vinblastine, a microtubule inhibitor that suppresses 
microtubule dynamics and induces cell cycle arrest and 
apoptosis in tumour cells [331].  Vinca alkaloids have been 
used to treat a wide variety of cancer types, notably, in the 
combination regime ABVD (Adriamycin, Bleomycin, 
Vinblastine, Dacarbazine) for Hodgkinʼs lymphoma.  Another 
microtubule inhibitor, paclitaxel, is widely used to treat 
patients with lung, ovarian and breast cancer.  The original 
taxol compound was isolated from the Pacific yew tree in 
1967 and since 1992 has been used clinically in 
chemotherapy regimes [332].  
Secondary metabolites produced by  plants provide a rich 
source of bioactive molecules and many extraction and 
purification methods have been developed for their isolation 
[333].  Commonly  in a laboratory setting, soxhlet extraction is 
employed to extract plant material with different solvents. 
Extracts can be analysed using a simple TLC technique and 
applied directly to a bioassay after removal of the extraction 
solvent.  This is a common first step in bioassay guided 
f ract ionat ion of p lant mater ia l and many novel 
chemotherapeutic agents have been discovered using this 
method [334].
The primary goal of a successful chemotherapeutic drug is 
inhibition of tumour growth or reduction in tumour cell viability 
while minimising damage to healthy tissue that may also 
come into contact with the cytotoxic agent.  A bioassay that 
measures treatment effects on cell viability is commonly 
employed to test the cancer-specific act iv i ty  of 
chemotherapeutic compounds in vitro.  The results can help 
with identifying novel compounds as candidates for drug 
discovery as it is possible to determine early  on if the alleged 
medicinal source has any anti-cancer potential.
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The cellular redox state is vital to the maintenance of 
signalling pathways that are altered by  reactive oxygen 
species (ROS).  Extensive work has provided evidence that 
excessive ROS production contributes to neoplasia, tumour 
growth and drug resistance [335].  Free radicals interact with 
DNA bases and can generate oxidative lesions that can 
result in tumorigenic mutations [336].  In contrast, 
chemotherapy-induced generation of ROS can specifically 
target cancer cells as they demonstrate elevated basal levels 
of ROS and so are more susceptible to lethal oxidative insult 
[337].  It is thought that higher ROS generation in cancer 
cells occurs as a result of increased metabolism and intrinsic 
generation of ROS as a by-product.  As well as this, cancer 
cells exhibit elevated levels of intrinsic anti-oxidants and it 
has been proposed that reduction of these antioxidant 
systems pharmacologically can have a positive impact on 
treatment efficacy  [338].  Furthermore, reductions in 
intracellular oxidants as a result of superoxide dismutase 
inhibition, has been shown to induce apoptosis in leukaemia 
cells [339].  On the contrary, anti-oxidant therapy is effective 
at reducing cancer initiation by lowering the risk of genomic 
mutations by free radicals.  Secondary  metabolites of plants 
contain redox modulating compounds in high abundance. 
They commonly occur as low molecular weight  anti-oxidants 
and as such are able to sequester damaging free radicals 
and alter the cellular redox state.  This can have widespread 
cellular consequences including potentiating cellular survival 
in response to oxidative stress, preventing tumorigenesis and 
modulating important signalling networks.
Little research has been conducted to investigate the 
chemotherapeutic potential of Fagonia cretica although its 
use as a cancer treatment are well documented [317, 318]. 
Interest lies mainly with an aqueous decoction, however, 
extraction with a range of solvents will allow isolation of 
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different compound species based on their polarity and a 
greater understanding of the bioactivity of the plant material. 
The primary aims described in this chapter are to develop a 
suitable extraction and preparation method to generate 
extracts that can be used to test bioactivity in a cell viability 
assay (MTT).  The initial effects of extract treatment on 
viability and intracellular ROS in several breast cancer cell 
lines was also investigated.
!
" 3.3:  Methods
! " 3.3.1:  Thin-layer chromatography
Dried Fagonia cretica (25 g) was subjected to Soxhlet 
extraction for 2, 5 or 24 hours as detailed in section 2.2. 
Extracts were dried under vacuum in a rotary evaporator and 
desiccated under vacuum for 24 hours.  Thin layer 
chromatography of the extracts was carried out as detailed in 
section 2.3.
! " 3.3.2:  MTT assay
The effect of compounds extracted by different solvents on 
MCF-7, MDA-MB-231 and HMEpC cell viability was 
determined using the MTT assay as detailed in section 2.5. 
Cells were treated with up to 2 mg/ml of various extracts for 
up  to 72 hours prior to analysis of cell viability  using the MTT 
assay.  The protective capability of NAC against extract 
treatment was determined by  pre-treating MCF-7 cells for 60 
minutes with 3 mM NAC prior to extract treatment.
" " 3.3.3:  DCF-DA assay
The level of intracellular ROS produced in MCF-7 cells was 
detected using the DCF assay as detailed in section 2.8.
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3.4:  Results
" " 3.4.1:  Extracted Fagonia cretica compound 
profiles differ depending on solvent used
Extracts of Fagonia cretica obtained by Soxhlet extraction 
were analysed by  TLC.  The compound profiles of all 
extractions, except the PET-Ether extraction, separated by 
TLC contained similar bands although were not 100% 
identical indicating some cross over in compound extraction 
(figure. 3.4.1).  Comparing individual extractions taken at the 
various time points revealed a uniform extraction with no 
degradation of compounds over the extraction process for 
any of the solvent extractions.  It is important to note 
concentration differences in compound profiles which can be 
attributed to loading of samples not being equal as this was 
not controlled.
! " 3.4.2:  All extracts reduce MCF-7 cell 
viability
All the solvent extracts were tested for activity against MCF-7 
cells using the MTT assay.  After 24 hours treatment all 
extracts reduced MCF-7 cell viability in a dose dependent 
manner, albeit with varying effectiveness (figure 3.4.2).  The 
PET-ether 40-60 extract demonstrated to be the most 
effective with an IC25 of 0.35 mg/ml and a reduction in cell 
viability of 87% with a 2 mg/ml extract treatment after 24 
hours (figure 3.4.2f).  Importantly for this study, the aqueous 
extract showed dose dependent activity  against MCF-7 cells 
with an IC25 of 0.43 mg/ml and a 47% reduction in cell 
viability with 2 mg/ml treatment at 24 hours (figure 3.4.2a). 
Our knowledge of Fagonia cretica as a therapeutic option for 
breast cancer patients claims that is is administered as a tea. 
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Therefore, subsequent experiments have been performed 
with an aqueous extract of Fagonia cretica.
" "
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Figure 3.4.1.  TLC analysis of Fagonia cretica solvent 
extractions.  Dried Fagonia cretica was subjected to 
Soxhlet extraction in either (a) water, (b) methanol, (c) 
dichloromethane, (d) diethylether,  (e) toluene or (f) pet-ether 
40-60 for up  to 24 hours.  Extractions were evaporated in a 
rotary  evaporator and desiccated under vacuum before 
analysis by TLC.  TLC  was carried out with a mobile phase 
of ethyl acetate:methanol (90:10) and visualised with vanillin 
stain.  Stains are representative of three independent 
experiments.
" "
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Figure 3.4.2.  The effect of extracts of Fagonia cretica on 
MCF-7 cell viability.  MCF-7 cells were treated for 24 hours 
with up to 2mg/ml of (a) water, (b) methanol, (c) 
dichloromethane, (d) diethyl ether, (e) toluene or (f) PET-ether 
(40-60) extracts of Fagonia cretica prior to analysis of cell 
viability using MTT assay.  Data denoted *  (p<0.05), ** 
(p<0.01) and *** (p<0.001) are significant compared to 
untreated control analysed by one-way ANOVA with Dunnettʼs 
multiple comparison post test (mean ±  standard deviation).  All 
data is representative of at least three independent 
experiments performed in triplicate.
A B
C D
E F
" " 3.4.3:  An aqueous extract  reduces MCF-7 
and MDA-MB-231 viability, but not HMEpC
An aqueous extract of Fagonia cretica was tested for its 
ability  to specifically  reduce breast cancer cell viability while 
not affecting human mammary epithelial cells.  The aqueous 
extract was able to reduce cell viability in a time and dose 
dependent manner in both MCF-7 (figure 3.4.3a) and MDA-
MB-231 (figure 3.4.3b).  After 24 hours treatment with 2mg/
ml extract, MCF-7 cell viability was significantly decreased by 
39.6%, while MDA-MB-231 cell viability was decreased by 
30.7%.  After 72 hours of extract treatment, MCF-7 cell 
viability had decreased by 70.1% and MDA-MB-231 cell 
viability had decreased by 66.7%.  Treatment was more 
effective against MCF-7 cells, which were sensitive to an 
extract IC25 of 0.4 mg/ml compared to an IC25 of 1.0 mg/ml 
against MDA-MB-231 cells after 24 hours.  In comparison, 
extract treatment could only induce a loss of cell viability  in 
HMEpC after 48 hours treatment with 2mg/ml (figure 3.4.3c). 
HMEpC cell viability was reduced 11.6% after 48 hours and 
16.3% after 72 hours treatment with 2 mg/ml extract.
" 3.4.4:  Aqueous extract treatment increases 
intracellular ROS levels in MCF-7 cells.
Plant extracts contain redox modulating molecules in high 
abundance.  Alterations in the cellular redox state can have a 
wide range of cellular consequences including modulation of 
cell survival responses.  Levels of intracellular ROS in 
response to extract treatment were assessed using the DCF-
DA probe.  Extract treatment of 1 or 2 mg/ml significantly 
increased the level of intracellular ROS in MCF-7 cells 
treated for 3 hours.  All increases could be attenuated to 
basal level by pre-treatment with 3 mM NAC for 60 minutes 
before extract treatment (figure 3.4.4).  Treatment with 1 mg/
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Figure 3.4.3.  Aqueous extract reduces breast cancer cell 
but not human mammary epithelial cell viability.  (a) MCF-7, 
(b) MDA-MB-231 and (c) HMEpC cells were treated with up  to 
2mg/ml aqueous extract for up  to 72 hours prior to analysis of 
cell viability by MTT assay.  Data denoted ***  (p<0.001) is 
significant at all time points compared to untreated control 
analysed by one-way ANOVA with Dunnettʼs multiple 
comparison post test.  Data denoted # (p<0.001) is significant at 
72 hours compared to untreated control analysed by one-way 
ANOVA with Dunnettʼs multiple comparison post test (mean ± 
standard deviation). All data is representative of at least three 
independent experiments performed in triplicate.
ml extract induced a 70.1% increase in intracellular ROS, 
while 2 mg/ml treatment induced a 76.3% increase, which 
was not significantly greater than the effect of 1 mg/ml 
extract.  In order to determine the role of ROS in extract 
induced-cytotoxicity, MCF-7 cells were pre-treated with 3 mM 
NAC, prior to extract treatment and analysis of cell viability 
using the MTT assay.  Cellular pretreatment with NAC  did not 
significantly alter loss of cell viability in MCF-7 cells following 
extract treatment (figure 3.4.5).
!
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Figure 3.4.4:  Aqueous Extract treatment increases 
intracellular ROS levels in MCF-7 cells.  MCF-7 cells were 
treated with and without 3mM NAC for 60 minutes prior to 
extract treatment of indicated concentrations for 3 hours. 
Intracellular ROS was detected using the DCF-DA probe. 
Data denoted ** (p<0.01) is significant to untreated control or 
as indicate analysed by one-way ANOVA with Bonferroniʼs 
multiple comparison post test (mean ±  standard deviation). 
Data is from three independent experiments performed in 
triplicate.
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Figure 3.4.5.  NAC does not  effect  extract-induced loss of 
cell viability in MCF-7 cells.  MCF-7 cells were treated with 
and without 3mM NAC for 60 minutes prior to 2mg/ml extract 
treatment for (a) 24, (b) 48 or (c) 72 hours.  Cell viability was 
determined by  MTT assay.  Data from three independent 
experiments performed in triplicate and representative of the 
mean ± standard deviation.
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b)
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" 3.5:  Discussion
Traditional eastern medicine documents that Fagonia cretica 
is administered as a herbal tea for the treatment of breast 
cancer [317, 318], however very little literature exists 
describing its anti-cancer activity in detail.  The present 
chapter aimed to describe the development of methods for 
efficient extraction of compounds from Fagonia cretica using 
various solvents and test these extracts, with particular 
interest on the aqueous extract, for potential bioactivity 
towards breast cancer cells.
Results from the current study  showed that extraction of 
Fagonia cretica using the Soxhlet method extracted 
compounds detectable by TLC  and vanillin staining for all the 
solvents selected for extraction.  Most of the TLC  profiles 
were similar in banding patterns suggesting crossover 
between solvents and the compound species isolated.  The 
PET-ether extract had a more individual TLC profile which 
may be reflected in its ability  to reduce MCF-7 cell viability 
more then the other extracts.  Precise differences in 
compound profiles between extracts could be determined by 
calculating the retardation factor of individual bands. 
However, in this case it is not necessary as this study is 
interested in developing suitable extraction methods  to 
produce extracts suitable for testing the bioactivity  of Fagonia 
cretica against cancer cells.  Although the primary focus is to 
elucidate the chemotherapeutic potential of an aqueous 
extract, it is important to note that the other extracts could all 
reduce MCF-7 cell viability in a dose dependent manner after 
24 hours.  However, the limitations of the MTT assay mean it 
is not clear if the reduction is due to cell death, growth 
inhibition or a change in the metabolic state of the cells. 
Hussain et al. showed previously that a methanolic extract of 
Fagonia cretica was cytotoxic in a shrimp brine assay as well 
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as exhibiting anti-tumour activity  against Agrobacterium in a 
potato disc assay  [318].  This chapter shows that indeed a 
methanolic extract is cytotoxic (to MCF-7 cells), and for the 
first time, demonstrates that other solvent extracts including 
an aqueous extract are cytotoxic to MCF-7 cells.  It is also 
shown here that an aqueous extract is cytotoxic to MDA-
MB-231 cells but not HMEpC, highlighting the extracts 
potential to kill or inhibit the growth of cancer cells but not 
their normal counterparts.  Furthermore, extract treatment 
increased intracellular ROS levels in MCF-7 cells, but 
attenuation with NAC  did not alter cell survival.  The anti-
oxidant molecule NAC is readily  taken up  by MCF-7 cells in 
culture and is capable of reducing a chemically induced 
oxidative load as shown in figure 2.8.1.
    
The MCF-7 cell line represents a phenotypically  different 
breast cancer cell line to MDA-MB-231 cells.  Both cell lines 
were derived from pleural effusions of metastatic mammary 
carcinoma patients and are tumorigenic in vivo but MDA-
MB-231 cells are considered to have a more aggressive 
phenotype [340].  This is due to changes in markers 
associated with epithelial to mensenchymal transition that 
are responsible for cell migration, invasion and mobility [341]. 
The MDA-MB-231 cell line also lacks expression of estrogen 
and Her2/neu receptors, a phenotype representative of the 
notorious ʻtriple negativeʼ breast cancers, for which effective 
treatment is rare.  One other important difference between 
the two cell lines is that MDA-MB-231 cells express a mutant 
non-functional form of the tumour suppressor p53 while 
MCF-7 p53 status is intact.  This has wide reaching 
consequences on the cellular response to chemotherapy as 
p53 is a critical regulator of apoptosis and cell cycle arrest. 
In light of these differences, it is unsurprising that extract 
treatment exerts a varying degree of cytotoxic potential 
against the different breast cancer cell lines.
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Modulation of intrinsic redox systems, in particular generation 
of excessive ROS or inhibition of conserved and adaptive 
anti-oxidant systems, can be detrimental to cellular survival. 
Excess ROS are a major cause of genomic damage and thus 
are implicated in tumorigenesis and other pathologies [342]. 
The oxidative DNA lesion, 8-oxo-dG, is the most mutagenic 
and is a prevalent mutation within tumour genetics.  Reactive 
oxygen species are a byproduct of normal cellular 
metabolism and are effectively regulated by intrinsic anti-
oxidant systems.  However, exogenous sources of ROS such 
as ionising radiation and tobacco smoke, as well as 
deregulation of anti-oxidant systems, can create an 
environment of oxidative stress that results in pathology.  In 
contrast to the tumorigenic properties of ROS, established 
tumours exhibit a higher basal level of ROS and are 
therefore, more susceptible to lethal damage by oxidative 
stress [338].  It is well documented that plant extracts contain 
a high level of redox modulating compounds.  Indeed an 
extract of Fagonia cretica has previously been shown to 
protect against oxidative stress in rat hippocampal slices by 
increasing GSH levels and demonstrating free radical 
scavenging properties [319].  In this investigation, extract 
treatment of MCF-7 cells resulted in an increase in 
intracellular ROS after 3 hours, suggesting that excess 
generation of ROS may contribute to loss of cell viability. 
However, upon attenuation of extract-induced ROS 
production, no improvement on cell survival was shown. 
This suggests that increased ROS does not play a role in 
extract-induced cytotoxicity  of MCF-7 cells.  It is probable 
that the extract contains a complex mixture of compounds 
and that changes in ROS may be associated with treatment 
but not with efficacy.  
!
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" 3.6:  Conclusion
This chapter has demonstrated that bioactive extracts of 
Fagonia cretica can be generated using the soxhlet 
extraction method and importantly, that an aqueous extract of 
Fagonia cretica is able to reduce cell viability  of two 
phenotypically different breast cancer cell lines (MCF-7 and 
MDA-MB-231), without affecting normal breast epithelial cells 
(HMEpC).  It has also been shown that aqueous extract 
treatment increase intracellular ROS levels in MCF-7 cells.
Although it is clear that extract treatment reduces cell viability 
in breast cancer cells, the limitations of the MTT assay mean 
that it is not possible to distinguish growth arrest from cell 
death, as the output measurement is based solely  on 
mitochondrial activity.  In order to determine if treatment 
induces cell death or growth inhibition, the effect of extract 
treatment on cell cycle and apoptosis, must first be 
investigated.  Increasing ROS levels in cancer cells has been 
shown to induce cell death and here it has been shown that 
extract treatment does indeed result in an increase in 
intracellular ROS.  However, it is not clear what the 
consequences of the increase are, as the relative increase 
observed in the DCF-DA assay  is not necessarily large 
enough to exert an effect. 
The results from this chapter highlight the potential for an 
aqueous extract to be useful in the treatment of breast 
cancer.  However, the mechanisms governing its activity, 
have yet to be elucidated.  The subsequent chapters focus 
on the characterisation of the aqueous extract because 
although it did not show the greatest efficacy for reducing 
MCF-7 cell viability  our understanding of Fagonia cretica as a 
breast cancer therapeutic is based on its administration as a 
herbal tea.
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Chapter 4:  Extract  induced cell cycle arrest and 
apoptosis
! 4.1:  Rationale
Cancer cells exhibit heightened proliferation and 
consequently  are susceptible to stresses that affect cell cycle 
progression such as DNA damage or nutrient deprivation. 
With respect to DNA damage, activation of the DNA damage 
response and subsequent DNA repair mechanisms confers 
cell survival.  When cellular DNA damage is too great to 
repair, initiation of the apoptotic machinery ensures organism 
survival by removing potentially tumorigenic cells.  This 
principle is exploitable for cancer therapy because an 
increased proliferation rate exposes DNA from the protection 
of histones during replication, making the cell susceptible to 
DNA damaging agents and subsequently to growth inhibition 
by cell cycle arrest and cell death by apoptosis.  As well as 
this, many cancers exhibit mutations within the DNA repair 
system and consequently  struggle to repair radio or 
chemotherapy induced DNA damage, ultimately  leading to 
apoptotic cell death.
Cell cycle arrest and apoptosis are two major targets for 
cancer chemotherapy as they  allow for reduced tumour 
growth (and disease progression) and the removal of mutant 
cells in a controlled, non-damaging manner.  The previous 
chapter demonstrated that an aqueous extract could reduce 
breast cancer cell viability  in vitro.  The limitations of the 
MTT assay mean that it is not possible to determine the 
action that results in a reduction in MTT conversion to 
formazan, thus further investigations are required to 
elucidate the mechanism of apparent loss of viability.  In this 
chapter, the effects of extract treatment on the cell cycle and 
induction of apoptosis are investigated in order to understand 
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how treatment reduces cell viability.  The effects on important 
proteins associated with controlling cell cycle checkpoints 
and apoptosis are also investigated.
" 4.2:  Introduction
Cancer cells exhibit many  characteristics that distinguish 
them from healthy cells and in fact many of these unique 
molecular features provide potential targets for therapy 
[343,344].  One important difference of a cancer cell is an 
increased replicative capacity, which ultimately, is 
responsible for tumour formation.  Loss of cell cycle inhibition 
and increased cycling rate is also a target for cancer 
treatment as during cell replication DNA is unwound and 
relatively exposed.  This loss of histone protection allows for 
DNA damaging agents to exert an effect and cause damage 
to DNA bases or interfere with DNA replication [343].  For 
example, cisplatin, a platinum based DNA inter and/or intra-
strand cross-linking agent, is widely used in cancer 
chemotherapy and is effective by inducing cell cycle arrest 
and apoptosis in cancer cells by stalling of replication forks 
[279].  This in turn activates DNA damage response 
signalling leading to cell cycle inhibition and protection from 
further DNA damage.  As well as this, starvation or nutrient 
deprivation can induce a quiescent state by initiating cell 
cycle arrest [345].  
The eukaryotic cell cycle is regulated by formation of phase-
specific cyclin/CDK complexes that allow progression 
through cell cycle checkpoints and are discussed in detail in 
chapter 1.2 [145].  In response to DNA damage, activation of 
cell cycle regulatory proteins such as p53 and p21, control 
cell cycle progression by preventing activation or 
transcription of specific cyclins [146].  The tumour suppressor 
p53 can be activated by various direct post-translational 
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modifications such as ATM/ATR-dependent phosphorylation 
as a result of DNA damage or indirectly such as modification 
of its negative regulator MDM2.  Upon activation, p53 is 
translocated to the nucleus where it is transcriptionally  active. 
An important cell cycle regulatory  protein, p21, is a p53 
transcription target and is responsible for inhibiting cell cycle 
progression [170].  The CDK-inhibitor, p21, directly  binds to 
and inhibits cyclin-CDK2/1 complexes and prevents 
progression through cell cycle checkpoints [171].
DNA damage-activated cell cycle arrest serves to allow DNA 
repair mechanisms to repair DNA lesions and protect against 
possible lethal genomic mutations [111].  Under certain 
conditions, such as excessive exposure to UV light, the level 
of DNA damage can exceed the repair capabilities and in 
order to protect the organism, the apoptotic machinery  is 
activated [286].  The DNA repair pathways are often 
dysregulated in cancers, thus providing a target for cancer 
therapy through an increased susceptibility to DNA damage 
[343].  p53 also plays an important role in modulating 
apoptosis through binding to its transcriptional target BAX. 
The bax protein is a pro-apoptotic member of the Bcl-2 gene 
family that regulates apoptosis.  It has been shown that p53 
promotes apoptosis by decreasing expression of the anti-
apoptotic Bcl-2 protein and increasing expression of bax 
[285].  It has also been demonstrated that cytoplasmic p53 
can act like a BH3-only Bcl-2 protein and activate bax 
independent of transcription [294].  Under pro-apoptotic 
conditions this has been shown to promote apoptosis by 
inducing mitochondrial outer membrane permeabilisation 
[263].
It was shown previously in chapter 3 that treatment with an 
aqueous extract of Fagonia cretica can significantly  reduce 
MTT reduction as a measure of viability in MCF-7 cells. 
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However, it is not yet known how this occurs.  In this chapter 
the effects of extract treatment on cell cycle and apoptosis in 
MCF-7 cells are described.  The effects of extract treatment 
on p53 expression and its transcriptional targets, p21 and 
bax, will also be investigated as they are influential in the 
activation of cell cycle arrest and apoptosis in response to 
cellular stress.
" 4.3:  Methods
" " 4.3.1:  Cell cycle analysis of aqueous extract 
treated cells
The effect of aqueous extract treatment on MCF-7 cells was 
determined using flow cytometry as detailed in section 2.6.
! ! 4.3.2:  Detection of apoptosis in aqueous 
extract treated cells
Apoptosis in treated MCF-7 cells was detected by flow 
cytometry as detailed in section 2.7.
" " 4.3.3:  Quantification of p53, p21 and Bax 
expression in aqueous extract treated cells
The effects of aqueous extract treatment on p53, p21 and 
Bax protein expression in MCF-7 cells was determined by 
SDS-PAGE and western blot as outlined in section 2.10. The 
protein (20 μg per lysate) was separated on a 16% SDS-
PAGE gel before western blot procedure.  Membranes were 
probed with rabbit anti-human p53 (1:1000), mouse anti-
human p21 (1:100) or rabbit anti-human bax (1:1000) before 
addition of sheep  anti-rabbit or anti-mouse HRP conjugated 
antibody (1:10000).  Bands were visualised using ECL 
reagent exposed to photographic film for 5 minutes.  
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" 4.4:  Results
" " 4.4.1:  Aqueous extract  treatment indues G0/
G1 growth arrest
The effect of aqueous extract treatment on MCF-7 cell cycle 
was determined in order to ascertain the mechanism by 
which extract treatment reduces MCF-7 cell viability. MCF-7 
cells were treated with 2 mg/ml extract for up to 24 hours 
before cell cycle analysis was carried out by flow cytometry. 
Extract treatment induced significant growth arrest in G0/G1 
phase of the cell cycle after 5 hours treatment (figure 4.4.1a); 
after 5 hours, extract treatment resulted in an increase from 
44.6% to 62.5% of cells in G0/G1 population which increased 
further to 73.3% after 24 hours treatment.  In parallel with an 
increasing G0/G1 population, extract treatment resulted in a 
significant decrease from 16.3% to 10.2% of cells in G2 after 
7 hours which decreased further to 5.4% after 24 hours 
(figure 4.4.1b).
" " 4.4.2:  Aqueous extract treatment increases 
expression of p53 and p21
Cell cycle arrest in G0/G1 phase of the cell cycle is regulated 
by activation of the p53 transcription target p21.  The CDK-
inhibitor, p21, inhibits cell cycle progression via inhibition of 
CDK activity, resulting in hypo-phosphorylation of pRB, 
inactivation of E2F and blockade of progression through G1. 
Thus, the protein expression levels of p53 and p21 in 
response to aqueous extract treatment were determined by 
western blot.  MCF-7 cells were treated with 2 mg/ml extract 
for up  to 24 hours before lysate collection and protein 
expression analysis.  Figure 4.4.2a shows that MCF-7 cells 
increase expression levels of p53 and p21 in a time 
dependent manner in response to extract treatment. 
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Densitometric analysis of protein expression revealed a 
48.4% increase in p53 after 5 hours treatment and a 129.2% 
increase after 24 hours (figure 4.4.2b).  The increase in p53 
expression was paralleled by a 49.1% increase in p21 
expression after 5 hours and an 82% increase after 24 hours 
(figure 4.4.2c).
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Figure 4.4.1:  Extract treatment induces G0/G1 arrest in 
MCF-7 cells.  MCF-7 cells were treated with 2mg/ml extract 
for up to 24 hours before cell cycle analysis by flow cytometry. 
Cell populations (a) G0/G1 and (b) G2 were determined 
based on fluorescence profiles.  Data denoted * (p<0.05), ** 
(p<0.01) and ***  (p<0.001) are significant compared to control 
(time=0 hours) as analysed by one-way ANOVA with 
Dunnettʼs multiple comparison post test (mean ± standard 
deviation).  Data is from three independent experiments 
performed in triplicate.
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Figure 4.4.2:  Extract treatment increases p53 and p21 
expression in MCF-7 cells.  MCF-7 cells were treated with 
2mg/ml extract for up to 24 hours before expression of (a) p53 
and p21 was determined by SDS-PAGE and western blot.  β-
actin was used as a loading control.  Densitometry for (b) p53 
and (c) p21 was calculated as a ratio to β-actin and expressed 
as fold change compared to control (time=0 hours).  Data 
denoted **  (p<0.01) and ***  (p<0.001) are significant 
compared to control analysed by one-way ANOVA with 
Dunnettʼs multiple comparison post test (mean ±  standard 
deviation).  Data is representative of three independent 
experiments.
" 4.4.3:"Aqueous extract treatment  induces 
apoptosis
Activation of apoptosis pathways in response to 
chemotherapy is an important outcome for effective 
treatment.  The tumour suppressor, p53, plays an important 
role in apoptotic cell death via transcription of pro-apoptotic 
genes such as BAX.  Apoptosis in treated MCF-7 cells was 
detected using flow cytometry after staining for the presence 
of phosphatidylserine on the cell surface using using the 
annexin V binding assay.  Extract treatment induced 
significant levels of apoptosis in MCF-7 cells after 24 hours 
treatment (figure 4.4.3b), which increased further after 48 
and 72 hours (figure 4.4.3c and d).  After 24 hours treatment, 
the level of detected apoptosis had increased from 3.9% to 
28.5% and further increased to 73.4% after 72 hours (figure 
4.4.4b).  In parallel, the level of live cells decreased from 
93.2% to 60.2% after 24 hours and further decreased to 
18.5% after 72 hours (figure 4.4.4a).  The pro-apoptotic Bcl-2 
family gene, BAX, is a transcriptional target for p53 and is 
up-regulated upon p53-mediated apoptotic signalling.  The 
effects of extract treatment on bax protein expression were 
also investigated to determine whether or not induction of 
apoptosis was related to the increase in p53 expression seen 
in 4.4.2.  Extract treatment of 2 mg/ml significantly increased 
Bax protein levels after 48 hours and sustained treatment (up 
to 72 hours) resulted in a further increase in bax protein 
expression (figure 4.4.5a).  Bax expression was increased 
19-fold in response to extract treatment after 48 hours and 
22-fold after 72 hours (figure 4.4.5b).
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a)
b)Figure 4.4.3.  Extract treatment induces apoptosis in MCF-7 cells.  MCF-7 cells were treated with 2mg/ml extract 
for either (a) 0, (b) 24, (c) 48 or (d) 72 hours prior to 
detection of apoptosis by flow cytometry.  Histograms were 
generated according to log annexin V-FITC (FL1) and log 
propidium iodide (FL3) fluorescence.  Data is representative 
of three independent experiments performed in triplicate.
a) b)
c) d)
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Figure 4.4.4.  Extract treatment induces apoptosis in 
MCF-7 cells.  MCF-7 cells treated with 2mg/ml extract for up 
to 72 hours were subjected to flow cytometric analysis for the 
detection of apoptosis.  Cell populations of (a) live cells [% 
annexin V -ve/PI -ve] and (b) apoptotic cells [% annexin V 
+ve/PI -ve] were isolated based on fluorescent profiles.  Data 
denoted ***  (p<0.001) is significant compared to control 
(time=0 hours) analysed by one-way ANOVA with Dunnettʼs 
multiple comparison post test .  Data is from three 
independent experiments performed in triplicate and 
presented as mean ± standard deviation.
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Figure 4.4.5.  Extract treatment induces bax expression 
in MCF-7 cells.  MCF-7 cells were treated with 2mg/ml 
extract for up to 72 hours before expression of (a) bax was 
determined by SDS-PAGE and western blot.  β-actin was 
used as a loading control.  Densitometry for (b) bax was 
calculated as a ratio to β-actin and expressed as fold change 
compared to control (time=0 hours).  Data denoted ** 
(p<0.01) is significant compared to control analysed by one-
way ANOVA with Dunnettʼs multiple comparison post test. 
Data is representative of three independent experiments and 
is presented as mean ± standard deviation.
" 4.5  Discussion
Cell cycle checkpoints are crucial in regulating cell cycle 
progression and provide a defence against lethal genomic 
mutations.  These restriction points provide decision points at 
different phases of the cell cycle that allow the cell to cease 
replication whilst the environment is optimised for successful 
cell division.  For example, following genomic insult, DNA 
repair is initiated and cell cycle halted to prevent replication 
of possibly  tumorigenic lesions [343].  Cancer cells are 
particularly sensitive to cell cycle modulation due to their 
hyper-proliferative phenotype and DNA damaging agents 
have been shown to induce growth arrest in a variety of 
breast cancer cell types [46].  Another important 
characteristic and drug target of many cancers is 
dysregulation of the DNA repair systems [343].  Thus, DNA 
damaging agents which activate cell cycle arrest can 
ultimately  cause apoptotic cell death if the damage is 
irreparable.
This chapter has demonstrated that cell cycle arrest and 
apoptosis can be induced upon extract treatment of MCF-7 
cells after both 5 and 24 hours.  The results also show that 
cell cycle arrest and apoptosis may be associated with 
stabilisation of p53 and an increase in its transcriptional 
activity  leading to activation of p21.  Stabilisation of p53 can 
occur in response to stress-induced dissociation of p53 from 
its negative regulator MDM2.  This has been shown to be 
regulated by kinase activity of ATM and ATR which, in 
response to DNA damage, can activate p53 directly  through 
site-specific phosphorylation or indirectly by phosphorylation 
of MDM2 and destabilisation of the MDM2-p53 complex. 
Extract treatment induced time dependent growth arrest in 
G0/G1 followed by apoptosis after 24 hours, suggesting that 
after 24 hours treatment, a threshold is reached that 
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activates apoptosis.  This effect has been shown with other 
plant extracts, for example the work of Hu et al. showed that 
an extract of Ganoderma lucidum induces G1 arrest at 12 
hours followed by significant apoptosis at 36 hours in MCF-7 
cells [346].  A delayed on-set of apoptosis suggests the 
possibility of the extract containing DNA damaging agents 
as,longer extract incubation times may increase the level of 
DNA damage and eventually lead to apoptosis when damage 
is beyond repair.  Alternatively, prolonged activation of DNA 
repair mechanisms may invoke metabolic catastrophe, which 
could induce autophagy and apoptosis or autophagic cell 
death [312].
A central cell cycle regulator is p21, a CDK inhibitor that 
blocks cyclin kinase activity by inhibiting the formation of 
cyclin-CDK complexes.  The protein, p21, is transcriptionally 
regulated by p53 which is rapidly stabilised under stress 
conditions by dissociation from its negative regulator MDM2 
[101].  The results described in this chapter show that in 
response to aqueous extract treatment, expression levels of 
p53 and p21 are both increased in a time dependent manner. 
The expression levels of p53 were significantly increased 
after 5 hours treatment which coincides with the significant 
level of G1 arrest seen also after 5 hours.  The level of p53 
and G1 arrest also both increased towards 24 hours 
suggesting that the latter may be effected by  the former. 
This effect was also seen in the expression levels of p21 in 
response to extract treatment, suggesting that in response to 
increased p53 levels, transcriptional activity  of p53 may be 
driving an increase in p21 expression resulting in cell cycle 
arrest.  The p53-p21 axis in cell cycle arrest is well 
documented and agrees with the current findings [347].  It 
was also evident, that in response to extract treatment, bax 
protein levels increased.  Bax expression correlated with 
induction of apoptosis detected by flow cytometry  and 
provides good evidence that extract treatment creates a pro-
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apoptotic environment that may be regulated by induction of 
bax.  As bax, like p21, is a transcriptional target of p53, the 
results provide further evidence that extract-induced p53 
expression drives cell cycle arrest and apoptosis in MCF-7 
cells.
These results demonstrate that loss of MCF-7 cell viability 
(chapter 3) is caused by extract induced G1 arrest and 
apoptosis, and that this effect may be a result of p53 
transcriptional activation and/or protein stabilisation.  It is well 
known that cell cycle arrest and apoptosis are major 
consequences of DNA damage, and the susceptibility of 
genomic material in cancer cells highlights the possibility that 
the extract may contain DNA damaging agent(s).
! 4.6:  Conclusion
This chapter describes the potential mechanisms by which 
an aqueous extract of Fagonia cretica reduces MCF-7 cell 
viability.  Flow cytometric and western blot methods were 
used to assess the effects of aqueous extract treatment on 
cell cycle and apoptosis with particular emphasis on p53 
mediated effects.  Cell viability  in MCF-7 cells appears to be 
reduced as a result of cell cycle arrest and apoptosis.  This 
could be controlled by transcriptional activation of p53 
because levels of p53 transcriptional targets p21 and bax 
were increased alongside increases in p53 expression.  This 
may be a result of extract induced stress, potentially, DNA 
damage.  Increases in expression of p53 transcriptional 
targets p21 and bax, which are involved in cell cycle arrest 
and apoptosis respectively, demonstrate a potential role for 
p53 in extract induced cytotoxicity towards MCF-7 cells. 
Further work to characterise the initiation steps leading to 
p53 stabilisation would provide a clearer insight into the 
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mechanism by  which the aqueous extract exerts activity 
towards breast cancer cells.
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Chapter 5:  Aqueous extract-induced DNA damage and 
activation of the DNA damage response
! 5.1:  Rationale
Cell cycle arrest and apoptosis can be induced by a variety 
of stimuli such as DNA damage and nutrient deprivation 
[146].  DNA damage results in activation of the DNA damage 
response which halts cell cycle progression in order to repair 
damaged DNA.  In response to irreparable DNA damage the 
cell initiates apoptosis in order to remove itself from the 
population [51].  As cancer cells are hyper-proliferative they 
are highly susceptible to DNA damaging agents and thus can 
be targeted efficiently with treatments that modulate the 
DNA damage response or induce genomic lesions.  Plant 
extracts contain a large variety of phenolic compounds that 
commonly  can protect against oxidative DNA damage 
through their radical scavenging properties [348].  However, 
there is also evidence of natural products inducing DNA 
damage in tumour models.  For example Doxorubicin was 
derived from daunorubicin, an antibiotic from Streptomyces 
peucetius that was discovered to have DNA damage-
inducing activity towards murine tumours [349].
The investigations described in chapters 3 and 4 have shown 
that treatment of MCF-7 cells with an aqueous extract of 
Fagonia cretica leads to cell cycle arrest and cell death 
probably via  p53-mediated mechanisms.  In this chapter, the 
effect of extract treatment on activation of the DNA damage 
response is described.  The involvement of p53 in the DNA 
damage response was also investigated to further 
understand how extract treatment initiates cell cycle arrest 
and apoptosis in MCF-7 cells.
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" 5.2:  Introduction
The DNA damage response (DDR) is a complex signal 
transduction network comprised of sensors, transducers and 
effectors.  In response to DNA damage, DNA damage 
sensors recruit mediators to the lesion which in turn signal 
transducers and effectors leading to a wide range of cellular 
responses such as cell cycle inhibition, autophagy, chromatin 
remodelling, DNA repair and apoptosis [50].  This network is 
critical to maintaining genomic integrity and prevent 
tumorigenesis, but is also utilised as a chemotherapeutic 
target for DNA damaging agents.
DNA damage can occur through a myriad of sources 
including UV-light, oxidative stress and chemo/radiotherapy. 
DNA damage lesions include, methylation or oxidation of 
bases and single or double strand breaks, which all corrupt 
the structural integrity of DNA [39].  The most lethal lesion to 
occur is a double strand break and results in recruitment of 
sensor proteins that are charged with eliciting a cellular 
response [60].  Detection of genomic lesions activates 
members of the phosphoinositide kinase (PIK)-related 
protein family, including ataxia telangiectasia mutated (ATM), 
ataxia telangiectasia and Rad3-related protein (ATR) and 
DNA-dependent protein kinase (DNA-PK) which relay the 
signal to transcription factors, such as p53, to elicit a cellular 
response [68].  Indeed, it has been shown that ATM 
activation is crucial for DNA damage-induced cell cycle arrest 
via its kinase activity on key  transcription factors such as p53 
[65].  In response to infra-red radiation, activation of ATM as 
measured by site specific phosphorylation at serine-1981 is 
maximal within minutes.  This highlights the importance of 
ATM within the DDR [114].
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In response to DNA damage, p53 becomes rapidly stabilised, 
in-part through site specific phosphorylation of serine-15 by 
the ATM kinase [82].  Post-translational modifications of p53 
such as phosphorylation and acetylation play a role in 
transactivation of p53 and serine phosphorylation within the 
C-terminus can activate the DNA binding function of p53 
[118].  Previous studies have demonstrated that DNA 
damaging agents can induce cell cycle arrest and apoptosis 
in cancer cells via activation of the DNA damage response, 
specifically through ATM/p53-mediated pathways [88,350]. 
Pharmacological inhibitors of ATM, such as caffeine, have 
been shown to sensitise tumour cells to genotoxic stress by 
reducing serine-15 phosphorylation of p53 and preventing 
DDR signalling [351].  However, caffeine-mediated 
suppression of ATM has also been reported to attenuate 
DNA damage induced cell cycle arrest and apoptosis [352].
It has been shown that loss of wild-type p53 accelerates 
tumour development in mice and that p53-dependent 
apoptosis is critical to regulating tumorigenesis [353].  It has 
been established that over 50% of tumours produce mutant, 
non-functional p53 and that mutations within the TP53 gene 
are the most frequent oncogenic mutation in human cancers 
[98].  The high frequency of TP53 mutations in tumours 
highlights the need for chemotherapeutic treatments that 
work independently of p53-mediated effects.  In fact many 
p53-independent mechanisms that lead to cancer cell death 
have been described [290,292,294].  The anti-diabetic drug 
metformin has been shown to reduce tumour growth of p53-/- 
xenografts via alterations in cellular metabolic state [354]. 
Studies carried out by Li et al. have also shown that DNA 
damage-induced XPA translocation activates cell cycle 
checkpoints independent of cellular p53-status and is not 
regulated by ATM/ATR pathways [355].  
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The research described in previous chapters has shown that 
treatment with an aqueous extract of Fagonia cretica can 
significantly reduce MCF-7 cell viability by initiating cell cycle 
arrest and apoptosis with increased expression of p53, p21 
and bax.  The current study aims to identify a possible 
mechanism for extract induced-cytotoxicity in MCF-7 cells 
and to investigate upstream targets involved in initiating cell 
cycle arrest and apoptosis.
!
" 5.3:  Methods
! ! 5.3.1:  DNA damage detection by comet 
assay
The ability of aqueous extract treatment to induce strand 
breaks in MCF-7 cells was assessed using the comet assay 
as detailed in section 2.9.
" " 5.3.2:  Protein expression analysis by 
western blot
The effects of aqueous extract treatment on γ-H2AX, p53 
and p21 protein expression in MCF-7 cells were determined 
by SDS-PAGE and western blot as outlined in section 2.10. 
A total of 20μg protein per lysate was separated on a 16% 
SDS-PAGE gel before western blot procedure.  Membranes 
were probed with rabbit anti-human γ-H2AX (1:1000),  rabbit 
anti-human p53 (1:1000) or mouse anti-human p21 (1:100) 
before addition of sheep anti-rabbit or anti-mouse HRP 
conjugated antibody (1:10000).  Bands were visualised using 
ECL reagent exposed to photographic film for 5-20 minutes. 
" "
"
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" " 5.3.3:  MTT - cell viability assay
The effect of aqueous extract treatment on MCF-7, MDA-
MB-231 cell viability was determined using the MTT assay as 
detailed in section 2.5.  Cells were pre-treated with 3 mM 
caffeine or 3 mM NAC for 60 minutes prior to  aqueous 
extract treatment  of up to 2 mg/ml for 24 hours prior to 
analysis of cell viability using the MTT assay.
" " 5.3.4:  siRNA interference
TP53 siRNA interference was used to knockdown p53 
expression in MCF-7 cells as detailed in section 2.11.!
! ! 5.3.5:  Cell cycle analysis of aqueous extract 
treated cells
The effect of aqueous extract treatment on the cell cycle of 
MDA-MB-231 cells was determined using flow cytometry as 
detailed in section 2.6.
!
!
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! 5.4:  Results
! ! 5.4.1:  Aqueous extract treatment induces 
non-oxidative DNA damage in MCF-7 cells
DNA damage initiates cell cycle arrest in order to permit 
repair of damaged DNA before replication.  Many cancers 
demonstrate dysfunctional DNA repair activity, thus rendering 
them susceptible to sustained DNA damage resulting in cell 
death.  The previous studies have shown that extract 
treatment induces cell cycle arrest and apoptosis in MCF-7 
cells associated with activation of p53 and an associated 
increase in its transcriptional targets p21 and bax.  DNA 
damage sensing via ATM/ATR is one mechanism by which 
p53 can become transcriptionally active.  Therefore, the 
effects of aqueous extract treatment on the level of DNA 
damage in MCF-7 cells, was investigated.  MCF-7 cells were 
treated with 1 or 2 mg/ml extract for either 3 or 24 hours, 
prior to analysis using the comet assay.  DNA damage was 
measured as the mean percentage of tail DNA taken from at 
least 50 comets per test.  The results in figure 5.4.1 show 
that extract treatment could induce significant dose 
dependent DNA damage in MCF-7 cells after 3 hours 
treatment (figure 5.4.1a) which was increased after 24 hours 
(figure 5.4.1b).  After 3 hours treatment, the percentage of tail 
DNA increased by 73.2% in response to 1 mg/ml extract 
treatment and 157.3% in response to 2 mg/ml extract 
treatment, compared to untreated control (figure 5.4.1a). 
This increase was elevated further after 24 hours with a 
226.6% and 304.3% increase in DNA damage compared to 
untreated control, after treatment with 1 mg/ml and 2 mg/ml 
extract respectively (figure 5.4.1b).
Oxidation by free radicals is one of the main sources of DNA 
damage.  Oxidation of DNA commonly results in the 
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formation of 8-oxoguanine which can be measured as a 
marker of oxidative DNA damage [39].  Formamidopyrimidine 
DNA glycosylase (FPG) protein, a key enzyme in the base 
excision repair (BER) pathway, is involved in the recognition 
and removal of 8-oxoguanine.  Therefore, it can be used in a 
modified comet assay to specifically detect oxidative DNA 
damage.  Aqueous extract treatment may induce oxidative 
DNA damage in MCF-7 cells based on the data shown 
previously in chapter 3 that extract treatment increases levels 
of intracellular ROS.  To investigate this hypothesis, MCF-7 
cells were treated as before, and prepared for analysis of 
DNA damage by comet assay with the addition of FPG 
incubation prior to alkaline unwinding of DNA and 
electrophoresis.  The results show that there is no significant 
increase in the percentage of tail DNA in the presence of 
FPG protein for any  of the extract treatments at any time 
point compared to non-FPG treated cells (figure 5.4.1a and 
b).  To verify the role of oxidative stress in extract-induced 
cytotoxicity, the effects of extract-induced cytotoxicity on 
MCF-7 cells was determined after pre-treatment with NAC. 
In chapter 3 pre-treatment of 3 mM NAC was shown to 
attenuate extract-induced ROS.  However, this modulation 
had no effect on extract-induced cytotoxicity, suggesting that 
increases in ROS by extract treatment may not play a role in 
cytotoxicity (figure 5.4.2).
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Figure 5.4.1:  Extract treatment induces non-oxidative 
DNA damage in MCF-7 cells.  MCF-7 cells were treated with 
up  to 2mg/ml extract for up to 24 hours prior to detection of 
DNA damage using the comet assay with and without FPG 
protein.  Comets were visualised after staining with propidium 
iodide (c), and DNA damage was determined as an average 
percentage of DNA in comet tails after (a) 3 or (b) 24 hours 
treatment.  Data denoted * (p<0.05) and ***  (p<0.001) are 
significant compared to untreated control analysed by one-
way ANOVA with Dunnettʼs multiple comparison post test. 
Data are from three independent experiments performed in 
triplicate and presented as mean ± standard deviation.
The presence of DNA damage in MCF-7 cells was also 
confirmed by the presence of the double strand break marker 
γ-H2AX.  Figure 5.4.3 shows that in expression of γ-H2AX is 
increased in a time dependent manner after treatment with 2 
mg/ml extract.  Expression of γ-H2AX was significant after 3 
hours treatment (figure 5.4.3a).  In response to aqueous 
extract treatment, γ-H2AX expression was increased 26.9% 
after 3 hours, with sustained treatment increasing γ-H2AX 
expression by 75.0% after 24 hours (figure 5.4.3b). 
" " 5.4.2:  Extract induced p53 expression is 
ATM/ATR dependent
The DNA damage response is controlled by activation of 
sensors such as ATM and ATR.  In response to single (ATR) 
or double (ATM) strand breaks, these proteins exerts kinase 
activity towards p53 resulting in phosphorylation, rapid 
stabilisation and transcriptional activation of p53.  ATM/ATR 
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Figure 5.4.2.  Pre-treatment with NAC does not attenuate 
extract-induced loss of MCF-7 cell viability.  MCF-7 cells 
were pre-treated with 3mM N-acetyl-cysteine (NAC) for 60 
minutes before treatment with up to 2mg/ml extract for 24 
hours.  Cell viability was determined by MTT assay.  Data is 
from at least three independent experiments performed in 
triplicate and presented as mean ± standard deviation.
activity  can be modulated pharmacologically by  caffeine, a 
protein kinase inhibitor with activity towards ATM and ATR 
[351].  Both ATM and ATR exert site specific kinase activity 
towards serine-15 of p53 in response to DNA damage and 
play a critical role in DDR signalling [83].  Here, caffeine has 
been used to inhibit ATM/ATR in MCF-7 cells to investigate 
the effects of kinase inhibition, on extract induced p53 and 
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Figure 5.4.3.  Aqueous extract treatment time increases 
γ-H2AX expression in MCF-7 cells.  MCF-7 cells were 
treated with 2mg/ml extract for up to 24 hours before 
expression of (a) γ-H2AX was determined by  SDS-PAGE and 
western blot.  β-actin was used as a loading control. 
Densitometry  for (b) γ-H2AX was calculated as a ratio to β-
actin and expressed as fold change compared to control 
(time=0 hours).  Data denoted ** (p<0.01) and ***  (p<0.001) 
are significant compared to control analysed by one-way 
ANOVA with Dunnettʼs multiple comparison post test.  Data is 
representative of three independent experiments and 
presented as mean ± standard deviation.
p21 expression.  The effects of ATM/ATR inhibition and 
extract treatment on cell viability  was also determined. 
MCF-7 cells were pre-treated with 3 mM caffeine or vehicle 
control for 60 minutes prior to 2 mg/ml extract treatment for 
up  to 24 hours.  Cell lysates were collected and expression 
of p53 and p21 was analysed by  western blot.  Pretreatment 
with 3mM caffeine significantly reduced extract-induced p53 
and p21 expression after 5 hours and 24 hours treatment 
(figure 5.4.4a).  Extract treatment alone induced a 112.0% 
increase in p53 expression after 5 hours and a 118.2% 
increase after 24 hours (figure 5.4.4b).  Pretreatment with 
caffeine prior to extract treatment induced a 17.3% increase 
after 5 hours and a 30.9% increase after 24 hours compared 
to caffeine treated controls (figure 5.4.4b).  This effect was 
also seen with p21 expression.  Extract treatment alone 
increased p21 protein expression 47.2% after 5 hours and 
82.1% after 24 hours.  Cells pretreated with caffeine prior to 
extract treatment demonstrated an insignificant change in 
p21 expression after 5 or 24 hours compared to control 
(figure 5.4.4c).  
The effect of ATM/ATR inhibition on extract induced cell 
death was determined by measuring cell viability  using the 
MTT assay.  MCF-7 cells were treated for 60 minutes with 3 
mM caffeine or vehicle control prior to extract treatment for 
24 hours.  Inhibition of ATM/ATR resulted in a significant 
reduction in extract induced loss of cell viability  at 
concentrations above 0.5 mg/ml.  Extract treatment alone (2 
mg/ml) reduced MCF-7 cell viability  by 39.1%, while pre-
treatment with caffeine followed by 2 mg/ml extract treatment 
resulted in a 21.7% reduction in cell viability (figure 5.4.5).
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Figure 5.4.4.  Aqueous extract induced p53 and p21 
expression is dependent on ATM/ATR activity.  MCF-7 cells 
pretreated with and without 3mM caffeine for 60 minutes were 
treated with 2mg/ml extract for up  to 24 hours before expression 
of (a) p53 and p21 protein expression by SDS-PAGE and 
western blot.  β-actin was used as a loading control. 
Densitometry  for (b) p53 and (c) p21 was calculated as a ratio 
of β-actin and expressed as fold change compared to control 
(time=0 hours).  Data denoted **  (p<0.01) and ***  (p<0.001) are 
significant compared to non-caffeine treatment analysed by 
one-way ANOVA with Bonferroniʼs multiple comparison post 
test.  Data is representative of three independent experiments 
and presented as mean ± standard deviation.
 
+ 3mM caffeine
Extract treatment time (hours):   0                5                  24                0               5                 24         
p53
p21
β-actin
a)
b) c)
Figure 5.4.4.  Extract induced p53 and p21 expression is dependent on ATM/ATR 
activity.  MCF-7 cells pretreated with and without 3mM caffeine for 60 minutes were 
treated with 2mg/ml extract for up to 24 hours before expression of (a) p53 and p21 
protein expression by SDS-PAGE and western blot.  β-actin was used as a loading 
control.  Densitometry for (b) p53 and (c) p21 was calculated as a ratio of β-actin and 
expressed as fold change compared to control (time=0 hours).  Data denoted ** (p<0.01) 
and *** (p<0.001) are significant co pared to non-caffeine treatment analysed by one-
way ANOVA with Bonferroniʼs multiple comparison post test.  Data is representative of 
three independent experiments.
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" 5.4.3:  Extract  cytotoxicity is not  fully dependent 
on p53
Although caffeine is known to be an effective inhibitor of ATM 
and ATR it also has other pharmacological functions that 
could potentially affect p53 and p21 expression not related to 
inhibition of the DNA damage response.  In order to 
determine whether extract induced-cytotoxicity  is completely 
dependent on a p53 mediated response in MCF-7 cells, 
TP53 was transiently knocked down by transfection with 
silencer siRNA.  Cells treated with and without TP53 siRNA 
were subjected to 2 mg/ml aqueous extract treatment for up 
to 24 hours prior to analysis of cell viability by MTT assay 
and quantification of p53 protein levels by western blot.  As 
shown previously, extract treatment significantly increased 
p53 expression up  to 24 hours.  Transfection of TP53 siRNA 
significantly reduced the extract mediated increase in p53 
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Figure 5.4.5.  Inhibition of ATM/ATR partly inhibits extract 
induced MCF-7 cell death.   MCF-7 cells pretreated with 3mM 
caffeine or vehicle control for 60 minutes were treated with up  to 
2mg/ml extract for 24 hours prior to MTT assay.  Data denoted 
**  (p<0.01) and ***  (p<0.001) are significant compared to extract 
only as analysed by two-way ANOVA with Bonferroni's multiple 
comparison post test.  Data is from at least three independent 
experiments performed in triplicate.
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expression at 5 or 24 hours (figure 5.4.6a).  Extract treatment 
for 5 and 24 hours induced a 29.8% and 72.3% increase in 
p53 expression, respectively (figure 5.4.6b).  Knockdown of 
p53 translation with siRNA prior to extract treatment resulted 
in an insignificant increase in p53 expression after 5 or 24 
hours treatment with extract.  Basal p53 expression was also 
significantly reduced by 12.3% in siRNA transfected cells. 
After successful TP53 knockdown, the effect of aqueous 
extract treatment on MCF-7 cell viability was assessed by 
MTT assay.  Transfection of TP53 siRNA significantly 
attenuated extract treatment-induced loss of cell viability in 
MCF-7 cells but a significant decrease in cell viability was still 
apparent after 24 hours compared to untreated cells.  Extract 
treatment of 2 mg/ml reduced MCF-7 cell viability  by 47.5% 
after 24 hours and had an IC25 of 0.5 mg/ml.  In comparison, 
in siRNA transfected cells, viability  was reduced 31.7% under 
the same conditions and had an IC25 of 1.6 mg/ml (figure 
5.4.7a).  It was shown in chapter 3 that an aqueous extract of 
Fagonia cretica could reduce cell viability  in MDA-MB-231 
breast cancer cells, albeit, not as effectively  as against 
MCF-7 cells.  In fact, the loss of cell viability  in extract treated 
MDA-MB-231 cell, is similar to the loss of cell viability of 
extract treated MCF-7 cells post TP53 siRNA interference 
(figure 5.4.7c).
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Figure 5.4.6.  Aqueous extract induced p53 expression is 
blocked with transfection of TP53 siRNA.  MCF-7 cells 
were transfected with and without 10nM TP53 siRNA for 24 
hours prior to 2mg/ml extract treatment for up to 24 hours. 
Cell lysates were collected and p53 protein expression was 
assessed by western blot.   β-actin was used as a loading 
control.  Data is expressed as a fold change in p53 density 
normalised to β-actin.  Data denoted ***  (p<0.001) are 
significant compared to non-siRNA treated counterpart.  Data 
was analysed by one-way ANOVA with Bonferroniʼs multiple 
comparison post test.  Data is representative of three 
independent experiments and presented as mean ± standard 
deviation.
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Figure 5.4.7.  Cell viability following aqueous extract 
treatment is improved in p53-deficient cells.  (a, b) MCF-7 
cells were transfected with and without TP53 siRNA for 24 
hours before extract treatment up  to 2mg/ml for 24 hours.  Cell 
viability was determined by MTT assay.  (c) MCF-7 cells 
transfected with and without TP53 siRNA and MDA-MD-231 
cells were treated with up  to 2mg/ml extract for 24 hours prior 
to MTT assay.  Data denoted ***  (p<0.001) are significant 
compared to untreated control or as indicated, analysed by 
one-way ANOVA with Bonferroniʼs multiple comparison post 
test.  Data denoted + (p<0.001) are significant compared to ʻno 
siRNAʼ as analysed by  two-way ANOVA with Bonferroniʼs 
" " 5.4.4: Aqueous extract treatment induces 
G0/G1 arrest in MDA-MB-231 cells
In order to assess the impact of p53 deficiency on aqueous 
extract activity, against breast cancer cells, the effects of 
aqueous extract treatment on cell cycle status of MDA-
MB-231 cells, was investigated.  Extract treatment induced 
significant cell cycle arrest in G0/G1 phase after 24 hours 
treatment.  Treatment with 2 mg/ml aqueous extract for 24 
hours increased the percentage of cell in G0/G1 phase from 
20.3% to 64.0%, which coincided with a decrease from 
30.4% to 5.0%% in the G2 cell population (figure 5.4.8 a and 
b).  In contrast, the results from chapter 4 show that in 
extract treated MCF-7 cells, significant G0/G1 arrest is 
present as early as 5 hours treatment.
! ! 5.4.5:  Aqueous extract treatment  increase 
Υ-H2AX expression in MDA-MB-231 cells
The results in this chapter show that p53-deficient breast 
cancer cells are less susceptible to aqueous extract-
dependent loss of viability then those with functional p53. 
However, cell cycle arrest and loss of cell viability, is still 
apparent.  The extract induced p53 response in MCF-7 cells 
appears to be initiated by activation of the DNA damage 
response, therefore, induction of γ-H2AX in MDA-MB-231 
cells was assessed as a marker of DNA damage in p53 
deficient cells.  Western blot analysis of aqueous extract 
treated MDA-MB-231 cells revealed a time-dependent 
increase in γ-H2AX expression (figure 5.4.9a).  Expression of 
γ-H2AX was significantly increased by  93.3% after 1 hour 
treatment and 317.3% after 24 hours (figure 5.4.9b).
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Figure 5.4.8.  Extract treatment induces G0/G1 arrest in 
MDA-MB-231 cells.  MDA-MB-231 cells were treated with 
2mg/l extract for up  to 24 hours before cell cycle analysis by 
flow cytometry.  Populations (a) G0/G1 and (b) G2 were 
determined according to cyclin A-FITC  (FL3) and propidium 
iodide (FL1) fluorescence.  Data denoted *** (p<0.001) are 
significant compared to control (time = 0 hours) analysed by 
one-way ANOVA with Dunnettʼs multiple comparison post 
test.  Data is representative of three independent 
experiments performed in triplicate and presented as mean ± 
standard deviation.
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" 5.5:  Discussion
Induction of DNA damage is an effective mechanism by 
which chemotherapeutic drugs selectively target cancer cells 
for growth arrest or death because they frequently  have 
impaired DNA repair responses and are rapidly  cycling. 
Activation of the DNA damage response initiates signalling 
pathways that result in cell cycle arrest, DNA repair and cell 
death.  Central to the downstream control of the DDR is the 
transcription factor p53, which regulates transcriptional 
targets involved in DNA repair, cell cycle arrest and cell 
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Figure 5.4.9.  Aqueous extract treatment increases γ-
H2AX expression in MDA-MB-231 cells.  MDA-MB-231 
cells were treated with 2mg/ml extract for up  to 24 hours 
before expression of (a) γ-H2AX was determined by SDS-
PAGE and western blot.  β-actin was used as a loading 
control.  Densitometry for (b) γ-H2AX was calculated as a 
ratio to β-actin and expressed as fold change compared to 
control (time=0 hours).  Data denoted **  (p<0.01) and *** 
(p<0.001) are significant compared to control analysed by 
one-way ANOVA with Dunnettʼs multiple comparison post 
test.  Data is representative of three independent 
experiments and presented as mean ± standard deviation.
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death, in response to DNA damage.  The importance of p53 
in the DDR has been shown in experiments involving over-
expression of functional p53 in mice, which show enhanced 
cellular response to DNA damage and significantly  protected 
mice from cancer [356].  The data described in previous 
chapters has demonstrated that aqueous extract treatment of 
MCF-7 cells induces cell cycle arrest and apoptosis which 
may be related to increased expression of p53 and its 
transcriptional targets p21 and bax.  In order to further 
understand the mechanisms by  which these events occur, 
the ability  of extract treatment to induce DNA damage and 
the DDR was investigated.  The present study has shown 
that extract treatment of MCF-7 cells can induce significant 
levels of non-oxidative DNA damage resulting in ATM/ATR-
dependent activation of p53.  It was also shown that p53 is 
not essential for the bioactivity in the extract and that TP53 
knockdown MCF-7 cells and mutant-p53 MDA-MB-231 cells 
are susceptible to extract treatment.
DNA damage, measured by the comet assay was significant 
after 3 hours treatment and further increased after 24 hours 
in MCF-7 cells suggesting a sustained response to extract 
treatment.  This agrees with the findings in chapter 3 as cell 
viability was decreased with longer incubation periods.  The 
standard comet assay analyses all types of strand breaks 
and modifications to the assay using FPG protein can 
specifically detect the presence of oxidative DNA damage. 
Incubation with FPG protein prior to DNA damage analysis 
showed no significant increase in tail DNA.  This indicates 
that the DNA damage is most likely not oxidative as FPG 
recognises and removes the most prevalent oxidative DNA 
lesions including 8-oxo-guanine, 8-oxo-adenine, fapy-
guanine, methyl-fapy-guanine and fapy-adenine [357].  In 
chapter 3 it was shown that extract treatment can 
significantly increase intracellular ROS levels in MCF-7 cell 
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which may lead to oxidative DNA damage.  However, it is not 
known what oxidative load would be necessary  to induce 
DNA damage in this model or how localised the ROS 
production is to specific cellular compartments.  The nucleus 
maintains a strong reducing potential which may resist 
cytoplasmic redox flux [358].  Therefore it is plausible that 
extract induced ROS production may not be sufficient in the 
nucleus to cause oxidative nuclear DNA damage.  ROS are 
involved in a variety of cellular processes and excessive 
production can mediate other effects than DNA damage 
[335].  Hydrogen peroxide is produced as a signalling 
molecule that exerts oxidative power on cysteine residues of 
effector proteins in response to activation of cell surface 
receptors [359].  ROS production also accompanies 
signalling events leading to critical roles determining cell fate 
such as activation of MAP kinase pathways [360].
It was previously  shown in chapter 4 that p53 and p21 
expression are increased as a result of extract treatment.  In 
order to determine if this was dependent on ATM/ATR-
mediated stabilisation of p53, the effects of the ATM/ATR 
inhibitor caffeine on extract induced p53 and p21 expression 
was assessed.  Inhibition of ATM/ATR prevented extract 
induced up-regulation of p53 and p21 expression suggesting 
that activation of p53 is dependent on ATM/ATR and most 
likely  induced by single or double DNA strand breaks.  The 
role of ATM/ATR in the DNA damage response is well 
characterised [59,88].  In response to DNA damage, both 
ATM and ATR can directly interact with p53 and induce site 
specific phosphorylation at serine-15, resulting in p53 
transactivation [117].  The kinase activity  of ATM could also 
increase p53 stabilisation through interaction with other 
kinases.  For example ATM may play a role in activating c-
Abl kinase activity on p53 and induce phosphorylation at 
serine-20.  This post-translational modification can stabilise 
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p53 and reduce its interaction with MDM2 [361].  This 
suggests a potential role for ATM/ATR in increasing p53 
expression in response to extract treatment and indeed 
results from this study show that inhibition of ATM/ATR with 
caffeine can prevent extract-mediated effects on p53 and its 
transcriptional target p21.  Although caffeine is reported to 
inhibit ATM/ATR activity it has also been shown to influence 
other cellular responses.  For example, caffeine may 
interfere with drug transport and DNA binding capability, by 
forming inhibitory complexes with poly-aromatic drugs [362].
  
An investigation by  Pabla et al. demonstrated that the DNA 
damaging agent, cisplatin, induces ATR activation and its co-
localisation with λ-H2AX at sites of DNA damage resulting in 
activation of p53 [363].  The current study shows evidence of 
increased γ-H2AX expression in response to extract 
treatment which is a common marker of DNA double strand 
breaks.  Gamma-H2AX is generated by  phosphorylation of 
serine-139 in H2AX by members of the PIK-related family 
including ATM and ATR.  It has been shown that γ-H2AX is 
required for activation p53/p21 axis and p21 induced cell 
cycle arrest in response to replication stalling during DNA 
synthesis [364].  These findings suggest that extract 
treatment may be either inducing double strand breaks in 
DNA of MCF-7 cells resulting in recruitment of ATM/ATR to 
sites of DNA damage and site specific phosphorylation of 
H2AX or allowing DNA breaks to accumulate due to inhibition 
of DNA repair processes.  It is important to note that H2AX 
activation can also occur independently of double strand 
breaks [365].  As well as this, the comet assay measures all 
types of DNA damage, so it is not possible to fully determine 
double strand breaks as the DNA damage induced by extract 
treatment. 
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It has been shown that caffeine increases radio-sensitivity in 
treated cells by  inhibition of ATM activity and abrogation of 
the G2/M DNA damage checkpoint [362].  Potentiation of 
DNA damaging agents by caffeine is specific to the G2/M 
checkpoint and it has been shown that loss of G1-arrest does 
not lead to increased radiosensitivity [366].  In agreement 
with these findings, extract treatment in caffeine treated cells 
does not decrease cell survival beyond extract treatment 
alone.  Taken together with previous results demonstrating 
extract induced G1-arrest and activation of DNA damage 
response it is expected that caffeine would not potentiate the 
effects of extract treatment.  In fact, cell survival was 
improved with caffeine treatment, suggesting that an 
independent mechanism other then p53 associated G1-
arrest and apoptosis may be working in parallel to reduce cell 
viability.  This is expected as a crude aqueous plant extract 
would probably contain multiple bioactive compounds which 
may elicit an anti-cancer response either individually  or in 
synergy with other compounds.  This finding also highlights 
that extract treatment could be effective against tumours 
carrying mutant p53.  This agrees with the data reported in 
chapter 3 that extract treatment could also reduce MDA-
MB-231 cell viability after 24 hours (figure 3.4.3).
Although p53 is important in suppressing oncogenesis, and 
loss of function in tumours is responsible for disease 
progression and drug resistance, p53-independent 
mechanisms which can inhibit cellular growth in response to 
stress, are also important for homeostatic control  [98].  The 
present study has demonstrated that although p53 
expression is increased in response to ATM/ATR activation, it 
is not crucial to extract activity, as shown by siRNA inhibition 
of p53 expression.  Knockdown of p53 expression attenuated 
some of the extract induced cytotoxicity suggesting that p53-
mediated mechanisms only play a part in the overall 
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cytotoxic effect.  This p53-independent effect was also shown 
in MDA-MB-231 cells, which carry a non-functional mutant 
p53, confirming that extract induced toxicity  is not fully reliant 
on expression of p53.  Evidence for p53-independent cell 
death can be found in the literature, for example, the 
antimicrobial agent sanguinarine has been shown to induce 
DNA damage and cell death independent of cellular p53 
status in human colon cancer cells.  Work by Liu et al. has 
also identified that the isoquinoline alkaloid, berberine, 
induces growth arrest and apoptosis in cancer cells, with 
arrest in G1 dependent on p53-status and G2/M arrest 
occurring independent of p53 [367,368].  Furthermore, 
E2F-1, a cell cycle regulator downstream of pRB, can induce 
apoptosis in p53 dependent and independent mechanisms 
[155].  There is also evidence that DNA damage activates 
JNK pathways to induce p53-independent cell death through 
up-regulation of the pro-apoptotic protein, bid [369]. 
In light of the results demonstrating that p53 deficient cells 
are less susceptible to extract, the effects of extract 
treatment on cell cycle status of MDA-MD-231 cells was 
investigated.  G0/G1 arrest was induced in MDA-MB-231 
cells in response to extract treatment which was also 
reported in MCF-7 cells.  However, cell cycle arrest was 
delayed in MDA-MB-231 cells and did not present 
significantly until after 24 hours treatment.  In comparison, 
G0/G1 arrest was significantly  induced in MCF-7 cells after 5 
hours treatment, suggesting that p53 is partly  responsible for 
extract induced cell cycle arrest.  This finding indicates that in 
the absence of p53, extract induced-stress, does not initiate 
a cellular response as rapidly as in the presence of functional 
p53.  This provides further evidence for the role of p53-
independent cell cycle arrest and cell death in extract 
treated-breast cancer cells.  As extract treatment was shown 
to induce γ-H2AX expression in MCF-7 cells, the effect of 
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treatment on γ-H2AX expression in MDA-MB-231 cells, was 
also investigated.  The results revealed that MDA-MB-231 
cells also show increased  γ-H2AX expression indicative of 
accumulating double strand breaks.  This, together with 
earlier data obtained using MCF-7 TP53 siRNA treated cells, 
suggests that DNA damage could be the initiating step  in 
extract-induced cytotoxicity  and that downstream signalling 
only partly involves p53.
It is known that stress signals activate FOXO transcription 
factors which play  a major role in regulating cell survival and 
cell death.  For example, in Taxol (paclitaxel) treated breast 
cancer cells, increases in FOXO3a activity up-regulated pop-
apoptotic bim and induced apoptosis [222].  The FOXO 
transcription factors have been implicated in a wide variety of 
physiological responses including glucose metabolism, 
oxidative stress, cell cycle regulation and apoptosis and are 
involved pathologically in many disease states including 
cancer [180].  DNA repair is an energy consuming process 
as recruitment and activation of the repair protein PARP 
requires NAD+ to generate ADP-ribose monomers.  This 
reliance on NAD+ as a substrate results in a depletion in 
available ATP and subsequently prolonged PARP activation 
can lead to metabolic crisis and activation of FOXO.  It has 
also been shown that FOXO proteins are involved in 
activation of DNA repair mechanisms through direct 
interaction with the DNA damage response gene GADD45a 
[209].  It has been reported that CDK2 dependent 
phosphorylation on FOXO1 allows normal cell cycle 
progression and that in response to DNA damage, 
cytoplasmic sequestering of FOXO1 is abrogated, which 
allows for FOXO-mediated cell cycle repression [175].  A 
study by Tsai et al. revealed that FOXO3a also has functional 
interaction with ATM.  In particular, FOXO3a phosphorylates 
ATM in response to DNA damage and propagates nuclear 
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activity  of downstream effectors [370].  The results from this 
investigation taken with evidence from the literature suggest 
a possible role for FOXO proteins in mediating extract 
induced cytotoxicity in both p53 proficient and deficient cells.
"
" 5.6:  Conclusion
The work described in this chapter aimed to understand the 
initiation step in inducing growth arrest and apoptosis in 
extract treated MCF-7 cells.  It is well documented that DNA 
damage is an important inducer of cell cycle inhibition and 
cell death, thus levels of extract-induced DNA damage were 
assessed using the comet assay.  Evidence of strand breaks 
in MCF-7 cells was apparent after extract treatment.  The 
role of the DNA damage sensors ATM/ATR and their 
influence on p53 expression was also investigated.  Extract-
induced DNA damage appeared to induce ATM/ATR-
dependent p53 expression, which could be attenuated with 
caffeine.  DNA damage was determined to be double 
stranded as there was increased γ-H2AX expression in 
response to extract treatment.  This provides evidence 
implicating ATM as the mediator of p53 expression as ATM 
primarily responds to this type of DNA damage.  It was also 
shown that DNA damage-induced p53 expression is 
responsible for increased p21 expression as both could be 
attenuated with caffeine treatment.  This suggests that DNA 
damage is an initiating step in cell cycle arrest of extract 
treated MCF-7 cells.  Inhibition of DNA damage-induced p53 
expression with caffeine improved cell survival in response to 
extract treatment, suggesting that the aqueous extract is 
activating multiple functional pathways leading to cell death 
and that its activity  is not fully dependent on p53.  This was 
confirmed with TP53 siRNA knockdown in MCF-7 cells and 
comparable with treatment effects on MDA-MB-231 cells. 
This result highlights the potential for extract treatment to be 
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effective towards cancer cells independent of their p53-
status, thus, increasing the range of efficacy for 
chemotherapy.  It was also shown that extract induced-cell 
cycle arrest is delayed but not abrogated in p53-deficient 
cells.  This provides further evidence for the role of p53 in 
extract induced MCF-7 cytotoxicity and the activation of p53-
independent mechanisms contributing to extract activity 
(figure 5.4.10).
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Figure 5.4.10.  The role of p53 in aqueous extract-induced 
cell cycle arrest and apoptosis in MCF-7 cells.  Treatment 
of MCF-7 cells with an aqueous extract of Fagonia cretica 
results in DNA damage and activation of the DNA damage 
response involving activation of p53 and its downstream 
transcriptional targets p21 and bax.  Inhibition of the p53 
response does not fully attenuate extract induced cytotoxicity 
in MCF-7 cells suggesting a role for p53-independent effects.
Chapter 6:  Extract-induced p53-independent 
cytotoxicity
" 6.1:  Rationale
The tumour suppressor protein, p53, is an important 
mediator of cell cycle arrest and apoptosis following 
exposure to DNA damaging agents.  In fact, over 50% of 
human cancers contain a functional mutation within the TP53 
gene, which contributes to their tumorigenic phenotype. 
Although this highlights the importance of p53 as a powerful 
guardian against tumorigenesis, there are also p53-
independent mechanisms of tumour suppression, by which 
DNA repair and apoptotic machinery can be activated 
following DNA damage.  It is becoming increasingly clear that 
utilising p53-independent driven apoptosis can be effective 
therapeutically for the treatment of cancer.  For example, the 
FOXO transcription factors control cell fate in response to a 
variety of stresses, including DNA damage.  Recent research 
has been aimed at understanding how FOXO signalling 
pathways can be used as a target for chemotherapy.
The investigation described in chapter 5 demonstrated that a 
p53-mediated DNA damage response was not vital to 
Fagonia cretica extract-induced cytotoxicity in human breast 
cancer cells.  In this chapter, the p53-independent effects of 
aqueous extract treatment governing cell death in breast 
cancer cells will be investigated focused on the extract-
induced effects on FOXO3a due to its importance in 
regulating cell cycle arrest and apoptosis in response to 
DNA damage.  The effects of aqueous extract treatment on 
SIRT1, a negative regulator of FOXO3, have also been 
investigated to understand any protein-protein interaction 
that may contribute to extract-mediated cytotoxicity.
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! 6.2:  Introduction
Functional mutations within the TP53 gene are a major 
contributor to tumorigenesis [98].  Loss of functional p53 also 
has an impact on chemotherapeutic drug efficacy and can 
drive drug resistance in certain tumours [371].  This is 
primarily due to loss of tumour suppressor functions that not 
only regulate cell cycle progression but also promote 
apoptosis in response to chemotherapy.  However, p53 loss 
of function does not always confer tumour resistance to DNA 
damaging agents, as parallel p53-independent signalling 
pathways can also induce cell cycle arrest and apoptosis in 
response to DNA damage [286,312].  Functional p53 
mutations are present in over 50% of tumours, thus, 
highlighting the importance for therapies that induce growth 
arrest or cell death in cancers independent of their p53-
status [104].
The Forkhead box class O (FOXO) proteins are a group of 
transcription factors involved in cellular differentiation, cell 
proliferation, metabolic stress and apoptosis [175].  It has 
been shown that loss of FOXO function in cancer cells may 
be responsible for an impairment in promotion of cell cycle 
arrest and cell death in response to DNA damage [180].  The 
FOXO proteins are negatively  regulated by the PI3K/AKT 
signalling pathway in the presence of survival signals and 
growth factors [198].  Under these condit ions, 
phosphorylation of conserved serine/threonine residues 
increases cytoplasmic shuttling of FOXO transcription 
factors, thus reducing their nuclear activity [175].  The FOXO 
protein, FOXO3a, has been shown to control cell cycle 
progression and pro-apoptot ic signal l ing through 
transactivation of its transcriptional targets such as p27 and 
bim [222].  Inhibition of FOXO3a has also been implicated in 
promoting tumorigenesis in multiple models where nuclear 
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translocation was restricted by  promoting phosphorylation of 
FOXO3a [182,183].  It has also been shown that activation of 
FOXO3a in breast cancer models can repress epithelial-
mesenchymal transition (EMT) as well as induce cell cycle 
arrest and apoptosis [222,223].  Furthermore, it has been 
shown that FOXO3a cytoplasmic retention is associated with 
poor prognosis in breast cancer patients due to repression of 
FOXO3a transcriptional activity, including up-regulation or 
cell cycle and pro-apoptotic genes [224].
  
It is unclear how FOXO transcription factors respond to DNA 
damage but ectopic over-expression of FOXO3a is not only 
able to reduce cellular proliferation but also potentiates 
growth arrest induced by DNA damage [372].  Moreover, 
induction of DNA damage by ionising radiation, activates 
FOXO3a and increases its nuclear translocation [221].  The 
resulting activation of bim and Fas ligand is associated with 
induction of apoptosis, and is observed independently  of p53, 
highlighting a potential FOXO3a mediated response to DNA 
damage.
Similar to the regulation of p53, the transcription factor 
FOXO3a is subjected to multiple phosphorylation and 
acetylation modifications, which alter its functionality  [196]. 
For example, analysis of the nematode worm homolog to 
FOXO, DAF-16, revealed four consensus sites for Akt-
dependent phosphorylation [373].  Signalling in the presence 
of growth factors leads to Akt-mediated phosphorylation of 
FOXO3a, subsequent nuclear export and cytoplasmic 
retention via interaction with 14-3-3 proteins [198].  The 
protein kinase CK1 is known to target FOXO proteins that 
have primed or phosphorylated serine/threonine residues 
and the activation of CK1 kinase activity occurs in response 
to DNA damage [374].
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Sirtuin 1 (SIRT1) is a NAD-dependent histone deacetylase 
which is involved in control of epigenetic gene silencing via 
histone modifications.  SIRT1 also exhibits deacetylase 
activity  against non-histone targets including the transcription 
factors p53 and FOXO3a [205].  Deacetylation of FOXO3a 
by SIRT1 has been shown to repress FOXO3a 
transcriptional activity, specifically by inhibiting binding to the 
promoter region of the cell cycle and pro-apoptotic target 
genes, p27 and bim [203].  As part of a negative feedback 
loop, FOXO3a is self-repressed by increasing SIRT1 
transcription [175].  Cell survival was initially associated with 
SIRT1 activity due to deacetylation of p53.  However, in 
certain cancers, over-expression of SIRT correlates with 
tumorigenesis and resistance to chemotherapy  [375].  The 
tumour suppressor, deleted in breast cancer-1 (DBC-1), 
interacts with SIRT1, which in turn represses DBC-1 activity 
in vitro and in vivo [376].  DBC-1 is commonly mutated in 
carcinoma of the bladder and its down-regulation potentiates 
the anti-apoptotic effects of SIRT1 in response to genotoxic 
stress, thus, implicating SIRT1 in tumorigenesis [377].
It has been shown that acetylation of p53 is crucial to 
destabilise the MDM2-p53 repressor complex and activate 
the p53-mediated stress response [125].  However, 
increased acetylation of p53 as a result of pharmacological 
inhibition of SIRT1, does not potentiate DNA damage-
induced cell death [378].  The natural product, resveratrol is 
a natural ly occurr ing polyphenol wi th extensive 
pharmacological characteristics including activation of SIRT1 
activity  [379].  It has also been reported that resveratrol 
inhibits phosphorylation of FOXO proteins, thus, potentiating 
nuclear translocation and FOXO transcriptional activity [380]. 
Given the significance of the FOXO3a pathway as a mediator 
of growth arrest and apoptosis, in this chapter the effects of 
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extract treatment on FOXO3a expression, will be 
investigated.  Furthermore, the extract-induced effects on 
SIRT1 and any role for SIRT1 in its toxicity will also be 
investigated, as SIRT1 plays an important role in not only 
regulating FOXO3a activity but also functioning as tumour 
promoter.
" 6.3:  Methods
" " 6.3.1:  Protein expression analysis by 
western blot
The effects of aqueous extract treatment on SIRT1 protein 
expression in MCF-7 cells and FOXO3a protein expression 
in MCF-7 and MDA-MB-231 cells was determined by SDS-
PAGE and western blot as outlined in section 2.10. A total of 
20μg protein per lysate was separated on a 10% SDS-PAGE 
gel before western blot procedure.  Membranes were probed 
with rabbit anti-human FOXO3a (1:1000),  rabbit anti-human 
SIRT1 (1:1000) before addition of sheep anti-rabbit HRP 
conjugated antibody (1:10000).  Bands were visualised using 
ECL reagent exposed to photographic film for 5-20 minutes.
! " 6.3.2:  MTT - cell viability assay
The effect of aqueous extract treatment following resveratrol 
pre-treatment or FOXO3a siRNA interference on MCF-7 and 
MDA-MB-231 cell viability  was determined using the MTT 
assay as detailed in section 2.5.  Cells were pre-treated with 
a non-toxic dose (50μM) of  resveratrol (figure 6.3.1) for 60 
minutes before co-incubation with extract for up  to 2mg/ml 
over 24 hours.
! !
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! !
! !
! ! 6.3.3:  SIRT1 activity assay
The effect of aqueous extract treatment on SIRT1 activity in 
MCF-7 cells was determined using the SIRT1 activity  kit 
(Sigma) as detailed in section 2.12.
! ! 6.3.4:  siRNA interference
FOXO3 siRNA interference was used to knockdown FOXO3a 
expression in MCF-7 and MDA-MB-231 cells as detailed in 
section 2.11.!
182
Figure 6.3.1.  Effect of resveratrol treatment on MCF-7 
cells.  MCF-7 cells were treated with up to 300μM resveratrol 
for 24 hours prior to analysis of cell viability by MTT assay. 
Data denoted *** (p<0.001) is significant compared to 
untreated control analysed by one-way ANOVA with Dunnettʼs 
multiple comparison post test.  Data is from three independent 
experiments performed in triplicate and presented as mean ± 
standard deviation.
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" " 6.3.5:  ATP assay
The effect of aqueous extract treatment on ATP levels in 
MCF-7 cells was assessed using the ATP assay kit 
(Promega) as detailed in section 2.13
" 6.4:  Results
" " 6.4.1:  Aqueous extract treatment increases 
FOXO3a expression in breast cancer cells.
The role of FOXO proteins as transcription factors controlling 
cell fate in response to stress is well documented.  The 
results in chapter 5 demonstrate that aqueous extract 
treatment is cytotoxic towards breast cancer cells in a p53-
dependent and independent manner.  Therefore, it was 
hypothesised that FOXO proteins may play a role in extract-
induced cell death.  In particular, emphasis was placed on 
FOXO3a because of its role in inducing cell cycle arrest and 
apoptosis via induction of its target genes p27 and bim. 
MCF-7 and MDA-MB-231 cells were treated for up  to 24 
hours with 2 mg/ml aqueous extract prior to protein 
expression analysis by SDS-PAGE and western blot.  The 
results in figure 6.4.1a and 6.4.2b  show that in response to 
extract treatment both MCF-7 and MDA-MB-231 cells 
significantly increase FOXO3a protein expression within 3 
hours.  Protein expression of FOXO3a in MCF-7 cells was 
increased 8.4-fold after 3 hours treatment compared to 
control (time = 0 hours).  Protein expression tapered off 
towards 24 hours treatment but remained significantly 
elevated by 3.8-fold compared to control levels (figure 
6.4.1b).  In extract-treated MDA-MB-231 cells, FOXO3a 
expression was increased 1.8-fold after 3 hours and peaked 
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at 5 hours treatment with a fold increase of 2.1 (figure 
6.4.2b).
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Figure 6.4.1.  Aqueous extract treatment increases 
FOXO3a expression in MCF-7 cells.  MCF-7 cells were 
treated with 2mg/ml aqueous extract for up to 24 hours before 
expression of (a) FOXO3a was determined by SDS-PAGE 
and western blot.  β-actin was used as a loading control. 
Densitometry  for (b) FOXO3a was calculated as a ratio to β-
actin and expressed as fold change compared to control 
(time=0 hours).  Data denoted ** (p<0.01) and ***  (p<0.001) 
are significant compared to control analysed by one-way 
ANOVA with Dunnettʼs multiple comparison post test.  Data is 
representative of three independent experiments and 
presented as mean ± standard deviation.
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! ! 6.4.2:  Expression of FOXO3a is required for 
aqueous extract-induced cytotoxicity.
In order to determine if an aqueous extract-induced increase 
in FOXO3a expression is required for loss of cell viability  in 
breast cancer cells, MCF-7 and MDA-MB-231 cells were 
transiently  transfected with FOXO3 siRNA, prior to extract 
treatment.  Knockdown of FOXO3a by siRNA transfection 
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Figure 6.4.2.  Aqueous extract  treatment increases 
FOXO3a expression in MDA-MB-231 cells.  MDA-MB-231 
cells were treated with 2 mg/ml aqueous extract for up to 24 
hours before expression of (a) FOXO3a was determined by 
SDS-PAGE and western blot.  β-actin was used as a loading 
control.  Densitometry for (b) FOXO3a was calculated as a 
ratio to β-actin and expressed as fold change compared to 
control (time=0 hours).  Data denoted **  (p<0.01) and *** 
(p<0.001) are significant compared to control analysed by 
one-way ANOVA with Dunnettʼs multiple comparison post 
test.  Data is representative of three independent 
experiments and presented as mean ± standard deviation.
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attenuated an extract-induced (2 mg/ml) increase in FOXO3a 
protein expression at 24 hours with complete abrogation of 5 
hour response (figure 6.4.3a).  In the presence of 5 nM 
siRNA, extract-treatment for 24 hours induced a significant 
23.3% increase in FOXO3a expression, compared to siRNA-
transfected controls (time = 0 hours).  However, after 24 
hours extract-treatment in siRNA treated cells, the level of 
FOXO3a expression was not significantly  greater than basal 
levels in non-siRNA treated MCF-7 cells, demonstrating 
complete abrogation of a later FOXO3a response to extract 
treatment.  In comparison, treatment with 2 mg/ml extract 
alone induced a 67.0% increase in FOXO3a expression after 
5 hours and a 47.0% increase after 24 hours (figure 6.4.3b). 
Transfection of MCF-7 cells with FOXO3 siRNA also 
significantly reduced basal levels of FOXO3a expression by 
32.1% which was consistent with the siRNA validation 
performed in section 2.11 (figure 2.11.5).  A similar response 
was obtained in siRNA transfected MDA-MB-231 cells which 
also demonstrated a reduction in extract induced FOXO3a 
expression (figure 6.4.4).  To determine wether or not 
expression of FOXO3a was required for extract induced 
cytotoxicity, both cell lines were transfected with siRNA prior 
to extract treatment, and assessment of cell viability by MTT 
assay.  Knockdown of extract-induced FOXO3a expression 
reduced the loss of cell viability in MCF-7 cells and 
completely abrogated cytotoxicity  in MDA-MB-231 cells 
(figure 6.4.5 a and b).
" " 6.4.3:  Extract treatment reduces ATP levels 
in MCF-7 cells
FOXO3a can be activated in response to metabolic stress 
brought on by energy depletion.  Therefore, the effect of 
extract treatment on intracellular ATP levels, was assessed in 
MCF-7 cells.  Extract treatment significantly reduced ATP 
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Figure 6.4.3.  Aqueous extract-induced FOXO3a expression 
in MCF-7 cells is blocked with transfection of FOXO3 
siRNA.  MCF-7 cells were transfected with and without 5nM 
FOXO3 siRNA for 24 hours prior to 2 mg/ml aqueous extract 
treatment for up  to 24 hours.  (a) Cell lysates were collected 
and FOXO3a protein expression was assessed by western blot. 
β-actin was used as a loading control. (b) Data is expressed as 
a fold change in FOXO3a density normalised to β-actin.  Data 
denoted *  (p<0.05) is significant compared to siRNA treated 
control (time = 0 hours).  Data denoted + (p<0.001) is 
significant compared to untreated control (time = 0 hours).  All 
data was analysed by  one-way ANOVA with Dunnettʼs multiple 
comparison post test.  Data is representative of three 
independent experiments and presented as mean ± standard 
deviation.
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Figure 6.4.4.  Aqueous extract induced FOXO3a expression 
in MDA-MB-231 cells is blocked with transfection of FOXO3 
siRNA.  MDA-MB-231 cells were transfected with and without 
5nM FOXO3 siRNA for 24 hours prior to 2 mg/ml aqueous 
extract treatment for up  to 24 hours.  (a) Cell lysates were 
collected and FOXO3a protein expression was assessed by 
western blot.   β-actin was used as a loading control. (b) Data is 
expressed as a fold change in FOXO3a density normalised to 
β-actin.  Data denoted *  (p<0.05) and ***  (p<0.01) and *** 
(p<0.001) are significant compared to siRNA-transfected 
control (time = 0 hours).  Data denoted + (p<0.01) and ++ 
(p<0.001) are significant compared to untreated control (time = 
0 hours).  All data was analysed by one-way ANOVA with 
Dunnettʼs multiple comparison post test.  Data is representative 
of three independent experiments and presented as mean ± 
standard deviation.
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Figure 6.4.5.  Aqueous extract-induced FOXO3a 
expression is required at least in part for cytotoxicity 
against human breast cancer cells.  (a) MCF-7 and (b) 
MDA-MB-231 cells were transfected with and without 5nM 
FOXO3a sirNA for 24 hours prior to up  to 2mg/ml aqueous 
extract treatment for 24 hours.  Cell viability was determined 
by MTT assay.  Data denoted  ***  (p<0.001) are significant 
compared to extract only analysed by two-way ANOVA with 
Dunnettʼs multiple comparison post test.  Data is from three 
independent experiments performed in triplicate and presented 
as mean ± standard deviation.
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levels after 3 hours treatment with 2 mg/ml extract. 
Furthermore, ATP levels were still depleted after 24 hours 
suggesting that the cells could not recover from the ATP 
depletion (figure 6.4.6).
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Figure 6.4.6.  Aqueous 2xtract treatment reduces 
intracellular ATP levels in MCF-7 cells.  MCF-7 cells 
were treated for up  to 24 hours with 2mg/ml aqueous 
extract or serum starved for 24 hours prior to ATP 
extraction and analysis of ATP content using a ATP assay 
kit.  ATP concentration was normalised to protein content 
determined by  BCA assay and expressed as moles of 
ATP per μg of protein.  Data denoted ** (p<0.01) and *** 
(p<0.001) are significant compared to untreated control 
analysed by one-way ANOVA with Dunnettʼs multiple 
comparison post test.  Data is from two independent 
experiments performed in duplicate and presented as 
mean ± standard deviation.
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" " 6.4.4:  Extract treatment decreases SIRT1 
expression and activity in MCF-7 cells
SIRT1 is a negative regulator of FOXO3a activity via its 
deacetylase activity.  It is also known to be over-expressed in 
some cancers and can inactivate proteins involved in tumour 
suppression.  Therefore, the effects of extract treatment on 
SIRT1 were evaluated in MCF-7 cells.  Extract treatment of 2 
mg/ml reduced levels of SIRT1 protein expression in MCF-7 
cells in a time-dependent manner over 24 hours (figure 
6.4.7a).  A significant reduction of 14.2% was seen by 
western blot after 1 hour treatment and by 24 hours, SIRT1 
protein expression had decreased by 87.3%, compared to 
control (time = 0 hours) (figure 6.4.7b).  The effects of extract 
treatment on SIRT1 activity in MCF-7 cells were determined, 
as a change in expressed protein does not necessarily 
correlate with any  change in SIRT1 activity.  In response to 
extract treatment (2 mg/ml) for 24 hours, relative SIRT1 
activity  was reduced by 27.4%, which could be attenuated by 
pre-treatment with 50 μM resveratrol (figure 6.4.8).  This 
demonstrates that SIRT1 activity as well as protein 
expression is modulated by extract treatment in MCF-7 cells. 
SIRT1 inhibition can improve chemotherapeutic efficacy by 
increasing acetylation status of transcription factors involved 
in cell death.  In fact, acetylation of p53 is crucial for its 
transcription independent and dependent functions, including 
induction of cell cycle arrest following DNA damage. 
Therefore, in order to test whether extract-induced SIRT1 
inhibition plays a role in cytotoxicity, MCF-7 cells were pre-
treated with the SIRT1 activator resveratrol for 60 minutes 
prior to 2 mg/ml extract treatment for 24 hours.  Analysis of 
cell viability  using the MTT assay showed that pre-treatment 
with resveratrol could not attenuate extract-induced 
cytotoxicity  in MCF-7 cells (figure 6.4.9) even though it was 
191
shown that 50μM resveratrol pre-treatment can attenuate 
loss of SIRT1 expression (figure 6.4.8 and 6.4.10).
!
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Figure 6.4.7.  Aqueous extract treatment reduces SIRT1 
protein expression in MCF-7 cells.  (a) MCF-7 cells were 
treated with 2mg/ml aqueous extract for up  to 24 hours 
before lysates were subjected to SDS-PAGE and western 
blot.  β-actin was used as a loading control. (b) Protein 
expression was expressed as a fold change in SIRT1 density 
relative to β-actin density.  Data denoted *  (p<0.05) and *** 
(p<0.001) are significant compared to control (time = 0 hours) 
analysed by  one-way ANOVA with Dunnettʼs multiple 
comparison post test  Data is representative of three 
independent experiments and presented as mean ±  standard 
deviation.
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Figure 6.4.8.  Aqueous extract treatment reduces SIRT1 
activity in MCF-7 cells.  MCF-7 cells were treated with and 
without 50μM resveratrol for 60 minutes prior to 2mg/ml 
aqueous extract treatment for 24 hours.  Nuclear lysates 
were obtained and SIRT1 activity  was determined based on 
relative deacetylase activity.  Data denoted * (p<0.05) is 
significant compared to untreated control or as indicated 
analysed by  one-way ANOVA with Bonferroniʼs multiple 
comparison post test.  Data is from three independent 
experiments performed in duplicate and presented as mean 
± standard deviation.
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Figure 6.4.9.  Resveratrol has no effect on aqueous 
extract-induced cytotoxicity in MCF-7 cells.  MCF-7 cells 
were treated with and without 50μM resveratrol for 60 
minutes prior to treatment of up to 2mg/ml aqueous extract 
for 24 hours.  Cell viability was determined by MTT assay. 
Data is from three independent experiments performed in 
triplicate and presented as mean ± standard deviation.
" 6.5:  Discussion
Tumours carrying mutations within p53 are associated with 
aggressive cancer phenotypes and predict poor response to 
therapy due to the loss of cell death pathways in the face of 
genotoxic agents [98,111].  However, certain anti-cancer 
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Figure 6.4.10.  Aqueous extract induced decrease in SIRT1 
expression is attenuated with resveratrol.  MCF-7 cells 
were pre-treated with and without 50μM resveratrol (Res.) for 
24 hours prior to 2mg/ml aqueous extract treatment for up to 
24 hours.  (a) Cell lysates were collected and SIRT1 protein 
expression was assessed by  western blot.   β-actin was used 
as a loading control. (b) Data is expressed as a fold change in 
SIRT1 density normalised to β-actin.  Data denoted **  (p<0.01) 
and *** (p<0.001) are significant compared to control (time = 0 
hours, no Res.).  Data was analysed by one-way ANOVA with 
Dunnett ʼs multiple comparison post test.  Data is 
representative of three independent experiments and 
presented as mean ± standard deviation.
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drugs such as Paclitaxel, can effectively  kill cancer cells 
harbouring a mutant-p53 phenotype [222].  It has also been 
shown previously that DNA damage can induce apoptosis in 
cancer cells irrespective of p53-status [286,369].  In chapter 
5, it was shown that the cytotoxic activity of an aqueous 
extract of Fagonia cretica is not fully dependent on p53 
functionality.  In the current chapter it has been demonstrated 
that in response to extract treatment, the expression of 
SIRT1 and FOXO3a are decreased/increased, respectively. 
Furthermore, inhibition of FOXO3a with siRNA abrogated 
loss of cell viability in p53-deficient cells whereas inhibition of 
SIRT1 activity did not appear to be critical to toxicity.  This 
provides evidence for FOXO3a-dependent cell death in 
response to extract treatment in human breast cancer cells.
The transcription factor FOXO3a regulates cellular 
responses to a variety  of stressors including energy 
depletion, oxidative stress and genomic insult.  Herein, it was 
shown that FOXO3a expression is increased in MCF-7 and 
MDA-MB-231 cells in response to extract treatment.  It was 
described previously in chapter 4 that DNA damage-induced 
activation of p53 drives a cytotoxic effect in MCF-7 cells. 
Therefore, it can by postulated that FOXO3a activation may 
occur as a consequence of DNA damage, particularly as 
elevation of FOXO3a expression coincides with detectable 
DNA damage levels.  Recent work by Tsai et al. elucidated a 
functional interaction of FOXO3a and ATM in response to 
DNA damage which suggests that ATM is directly regulated 
by FOXO3a [370].  It is also apparent that DNA damage 
induced by  ionising radiation results in cell cycle arrest and 
apoptosis independent of p53-status [221].  FOXO3a 
transcriptional activity was increased by ionising radiation 
resulting in expression target genes including bim and Fas-L. 
In this chapter, abrogation of extract-induced FOXO3a 
expression did not fully alleviate cell death in MCF-7 cells 
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carrying functional p53.  However, in the absence of 
functional p53, MDA-MB-231 cells were saved from extract-
induced cytotoxicity by abrogation of FOXO3a expression. 
This suggests that in the presence of functional p53 in 
MCF-7 cells, an active DNA damage response pathway can 
mediate cell death.  This agrees with the findings by Stan et 
al. which show that Withaferin A, a derivative from a 
medicinal plant, was able to decrease cell viability in MCF-7 
and MDA-MB-231 cells in a FOXO3a-dependent manner that 
relied on induction of pro-apoptotic bim [381].
FOXO proteins are key regulators of cellular responses to 
metabolic stress including activation in response to energy 
depletion.  In C. elegans it has been shown that dietary 
restriction activates AMPK which exerts changes in metabolic 
function in a FOXO-dependent manner [216].  Furthermore, 
in mammalian cells, activated AMPK directly phosphorylates 
FOXO3a at 6 specific regulatory sites, allowing nuclear 
retention and transcription of energy metabolism genes 
[215].  In response to double strand breaks, ATM coordinates 
multiple cellular responses following phosphorylation from 
DNA repair enzymes, which are recruited to sites of DNA 
damage.  Subsequently, ATM activates a variety of 
downstream signalling molecules to elicit a response.  For 
example, etoposide-induced DNA damage results in ATM-
mediated phosphorylation of AMPK leading to mitochondrial 
biogenesis [382].  This provides evidence demonstrating that 
the DDR can challenge the cell metabolically and can induce 
survival responses which in part are mediated by FOXO 
proteins.  In this chapter, increased FOXO3a expression 
correlated with time-points associated with DNA damage 
detected by comet assay and by  the presence of γ-H2AX. 
Therefore, it is plausible that FOXO3a-mediated cell cycle 
arrest or apoptosis in response to extract treatment may be a 
direct result of DNA damage or as a consequence of 
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metabolic stress.  It was shown in this chapter that 
intracellular ATP levels are depleted in MCF-7 cells in 
response to extract treatment.  This could provide an 
explanation for the increased expression of FOXO3a, 
particularly as levels of ATP are depleted at time points 
coinciding with elevated FOXO3a expression.
As previously discussed, the transcription factors p53 and 
FOXO3a are both subjected to post-translational 
modifications, which are required for activity.  Members of the 
sirtuin class of proteins are enzymes that possess 
deacetylase activity against histones and non-histone 
proteins.  Sirtuin1 (SIRT1) is a class III histone-deacetylase 
(HDAC) that catalyses the deacetylation of acetyl-lysine 
residues in a NAD+ dependent manner.  As well as 
suppressing gene expression via histone modifications, 
SIRT1 has catalytic activity towards p53 and FOXO3a, and 
inhibition of SIRT1 activity  increases acetylation of both 
proteins [202,205].  It has been shown that over-expression 
of SIRT1 in C. elegans extends life-span dependent on the 
activity  of the FOXO homolog DAF-16.  Deacetylation of 
FOXO3a creates a shift in transcriptional program from cell 
death to cell survival that leads to increases in organismal 
lifespan [378].  However, it is clear that a cell which is 
switched to a survival program may become tumorigenic, 
suggesting that the role of SIRT1 in pathology is complex.  It 
has been reported that SIRT1 represses the pro-apoptotic 
function of FOXO3a related to an inhibition in bim 
transcription [203].  On the other hand, SIRT1 over-
expression has been shown to increase FOXO3-transcription 
of the DNA repair gene GADD45, suggesting that 
deacetylation of FOXO3a could contribute to tumorigenesis 
by inducing cell survival following DNA damage [383].  In 
light of these findings, the effect of extract treatment on 
SIRT1 was assessed in MCF-7 cells, in order to understand 
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any relationship  between SIRT1 and treatment outcome. 
The results demonstrated that SIRT1 protein expression is 
decreased in extract-treated MCF-7 cells in a time dependent 
manner which was associated with a decrease in SIRT1 
enzyme activity.  However, because the assay used crude 
nuclear extracts as a purified source of SIRT1, it is difficult to 
ascertain if SIRT1 catalytic activity is inhibited or if the effect 
is due solely  to reduced SIRT1 protein levels.  It is known 
that p53 and FOXO3 regulate SIRT1 expression as part of a 
feedback loop that enables a self-regulated negative control 
[378].  Therefore, reduced SIRT1 expression in response to 
extract treatment, may help  to sustain the tumour suppressor 
function of p53 and FOXO3a.  This hypothesis was tested by 
using resveratrol to sustain SIRT1 protein expression during 
extract treatment of MCF-7 cells.  It was shown that 
resveratrol treatment inhibited the extract-induced reduction 
in SIRT1 protein expression.  However, maintaining SIRT1 
levels did not block extract-induced loss of cell viability, 
suggesting that the reduction in SIRT1 does not affect 
cytotoxic activity of the extract.
" 6.6:  Conclusion
The work described in this chapter identifies possible p53-
independent mechanisms that may contribute to cell cycle 
arrest and death in extract-treated human breast cancer 
cells.  The FOXO proteins, in particular FOXO3, are 
important in maintaining cellular homeostasis in response to 
nutrient deprivation, metabolic stress and oxidative stress. 
FOXO3 has also been implicated in DNA repair pathways.  In 
the presence of DNA damage, FOXO3 is normally 
phosphorylated and retained in the nucleus where it is 
responsible for switching on apoptotic and DNA repair genes. 
Extract treatment was shown to increase FOXO3a 
expression and inhibition with siRNA fully abrogated extract-
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induced cytotoxicity in mutant-p53 MDA-MB-231 cells.  This 
demonstrates that in the absence of p53, extract-induced cell 
death, is dependent on FOXO3a.  Interestingly, induction of 
FOXO3a expression following extract treatment coincides 
with detectable DNA damage, suggesting that FOXO3a may 
be directly increased by DNA damage.  Extract treatment 
also reduced levels of SIRT1, a known negative regulator of 
FOXO3a and p53, in MCF-7 cells.  However, inhibition of 
SIRT1 depletion by  extract using resveratrol failed to 
attenuate extract-induced cytotoxicity, suggesting that SIRT1 
may not play a role in extract activity towards breast cancer 
cells.
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Chapter 7:  Bioassay-guided fractionation of Fagonia 
cretica
" 7.1:  Rationale
Many successful drugs have been derived from natural 
products.  The rise of synthetic chemistry meant that drug 
discovery from natural products took a back seat to high-
throughput analysis of compound libraries based on known 
molecular targets [384].  Recently, the pharmaceutical 
industry has moved back to the isolation of therapeutic 
compounds from natural products, due to the lack of leads 
from high-throughput chemistry and the successes 
experienced in the past with natural products [385].  One 
popular method of isolating compounds from natural 
products is known as bio-assay guided fractionation.
The aims of the work described in this chapter were to 
develop a method for the extraction and isolation of the 
compound(s) responsible for cytotoxicity in human breast 
cancer cells.  A method involving sold-phase extraction 
(SPE) and high-performance liquid-chromatography (HPLC) 
was developed to isolate therapeutic compounds.  The MTT 
cell viability  assay was used to determine active fractions 
and indicated what fractions should be taken forward for 
further analysis.  Identification and characterisation of 
compounds within active fractions was partially tested using 
electro-spray ionization mass-spectrometry (ESI-MS).
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" 7.2:  Introduction
The development of novel drugs from natural products has 
played a major role in past and present advancements of 
clinical science.  Before the arrival of synthetic chemistry and 
high-throughput library  screening, more than 80% of 
therapeutic compounds were of natural product origin [316]. 
Since 1994, almost half of all approved drugs have derived 
or modified structures isolated from natural products [384]. 
In fact, modern drug discovery is reverting to a ʻback-to 
basicsʼ approach due to the success seen with drug 
development from natural products in the past [315].  Anti-
cancer drug development in particular has experienced 
success from natural product chemistry.  For example, the 
widely used chemotherapeutic compounds paclitaxel, 
vinblastine and etoposide were all derived from plants [385].
Natural product drug discovery represents a field of research 
encompassing a wide range of disciplines that fall under the 
umbrella term pharmacognosy.  It begins with identification of 
a potential therapeutic source, such as a plant or herb  that is 
used in a traditional herbal remedy and preparation of 
extracts for screening [314].  Methodologies such as 
bioassay-guided fractionation are used to isolate compounds 
of interest from complex mixtures [333].  Bio-assay guided 
fractionation involves a mixture of separation and analytical 
techniques where fractionated material is periodically tested 
for activity in a bioassay  and for purity by analytical methods. 
Initially  a crude extract is produced with confirmed bioactivity 
such as demonstrating anti-cancer properties.  This extract is 
then fractionated using HPLC, gel filtration or other 
chromatographic methods before testing isolated fractions in 
the same bioassay.  Active fractions can then tested for purity 
by LC/MS.  In the case of an impure fraction, further 
purification techniques can be used before re-testing in the 
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bioassay and rechecking for purity.  Pure active compounds 
can be characterised structurally using analytical techniques 
such as mass-spectrometry and NMR (figure. 7.2.1) [316].
" 7.3: Methods
! ! 7.3.1:  Solid-phase extraction
Solid-phase extraction (SPE) was carried out as outlined in 
section 2.14.2.
! ! 7 . 3 . 2 :  H i g h - p e r f o r m a n c e l i q u i d 
chromatography
HPLC separation of extract was carried out as outlined in 
section 2.14.2
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Figure 7.2.1.  Bio-assay guided fractionation work flow. 
Adapted from Koehn et al. 2005,  the evolving role of natural 
products in drug discovery.  Bio-assay  guided fractionation is 
a method for isolating and characterising bio-active natural 
products.  Raw material is first processed and fractionated by 
chromatographic methods before fractions are analysed for 
bio-activity.  Active fractions are tested for purity by liquid 
chromatography (LC) or mass spectrometry (MS) before 
structural characterisation using analytical techniques.
" " 7.3.3:  Mass spectrometry
Mass spectral (MS) analysis of HPLC  fractions was carried 
out as outlined in section 2.14.2
! ! 7.3.4:  MTT assay
Bioactivity of extract fractions generated by  SPE and HPLC 
was determined using the MTT cell viability  assay outlined in 
2.5.2.  Fractions were dried under vacuum and resuspended 
in 1ml of culture media.  This was to ensure that the final test 
concentration of the fraction was approximately equal to the 
concentration that would be in 2mg/ml of whole extract 
(ignoring losses during the fractionation process).  Elution 
and flow-through generated by SPE were tested neat at 1:2 
and 1:4 for 24 hours.  Fractions generated by HPLC were 
tested neat only for 24 hours.
" 7.4:  Results
" " 7.4.1:  SPE and HPLC separation of an 
aqueous Fagonia cretica extract
Solid-phase extraction is a separation method used to isolate 
compounds from a mixture based on their specific chemical 
properties.  In this investigation, a C18 matrix was used to 
separate compounds from an aqueous extract of Fagonia 
cretica based on their polarity.  SPE was used as an initial 
work-up prior to higher resolution separation by HPLC.  A 
total of 20 mg of plant material extracted into water as 
previously described in chapter 2 was resuspended in 0.5% 
v/v acetic acid (aq), separated by gravity flow and bound 
material was eluted with 100% methanol.  Both the flow-
through and elution were dried under vacuum, resuspended 
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in culture media and bioactivity  determined by MTT assay. 
Treatment of MCF-7 cells for 24 hours with SPE flow-through 
induced no significant reduction in cell viability.  In 
comparison, the SPE elution significantly reduced MCF-7 cell 
viability (20.5%) when applied as neat eluate but not at any 
other tested dilutions (figure 7.4.1).
The SPE elution (100% methanol) was subjected to further 
purification by HPLC using a C18 column.  The elution was 
first dried under vacuum and resuspended in 500 μl of 0.5% 
v/v acetic acid (aq.) for injection into the HPLC system. 
Separation of compounds by HPLC generated the 
chromatogram in figure 7.4.2.  Compounds detectable by UV 
absorbance at 254 nm were eluted in all mobile phases. 
Fractions were collected at 1 ml intervals and pooled 
according to the retention time to generate 6 fractions (table 
7.4.1).  Each fraction was dried under vacuum and 
resuspended in culture media prior to bioactivity testing using 
the MTT assay.  Treatment of MCF-7 cells for 24 hours with 
any of the fractions, except for fraction 5, failed to 
significantly reduce cell viability (figure 7.4.3).  Fraction 5 
reduced MCF-7 cell viability by 40.1%, compared to 
untreated control, after 24 hours treatment.
" " 7.4.2:  Mass-spectral analysis of bioactive 
HPLC-purified fraction
The bioactive fraction was checked for total ion current (TIC) 
by electrospray ionisation (ESI)-MS.  The bioactive fraction 
was eluted from the HPLC using the method described in 
section 2.14 in eight 1 ml fractions and each fraction was 
subjected to mass-spectral analysis in negative ion mode 
(figure 7.4.4).  The major parent ion masses detected in each 
of the eight samples is outlined in table 7.4.2.  Analysis of the 
mass-spectra revealed parent ions [M-H]- 367.2 and 403.2 to 
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be highly  abundant in all eight of the fractions and [M-H]- 
727.3 and 375.2 to be present in fraction 1 and 8 
respectively.  The high relative abundance of 367.2 and 
403.3 suggests that they would both be good candidates to 
take forward for further bio-assay and structural analysis.
!
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Figure 7.4.1.  SPE elution reduces MCF-7 cell viability. 
Aqueous extract was separated by SPE on a C18 matrix by 
gravity flow.  Compounds were eluted in 100% methanol. 
MCF-7 cells were treated with flow-through (FT) and elution 
(E) at indicated dilutions for 24 hours prior to assessment of 
cell viability  by MTT assay.  Data denoted **  (p<0.01) are 
significant compared to untreated control analysed by one-
way ANOVA with Dunnettʼs multiple comparison post test. 
Data is from three independent experiments and presented 
as mean ± standard deviation.
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Figure 7.4.2.  HPLC separation of an aqueous extract of Fagonia cretica.  Following aqueous extract purification by SPE, the 
eluate was subjected to HPLC on a C18 colum
n.  This figure is typical of chrom
atogram
s observed using detection at 280nm
. X axis - 
retention tim
e, Y-axis - relative absorbance units (UV detection: 254nm
).  Black lines represent percentage of m
ethanol in m
obile phase.
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Figure 7.4.2.  HPLC separation of an aqueous extract of Fagonia cretica.  Following 
aqueous extract purification by SPE, the eluate was subjected to HPLC on a C18 
colum
n.  This figure is typical of chrom
atogram
s observed using detection at 280nm
. X 
axis - retention tim
e, Y-axis - relative absorbance units (UV detection: 254nm
).  Black 
lines represent percentage of m
ethanol in m
obile phase.
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Figure 7.4.3.  Effects of HPLC fractions on MCF-7 cell viability.  SPE purified aqueous 0
extract was subjected to separation by HPLC on a C18 column.  MCF-7 cells were treated 
with isolated fractions for 24 hours prior to analysis of cell viability by MTT assay.  Data 
denoted *** (p<0.001) is significant compared to untreated control analysed by one-way 
ANOVA with Dunnettʼs multiple comparison post test.  Data is representative of at least 
three independent experiments performed in triplicate.
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Table 7.4.1.  Retention times for pooled HPLC fractions. 
SPE-purified aqueous extract of Fagonia cretica was 
subjected to HPLC on a C18 column.  Fractions were 
collected at 1ml intervals and pooled according to retention 
time.
Figure 7.4.3.  Effects of HPLC fractions on MCF-7 cell 
viability.  SPE purified aqueous extract was subjected to 
separation by HPLC on a C18 column.  MCF-7 cells were 
treated with isolated fractions (F1-F6) for 24 hours prio  
o analysis of cell viability by MTT assay.  Data denot d 
*** (p<0.001) i  significant compared to untreated control 
analysed by one-way ANOVA with Dun ettʼs multiple 
comparison p st test.  Data is from three independent
ri t  perfor ed in triplicate and presented as 
mean ± standard deviation.
Fraction Retention Time (mins
1 0-8
2 8-16
3 16-24
4 24-32
5 32-40
6 40-48
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Figure 7.4.5.  Mass spectral analysis of bioactive fraction 
from an aqueous extract of Fagonia cretica.  An aquoues 
extract was subjected to SPE and HPLC purification to generate 
a bioactive fraction.  The bioactive fraction was isolated as 8 x 
1ml fractions(F1 (a), F2 (b), F3 (c), F4 (d), F5 (e), F6 (f), F7 (g), 
F8 (g)) and each fraction subjected to ESI-MS.  Mass spectra 
were generated in negative ion mode.
" 7.5: Discussion
Bio-assay guided fractionation is a popular method for the 
extraction and purification of medicinal compounds from 
natural products.  Recently, the use of natural products to 
source new therapeutic compounds has had a resurgence, 
primarily due to the clinical use of taxol, etoposide and 
artemisinin [316].  In this chapter, a bio-assay guided 
fractionation method was developed to isolate the active 
compound(s) in an aqueous extract of Fagonia cretica.  A 
systematic approach involving purification of the extract on 
SPE and HPLC columns, punctuated with bioactivity  testing 
by the MTT assay, revealed 4 potentially therapeutic 
compounds.  These compounds with masses 368.2, 376.2, 
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Fraction [M-H]-
1 367.2, 727.3
2 367.2, 403.3
3 367.2, 403.2
4 367.2, 403.2
5 367.2, 403.2
6 367.2, 403.3, 430.2
7 367.2, 403.3, 430.2
8 367.2, 375.2, 403.3
Table 7.4.2.  Charge to mass ratio of parent ions [M-H]- 
detected by ESI-MS in bioactive fractions of Fagonia 
cretica.  An aquoues extract was subjected to SPE and HPLC 
purification to generate a bioactive fraction.  The bioactive 
fraction was isolated as 8 x 1ml fractions and each fraction 
subjected to ESI-MS.  Mass spectra were generated in 
negative ion mode.
404.3 and 728.3 were detected by ESI-MS analysis of the 
bioactive fraction.
Although, it is possible that just one of these compounds is 
responsible for the cytotoxic activity against human breast 
cancer cells, it cannot be disregarded that bioactivity may 
depend on synergistic action of multiple compounds.  In fact, 
as previously  shown in chapter 6, extract-treatment 
modulates SIRT1 which does not appear to contribute to 
cytotoxicity.  Furthermore, in chapter 3 it was shown that 
extract-induced increases in intracellular ROS do not 
contribute to cytotoxicity.  This demonstrates that ROS and 
SIRT1 modulation may be caused by a separate compounds 
to those which are responsible for cell death.  In response to 
extract treatment, MCF-7 cells were subjected to DNA 
damage, which mediated a p53-dependent response.  In 
MDA-MB-231 cells harbouring a non-functional form of p53, 
evidence of DNA damage was still apparent, and cell death 
was induced independently of p53.  It was speculated that 
DNA damage may have increased FOXO3a expression 
leading to cell death in MDA-MB-231 cells.  This would 
indicate that one DNA damaging agent present in the extract 
may be responsible for cytotoxicity in human breast cancer 
cell lines.  However, no direct evidence has been presented 
that links DNA damage to both p53 and FOXO3a expression. 
Therefore, it is still plausible that a separate compound may 
be exerting an effect on FOXO3a, independent of DNA 
damage.  It has recently been shown that troglitazone, a 
potent inhibitor of PPAR gamma and PI3K/AKT signalling, 
and aspirin, a NSAID, synergistically inhibit the growth of 
colon cancer cells [386].  This may in part be caused by 
FOXO3 activation as the authors report increased p27 
expression, apoptosis and decreased PI3K/AKT signalling in 
response to synergistic treatment.  Interestingly, is has 
recently been reported that a formulation of two DNA 
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damaging agents, doxorubicin and mitomycin C, was able to 
synergistically  induce cell death in multi-drug resistance 
breast cancer cells [387].
" 7.6:  Conclusion
In this chapter a novel method for the extraction and isolation 
of compounds from an aqueous extract of Fagonia cretica 
was created.  The method involved bio-assay guided 
fractionation using a reduction in MCF-7 cell viability  as a 
guide to nominating potential hits.  It was reported that the 
chemotherapeutic activity  of the aqueous extract can 
potentially be attributed to 4 compounds detected by mass-
spectrometry.  However, it is not known if the compounds act 
synergistically, or if one compound is solely responsible for 
extract-induced cytotoxicity.
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Chapter 8:  Discussion and Conclusion
" 8.1:  Discussion
The investigation presented here aimed to (1) validate an 
aqueous extract of Fagonia cretica as a potential treatment 
for breast cancer based on ethno-pharmacological 
information, (2) characterise the mechanism responsible for 
any chemotherapeutic activity  and (3) isolate and 
characterise the active compound(s) from the extract. 
Herein, it has been shown that an aqueous extract does 
demonstrate cytotoxic properties against human breast 
cancer cells (MCF-7 and MDA-MB-231 cells), with a 
markedly  reduced effect against normal mammary epithelial 
cells (HMEpC).  Furthermore, it has been shown in MCF-7 
cells that extract-treatment was associated with p53-
mediated cell cycle arrest and apoptosis, as a result of 
double strand breaks and activation of the DNA damage 
response (DDR).  In the absence of extract-induced p53 
induction or in extract-treated MDA-MB-231 cells, loss of cell 
viability  was attenuated, but not completely abrogated. 
Therefore, a separate, p53-independent mechanism was 
sought that could drive cell death in both cell lines.  Here, it 
has been shown  that extract-induced FOXO3a expression 
was required for loss of cell viability  in both MCF-7 and MDA-
MB-231 cells.  In addition to these findings, it was shown that 
in MCF-7 cells, expression and activity of the deacetylase 
SIRT1 was reduced in response to extract treatment. 
However, attenuation of extract-induced SIRT1 repression, 
did not affect cell viability in MCF-7 cells.  The final section of 
this investigation dealt with the isolation and characterisation 
of the active compound(s) within the aqueous extract.  In this 
report a novel, reproducible, bio-assay guided fractionation 
method was developed.  Using chromatographic techniques 
coupled with a MTT cell viability assay, a final fraction was 
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produced, which revealed several compounds that may be 
responsible for the extracts chemotherapeutic activity.  In 
addition to this, mass-spectral analysis determined the 
molecular weights of the most abundant compounds to be 
368.2,  376.2, 404.3 and 728.3.
Chemotherapeutic compounds isolated from natural products 
are responsible for many of the clinical drugs in use today 
[384,385].  Compounds such as Paclitaxel are sourced 
directly from nature, but alternatively, many drugs are based 
on chemical structures derived from natural products.  For 
example, the topoisomerase inhibitor, etoposide, is a semi-
synthetic derivative of the natural product, epipodophyllotoxin 
[334].  Upon discovery of novel chemotherapeutic agents, it 
is important to understand the mechanisms by which they 
are active towards cells, in order to predict clinical efficacy 
and prepare for potential side-effects.
  
Modulation of the DNA damage response has been 
highlighted as a target for cancer therapy.  DNA repair 
pathways exist to protect the cells from genotoxic stress that 
may induce tumorigenic mutations.  Dysregulation in this 
system produces a paradox where loss of repair networks 
can drive tumorigenesis but also makes neoplastic tissue 
more susceptible to DNA damaging agents [343].  In 
particular, it has been shown that inhibition of the DNA repair 
enzyme, DNA topoisomerase II, increases the frequency  of 
DNA double strand breaks, cell cycle arrest and apoptosis in 
cancer cells [388].  As well as inhibition of DNA repair 
pathways, direct induction of DNA damage from alkylating 
agents and platinum-based chemotherapy, can also target 
cancer cells through the DNA repair pathways [350].  For 
example, cyclophosphamide and etoposide, induce DNA 
damage-mediated activation of cell cycle arrest and 
apoptosis in cancer cells [50,343].  Although the DDR is 
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evolutionarily conserved as a barrier to cellular age-related 
pathology, targeting the mechanisms by  which it ensures 
organismal survival such as DNA repair, cell cycle arrest and 
apoptosis can be used to treat cancers.  Even in the 
presence of intact DNA repair pathways, sustained DNA 
damage eventually leads to cell death, as a means of 
removing potentially harmful cells from the population [284].
The work reported in this thesis has demonstrated that 
extract-induced DNA damage activates the DDR and 
mediates a p53/p21/Bax induced cell death in MCF-7 cells. 
Presence of the DNA damage marker, γ-H2AX, in extract-
treated cells is indicative of double strand breaks (DSBs).  It 
has been shown elsewhere that phosphorylated H2AX is 
essential to the recognition of DSBs [365].  It was also shown 
that extract-treatment most likely activated the DDR in an 
ATM/ATR dependent manner.  The DNA-damage checkpoint 
kinases ATM and ATR are both activated in response to 
double strand breaks and both act ivate p53 by 
phosphorylation of serine-15 residue [83].  Inhibition of 
extract-induced ATM/ATR-mediated p53 expression using 
caffeine, resulted in a reduction in extract toxicity  towards 
MCF-7 cells, suggesting that the p53-mediated DNA damage 
response is party  involved in extract activity.  Activation of 
this signalling pathway to induce cell death in cancer lines 
has been demonstrated by Rong et al.  with the natural 
product gambogic acid.  The authors show that gambogic 
acid treatment induces ATM/ATR-dependent p53 
phosphorylation, via DNA damage, which results in p21-
mediated cell cycle arrest [389].
The fact that extract treatment is still able to reduce MCF-7 
cell viability  in the absence of a p53-driven DNA damage 
response suggests that other mechanisms are involved in 
extract activity.  This was confirmed by showing that extract 
treatment could reduce cell viability  in MDA-MB-231 breast 
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cancer cells that harbour a non-functional p53 mutant, albeit, 
the effect was reduced compared to MCF-7 cells. 
Interestingly, the level of cytotoxicity demonstrated against 
MDA-MB-231 cells, was similar to the effect shown against 
MCF-7 cells which were transiently transfected with TP53 
siRNA.  This provides further evidence that the p53-mediated 
DDR is only part-responsible for the overall extract activity. 
However, this does not disregard DNA damage as the 
initiating step in extract-induced cell death in human breast 
cancer cells, as p53-independent DDR mechanisms exist 
that could drive similar effects [146].  DNA damage has been 
shown to activate the JNK pathway, resulting in expression of 
pro-apoptotic hid in Drosophila with mutant p53 [369].  As 
well as this, members of the Forkhead ʻOʼ (FOXO) family of 
transcription factors have been shown to regulate cell 
survival and proliferation, in response to various stress 
signals [177].  It has been reported that FOXO3a directly 
interacts and phosphorylates ATM to activate the DDR in 
response to double strand breaks [370].  It has also been 
shown that DNA damage can induce FOXO3a-dependent 
DNA repair via transcription of Gadd45 [209].  Other 
transcriptional targets of FOXO3a including pro-apoptotic 
Bim and Fas-ligand and the CDk-inhibitors p21 and p27 are 
all inducible by DNA damage [182,221,372].  It has recently 
been reported that activation of FOXO3a reduces p53-
transcriptional activity but increases cytoplasmic localisation 
and transcription-independent apoptosis [298].  Therefore a 
mechanism has been proposed by which FOXO3a can drive 
p53-dependent cell death in cells carrying a transcriptionally-
inactive form of p53.
In this investigation it was shown that extract-treatment of 
MCF-7 and MDA-MB-231 cells increased FOXO3a protein 
expression.  Furthermore, it was demonstrated that in the 
absence of p53, increased expression of FOXO3a was 
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required for extract-induced cytotoxicity.  However, it is not 
clear if FOXO3a expression is being increased as a result of 
DNA damage, or as a result of an alternative stress 
response.  Regulation of FOXO3a is controlled by the PI3K/
Akt signalling pathway which negatively regulates FOXO3a 
transcriptional activity by promoting its nuclear exclusion 
[175].  In the presence of cytokine signalling, Akt is activated 
and phosphorylates FOXO3a at conserved thymidine and 
serine residues, which promotes binding to the adapter 
14-3-3 proteins and subsequent nuclear export [374].  The 
chemotherapeutic agent, paclitaxel, has been shown to 
induce apoptosis in breast cancer cells in a FOXO3a-
mediated mechanism.  In fact, it was demonstrated that 
decreased Akt signalling in conjunction with increased JNK 
signalling, was responsible for nuclear translocation of 
FOXO3a following paclitaxel treatment [223].
Activation of FOXO3a can occur as a response to energy 
depletion and the AMP-activated protein kinase (AMPK)-
FOXO3a axis has been implicated as a mediator of the 
cellular response to metabolic stress [211].  AMPK can detect 
fluctuations in the AMP/ATP ratio and is activated during 
energy depletion.  It has been shown that AMPK 
phosphorylates FOXO3a and promotes transcription of 
stress resistance genes including energy metabolism genes 
such as aldehyde dehydrogenase and anti-oxidant genes 
such as thioredoxin [215,216].  Emerging research has 
highlighted AMPK signalling as a potential tumour 
suppressor by regulating metabolic homeostasis [246]. 
Furthermore, epidemiological studies have demonstrated a 
lower cancer incidence rate in diabetic patients treated with 
metformin, a powerful AMPK agonist [390].  It has also been 
shown recently, that AMPK is directly regulated by the 
tumour suppressor LKB1, which phosphorylates AMPK in 
response to ATP depletion [241].  Loss of LKB1 function has 
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been shown to induce cancer phenotypes in mouse models 
and is associated with an increased risk of developing cancer 
[214,243].
Cancer cells often exhibit a metabolic switch from oxidative 
phosphorylation to glycolysis as a major source of ATP.  This 
phenomenon known as the Warburg effect results in 50% of 
cellular ATP being produced from glycolysis as opposed to 
only 10% in normal cells [213,227].  Interestingly, even under 
normal culture conditions this metabolic phenotype is 
sustained, suggesting a permanent alteration in the 
transcriptional program involved in metabolism [230].  It has 
recently been proposed that changes in cellular energy 
metabolism may be an effective target for cancer 
chemotherapy [229].  Indeed, a mechanism sustaining 
aerobic glycolysis in cancer cells was described, which 
involved activation of the transcription factor HIF-1 and may 
be reliant on over-activation of Akt signalling [231,237].  It 
was shown recently that inhibition of p38-MAPK can inhibit 
colorectal carcinogenesis by inducing a switch in 
transcriptional switch from HIF-1 to FOXO-dependent gene 
expression [218].  In the authors investigation they report that 
upon p38 blockade an AMPK/FOXO3a-mediated autophagic 
phenotype is induced as a survival response to impaired 
metabolism with sustained inhibition leading to cell cycle 
arrest and cell death.  Interestingly, in the study presented 
here it was shown that extract-induced cell cycle arrest is 
delayed in the absence of functional p53.  Potentially this 
could be a result of the cells activating an autophagic survival 
response before succumbing to cell cycle arrest and cell 
death via FOXO3a-dependent mechanisms.  This may be a 
result of modulation of the metabolic program through the 
AMPK/FOXO3a axis.
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Activation of the DNA damage response by ionising radiation 
can induce AMPK signalling, in tumour cells, independent of 
LKB1 [391].  It is also apparent that etoposide treatment can 
increase AMPK, independent of p53 status, suggesting that 
DNA damage induced AMPK activation may facilitate cancer 
cell death [392].  As well as this, extensive activation of the 
DNA repair enzyme, PARP-1, can induce cell death via 
cytosolic NAD+ depletion [393].  It is therefore possible that 
significant DNA damage may lead to metabolic stress.  This 
in turn could be detected by AMPK and drive FOXO3a-
dependent autophagy and cell death.   Indeed, it has been 
shown that hyper-activation of PARP-1 can cause ATP 
depletion, eventually leading to irreversible energy failure 
and cell death [28].  As well as this, FOXO3a is known to 
regulate autophagy-related genes including LC3, ATG12 and 
BNIP3 [178].
In summary, the work presented in this investigation 
implicates FOXO3a as an important therapeutic target for 
Fagonia cretica treatment.  In the presence of functional p53, 
other pathways connected to cell cycle arrest and death, are 
activated.  However, these pathways are activated 
independently  of FOXO3a expression, showing that they are 
not required for each otherʼs activity.  The broad spectrum of 
effects elicited by FOXO3a means that anti-cancer activity 
may not be the only beneficial effect of drinking a herbal tea 
containing  Fagonia cretica.  This may explain in part why the 
plant is considered useful to treat such a diverse range of 
illnesses and diseases in Pakistan.  Alternatively, the fact that 
an extract would contain many diverse compounds, could 
provide a plethora of possible bioactive molecules effective 
against different cellular targets.  As in vitro tests show, 
chemotherapeutic potential is independent of p53-status and 
presence of hormone receptors, revealing that Fagonia 
cretica may be effective against a diverse range of breast 
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cancer phenotypes.  In particular, for treatment of the 
aggressive triple-negative phenotype, modelled in this 
investigation by the MDA-MD-231 cell line.
" 8.2:  Conclusion
Fagonia cretica is a herbaceous plant which is commonly 
used in Pakistan as a treatment for a variety of ailments.  For 
patients suffering from breast cancer, an aqueous extract in 
the form of a tea, is administered with the aim of inhibiting 
tumour growth and extending life-span.  This investigation 
demonstrates that an aqueous extract of Fagonia cretica is 
cytotoxic towards human breast cancer cells and for the first 
time provides a mechanism of action.  Extract treatment was 
able to induce a time and dose-dependent decrease in cell 
viability of two phenotypically different breast cancer cell 
lines while demonstrating a markedly decreased effect on 
normal mammary epithelial cells.  Cell cycle arrest and 
apoptosis was induced in both MCF-7 and MDA-MB-231 
cells.  Loss of cell viability is associated with induction of 
DNA double strand breaks which was detected in both cell 
lines.  In MCF-7 cells, stabilisation of p53 by ATM/ATR may 
have increased its transcriptional activity and induced up-
regulation of the CDK inhibitor, p21, and pro-apoptotic Bax. 
Inhibition of extract-induced p53 expression using TP53 
siRNA reduced the cytotoxic effect against MCF-7 cells 
suggesting that p53 is important but not vital for extract-
induced cytotoxicity.  Extract treatment was also able to 
increase FOXO3a expression in MCF-7 and MDA-MB-231 
cells.  Inhibition of extract-induced FOXO3a expression using 
FOXO3 siRNA reduced cytotoxicity against MCF-7 cells and 
completely  abrogated cytotoxicity against MDA-MD-231 
cells.  This suggests that activation of FOXO3a in the 
absence of functional p53 plays a vital role in extract-induced 
cytotoxicity.  Extract treated MCF-7 cells demonstrated a 
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depletion in ATP that coincided with increased FOXO3a 
expression and may provide an explanation for extract-
induced FOXO3a expression.  Figure 8.2.1 provides an 
overview of the proposed mechanisms governing the 
chemotherapeutic effects of an aqueous extract of Fagonia 
cretica against human breast cancer cells in vitro.
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Figure 8.2.1.  Mechanisms governing the chemotherapeutic effects of Fagonia cretica. 
Extract treatment of human breast cancer cells induces double strand breaks (DSBs) to DNA 
associated with activation of ATM/ATR and the DNA repair protein γ-H2AX.  This initiates 
downstream signalling of the DNA damage response involving p53, p21 and bax, which ultimately 
leads to cell cycle arrest and apoptosis.  In the presence and absence of functional p53, extract 
treatment increases FOXO3a expression, which leads to cell death.  This may  be due to activation 
of metabolic sensors as a direct treatment effect or through over-activation of DNA repair 
mechanisms.  Metabolic dysregulation could drive FOXO3a-dependent autophagy with sustained 
stress leading to autophagic cell death.
Figure 8.2.1.  Proposed mechanisms governing the 
chemotherape tic effects of Fag nia cretica.  Extract 
treatment of human breast cancer cells induces double strand 
breaks (DSBs) o DNA associat d with activation of ATM/ATR 
and the DNA repair prot in γ-H2AX.  This initiates downstream 
signalling of the DNA damage response involving p53, p21 and 
bax, which ultimately leads to cell cycle arrest and apoptosis. 
In the presence and absence of functional p53, extract 
treatment increases FOXO3a expression, which leads to cell 
death.  This may be due to activation of metabolic sensors as a 
direct treatment effect or through over-activation of DNA repair 
mechanisms.  Metabolic dysregulation could drive FOXO3a-
dependent autophagy with sustained stress leading to 
autophagic cell death.
Chapter 9:  Future Work
In this thesis the chemotherapeutic potential of an aqueous 
extract of Fagonia cretica  has been well characterised. 
However, several key questions remain unanswered and 
warrant further investigation.  Herein, it was shown that 
extract-induced FOXO3a expression is vital for activity 
against breast cancer cells, yet it is not clear how treatment 
causes this effect.  It was postulated that metabolic 
dysregulation may be responsible and it was shown that 
extract-treatment reduces intracellular ATP levels.  However, 
low experimental repeats (n=2) and issues regarding 
luminometer sensitivity, make the data from this experiment 
questionable.  Therefore, a key future experiment would be 
to repeat this assay on a dedicated luminometer with higher 
sensitivity, in order to validate the results.  Furthermore, it 
would be useful to repeat this experiment on MDA-MB-231 
cells as so far it has only  been carried out on MCF-7 cells. 
Investigating the role of AMPK and the PI3K/Akt signalling 
pathway would also provide further insight into the role of 
metabolism in extract-induced cytotoxicity.  It is known that 
autophagic cell death mediated by  FOXO3a can occur in 
response to prolonged metabolic stress.  Investigating 
downstream FOXO3a targets that regulate autophagy in 
response to stress could provide a more detailed insight into 
the mechanism driving extract-induced cell death, particularly 
how it occurs in the absence of functional p53.
In this investigation extract toxicity  profiles were developed 
against MCF-7 and MDA-MB-231 cells.  For both these cell 
lines it would be useful to look at the effects of treatment 
combined with low-dose chemotherapy to see if it can 
potentiate activity.  It would also be useful to look at colony 
forming assays to determine if clonality of viable post-treated 
cells is restricted.  Another interesting experiment would be 
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to see what effects reducing treatment time or withdrawing 
treatment has on cell growth and viability.
It was demonstrated that extract treatment is cytotoxic 
towards two phenotypically different breast cancer cell lines. 
An interesting line of enquiry to pursue would be to screen 
the extract against a diverse range of cancer cell lines to 
determine the specificity  of the treatment.  It would also be 
useful to obtain data against human gut epithelial cells as 
they are at the front line of compound exposure following 
ingestion.  Following this, the extract needs to be tested in 
vivo and on primary breast epithelial cells from a diverse 
range of tumours.
Human metabolism is a major influence on the therapeutic 
influence of natural products from dietary sources.  Before an 
agent can enter the bloodstream and reach a therapeutic 
target it is first subjected to metabolic processes by the 
digestive system including foreign metabolism by the gut 
microflora and by  gut epithelial cells responsible for nutrient 
uptake.  This process can result in the modification of natural 
products through metabolic pathways that could effect their 
therapeutic potential once at their target site.  This is an 
aspect that needs to be taken into consideration to fully 
understand the therapeutic potential of Fagonia cretica.
The key question currently surrounding this project is ʻwhat is 
the active compound(s)?ʼ.  Although it was shown here that a 
reproducible fraction containing four major compounds can 
be produced by SPE and HPLC purification so far no 
compounds have been identified.  This is due to the fact that 
yields after purification are too small to analyse by NMR. 
Further work is required to scale up  the methods developed 
in this thesis to produce larger yields of a bioactive fraction 
that can be used to identify  compound structures. 
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Identification of the key components should provide more 
information regarding the therapeutic targets associated with 
reduced breast cancer cell survival and enable effective 
progression of future research.
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